<?xml version="1.0" encoding="UTF-8" standalone="yes"?>
<STUDY_SET>
  <STUDY alias="JSUB000002_Study_0001" center_name="Individual" accession="JGAS000001">
    <IDENTIFIERS>
      <SECONDARY_ID>JGAS00000000001</SECONDARY_ID>
    </IDENTIFIERS>
    <DESCRIPTOR>
      <STUDY_TITLE>Identification and Characterization of Cancer Mutations in Japanese LungAdenocarcinoma without Sequencing of Normal Tissue Counterparts</STUDY_TITLE>
      <STUDY_TYPES>
        <STUDY_TYPE existing_study_type="Exome Sequencing"/>
      </STUDY_TYPES>
      <STUDY_ABSTRACT>We analyzed whole-exome sequencing data from 97 Japanese lung adenocarcinomapatients and identified several putative cancer-related genes and pathways. Particularly, we observed that cancer-related mutation patterns were significantly different between different ethnic groups. As previously reported, mutations in the EGFR gene were characteristic to Japanese, while those in the KRAS gene were more frequent in Caucasians. Furthermore, during the course of this analysis, we found that cancer-specific somatic mutations can be detected without sequencing normal tissue counterparts. 64% of the germline variants could be excluded using a total of 217 external Japanese exome datasets. We also show that a similar approach may beused for other three ethnic groups, although the discriminative power depends on the ethnic group. We demonstrate that the ATM gene and the PAPPA2 gene could be identified as cancer prognosis related genes. By bypassing the sequencing of normaltissue counterparts, this approach provides a useful means of not only reducing the time and cost of sequencing but also analyzing archive samples, for which normal tissue counterparts are not available.</STUDY_ABSTRACT>
    </DESCRIPTOR>
  </STUDY>
  <STUDY alias="JSUB000003_Study_0001" center_name="Individual" accession="JGAS000006">
    <IDENTIFIERS>
      <SECONDARY_ID>JGAS00000000006</SECONDARY_ID>
    </IDENTIFIERS>
    <DESCRIPTOR>
      <STUDY_TITLE>DNA methylation dynamics during early human development</STUDY_TITLE>
      <STUDY_TYPES>
        <STUDY_TYPE existing_study_type="Other" new_study_type="Whole genome bisulfite sequencing"/>
      </STUDY_TYPES>
      <STUDY_ABSTRACT>DNA methylation is globally reprogrammed during mammalian preimplantation development, which has been well characterized in the mouse but not in other mammals. Here we report on the single base-resolution DNA methylome of human gametes and blastocysts. Near complete demethylation of the paternal genome was apparent, except for tandem repeat-containing CpG-rich regions, whereas the maternal genome was essentially resistant to replication-dependent global demethylation. The human oocyte methylome was characterized by a unique bimodal distribution of gene body methylation, a particular promoter methylation profile and a high proportion of hypomethylated transposable elements. Methylome and transcriptome comparisons between the human and mouse suggested species-specific regulation of many genes including the important DNA methylation regulators. Our findings are essential to understand the unique gene regulatory mechanisms during early human development and will facilitate preimplantation epigenetic diagnosis of human embryos.</STUDY_ABSTRACT>
    </DESCRIPTOR>
  </STUDY>
  <STUDY alias="JSUB000007_Study_0001" center_name="Individual" accession="JGAS000004">
    <IDENTIFIERS>
      <SECONDARY_ID>JGAS00000000004</SECONDARY_ID>
    </IDENTIFIERS>
    <DESCRIPTOR>
      <STUDY_TITLE>Genomic and Genetic Analysis of Brain Tumors and Analysis of Their Clinicopathological Significance</STUDY_TITLE>
      <STUDY_TYPES>
        <STUDY_TYPE existing_study_type="Tumor vs. Matched-Normal"/>
        <STUDY_TYPE existing_study_type="Exome Sequencing"/>
        <STUDY_TYPE existing_study_type="Transcriptome Sequencing"/>
        <STUDY_TYPE existing_study_type="Other" new_study_type="DNA methylation array"/>
      </STUDY_TYPES>
      <STUDY_ABSTRACT>The treatment outcome of glioma patients remains disappointing, and more studies are needed to improve therapeutic strategies. In particular, it is crucial to understand the mechanisms underlying resistance to treatment and malignant transformation, as well as the intratumoral heterogeneity and interaction of tumor cells and host immunity. Recent advances in omics analysis techniques, such as next-generation sequencing (NGS), have enabled us to obtain omics data more easily and accelerated our ability to integrate this information and precisely characterize cases. In our project, we have already collected more than 100 pairs of human glioma/normal tissue samples, of which some are multiple specimens collected from initial and recurrent tumors, and some include multiple specimens collected from different regions within a single tumor. We used our in-house algorithms, composed of alignment and variant calling programs, to analyze omics data from multiple platforms, such as whole-exome sequencing (WES), RNA sequencing (RNA-seq), and methylation array, with our original cohort of glioma patients. Using several informatics tools, the information about genetic and epigenetic status and expression signatures were analyzed. Those data are expected to provide key information for investigating the mechanisms discussed above. Through this project, we hope to improve strategies for personalized therapy based on comprehensive omics data.</STUDY_ABSTRACT>
    </DESCRIPTOR>
    <GRANTS>
      <GRANT grant_id="">
        <TITLE>P-DIRECT: Project for Development of Innovative Research on Cancer Therapeutics</TITLE>
        <AGENCY abbr="MEXT">Ministry of Education, Culture, Sports, Science and Technology</AGENCY>
      </GRANT>
    </GRANTS>
    <PUBLICATIONS>
      <PUBLICATION id="24336570" status="published">
        <DB_TYPE>PUBMED</DB_TYPE>
      </PUBLICATION>
      <PUBLICATION id="28270234" status="published">
        <DB_TYPE>PUBMED</DB_TYPE>
      </PUBLICATION>
    </PUBLICATIONS>
    <STUDY_ATTRIBUTES>
      <STUDY_ATTRIBUTE>
        <TAG>NBDC Number</TAG>
        <VALUE>hum0006</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Submitting organization</TAG>
        <VALUE>Department of Neurosurgery, The University of Tokyo</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Principal Investigator</TAG>
        <VALUE>Nobuhito Saito</VALUE>
      </STUDY_ATTRIBUTE>
    </STUDY_ATTRIBUTES>
  </STUDY>
  <STUDY alias="JSUB000008_Study_0001" center_name="Individual" accession="JGAS000005">
    <IDENTIFIERS>
      <SECONDARY_ID>JGAS00000000005</SECONDARY_ID>
    </IDENTIFIERS>
    <DESCRIPTOR>
      <STUDY_TITLE>Gene expression of human Th17 cells before and after activation</STUDY_TITLE>
      <STUDY_TYPES>
        <STUDY_TYPE existing_study_type="Other" new_study_type="Transcriptome Analysis"/>
      </STUDY_TYPES>
      <STUDY_ABSTRACT>Although gene expression of human Th17 clones has been studies, to date, molecular mechanisms for human Th17 development remain unclear. We have analyzed gene expression of human Th17 cells before and after activation. Th17-cell clones from peripheral blood CD4 T cells cultured with LPS-stimulated dendritic cells derived from monocytes stimulated by TNF were established by a limited dilution method. One of the Th17 clones was proliferated significantly, and high percentages (&gt;70%) of Th17 cells in the cultured cells were maintained by addition of monocytes, IL-1b, and IL-15. CD161+CXCR3- cells (CD161+Th17) in the cultures were sorted and purified up to approximately 97% of IL-17-producing cells after treatment with PMA/ionomycin. Furthermore, these cells were treated with TCR-stimuli, IL-1b, and IL-23 for 2 days, and IL-17-producing Th17 cells (active-Th17) detected by IL-17-catch-up antibodies were sorted. Total RNA sampled from 1x 106 CD161+Th17, active-Th17, na?ve CD4 T cells, or CXCR3+ Th1 cells from combined CD4 T and dendritic cell cultures was used for SAGE. SAGE was performed by using SOLID TM SAGETM kit with barcoding adaptor molecules (Applied Biosystems). DNA sequence was analyzed by using AB5500 Genetic Analyzer (Applied Biosystems), and gene expression was analyzed by using SOLID? SAGETM software (Applied Biosystems). Our data shows high levels of IL-17A-mRNA expression by active-Th17; however, but only slight expression by CD161+Th17. Therefore, the data could provide alteration of gene expression by Th17 cells before and after stimulation. </STUDY_ABSTRACT>
    </DESCRIPTOR>
  </STUDY>
  <STUDY alias="JSUB000009_Study_0001" center_name="Individual" accession="JGAS000007">
    <IDENTIFIERS>
      <SECONDARY_ID>JGAS00000000007</SECONDARY_ID>
    </IDENTIFIERS>
    <DESCRIPTOR>
      <STUDY_TITLE>Research for genetic causes and mechanisms of Hirschsprung's or Hirschsprung's related diseases</STUDY_TITLE>
      <STUDY_TYPES>
        <STUDY_TYPE existing_study_type="Exome Sequencing"/>
        <STUDY_TYPE existing_study_type="Case-Control"/>
        <STUDY_TYPE existing_study_type="Family"/>
      </STUDY_TYPES>
      <STUDY_ABSTRACT>Hirschsprung's disease (HD) is an abdomen disorder which is caused by absence of enteric neurons. HD is a complex genetic disorder and several causing gene mutations have been identified including the receptor tyrosine kinase gene. However, the whole mechanism of HD remains unknown and additional genetic causalities are implicated. To further investigate the genetic causalities of HD, we conducted whole-exome sequencing of patients with HD and unaffected patient's families.</STUDY_ABSTRACT>
    </DESCRIPTOR>
    <PUBLICATIONS>
      <PUBLICATION id="28799054" status="published">
        <DB_TYPE>PUBMED</DB_TYPE>
      </PUBLICATION>
    </PUBLICATIONS>
  </STUDY>
  <STUDY alias="JSUB000010_Study_0001" center_name="Individual" accession="JGAS000008">
    <IDENTIFIERS>
      <SECONDARY_ID>JGAS00000000008</SECONDARY_ID>
    </IDENTIFIERS>
    <DESCRIPTOR>
      <STUDY_TITLE>Research for candidate genes of splenic epidermoid cyst</STUDY_TITLE>
      <STUDY_TYPES>
        <STUDY_TYPE existing_study_type="Exome Sequencing"/>
        <STUDY_TYPE existing_study_type="Family"/>
      </STUDY_TYPES>
      <STUDY_ABSTRACT>Splenic epidermoid cyst is a very rare benign tumor-like lesion filled with fluid or semi-fluid material. It occurs mostly in 2nd or 3rd decades of life with some female dominance. Most cases are asymptomatic and the clinical symptoms are dependent on the size of the cyst. Exome re-sequencing is an efficient strategy to selectively sequence the protein-coding regions of the genome, and has increasingly been used to identify novel genetic variants underlying Mendelian diseases. In this study, exome re-sequencing of 8 Japanese patients with splenic epidermoid cyst were conducted.</STUDY_ABSTRACT>
    </DESCRIPTOR>
  </STUDY>
  <STUDY alias="JSUB000012_Study_0001" center_name="Individual" accession="JGAS000002">
    <IDENTIFIERS>
      <SECONDARY_ID>JGAS00000000002</SECONDARY_ID>
    </IDENTIFIERS>
    <DESCRIPTOR>
      <STUDY_TITLE>Rapid detection of expanded short tandem repeats in personal genomics using hybrid sequencing.</STUDY_TITLE>
      <STUDY_TYPES>
        <STUDY_TYPE existing_study_type="Whole Genome Sequencing"/>
        <STUDY_TYPE existing_study_type="Case Set"/>
      </STUDY_TYPES>
      <STUDY_ABSTRACT>Long expansions of short tandem repeats (STRs); i.e., DNA repeats of 2-6 nucleotides, are associated with some genetic diseases. Cost-efficient high throughput sequencing can quickly produce billions of short reads that would be useful for uncovering disease-associated STRs. However, enumerating STRs in short reads remains largely unexplored because of the difficulty in elucidating STRs much longer than 100 bp, the typical length of short reads. We propose ab initio procedures for sensing and locating long STRs promptly by utilizing the frequency distribution of all STRs and paired-end read information. We validated the reproducibility of this method using biological replicates and used it to locate an STR associated with a brain disease (SCA31). Subsequently, we sequenced this STR site in eleven SCA31 samples using SMRT? sequencing (Pacific Biosciences), determined 2.3-3.1 kb sequences at nucleotide resolution, and revealed that (TGGAA)- and (TAAAATAGAA)-repeat expansions determined the instability of the repeat expansions associated with SCA31. Our method could also identify common STRs, (AAAG)- and (AAAAG)-repeat expansions, which are remarkably expanded at four positions in an SCA31 sample. This is the first proposed method for rapidly finding disease-associated long STRs in personal genomes using hybrid sequencing of short and long reads.</STUDY_ABSTRACT>
    </DESCRIPTOR>
    <GRANTS>
      <GRANT grant_id="22129008">
        <TITLE>Grant-in-Aid for Scientific Research on Innovative Areas</TITLE>
        <AGENCY abbr="MEXT">Ministry of Education, Culture, Sports, Science and Technology</AGENCY>
      </GRANT>
    </GRANTS>
    <PUBLICATIONS>
      <PUBLICATION id="24215022" status="published">
        <DB_TYPE>PUBMED</DB_TYPE>
      </PUBLICATION>
    </PUBLICATIONS>
  </STUDY>
  <STUDY alias="JSUB000015_Study_0001" center_name="Individual" accession="JGAS000015">
    <IDENTIFIERS>
      <SECONDARY_ID>JGAS00000000015</SECONDARY_ID>
    </IDENTIFIERS>
    <DESCRIPTOR>
      <STUDY_TITLE>DNA methylation at HBV integrants and flanking host genomes</STUDY_TITLE>
      <STUDY_TYPES>
        <STUDY_TYPE existing_study_type="Tumor vs. Matched-Normal"/>
      </STUDY_TYPES>
      <STUDY_ABSTRACT>Integration of DNA viruses into the human genome plays an important role in various types of tumors, including hepatitis B virus (HBV)-related hepatocellular carcinoma. However, the molecular details and clinical impact of HBV integration on either the human or HBV epigenomes are unknown. Here, we show that methylation of the integrated HBV DNA is related to the methylation status of the flanking human genome. We developed a next-generation sequencing-based method for structural methylation analysis of integrated viral genomes (denoted G-NaVI). This method is a novel approach that enables enrichment of viral fragments for sequencing using unique baits based on the sequence of the HBV genome. We detected integrated HBV sequences in the genome of the PLC/PRF/5 cell line and found variable levels of methylation within the integrated HBV genomes. Allele-specific methylation analysis revealed that the HBV genome often became significantly methylated when integrated into highly methylated host sites. After integration into unmethylated human genome regions such as promoters, however, the HBV DNA remains unmethylated and may eventually play an important role in tumorigenesis. The observed dynamic changes in DNA methylation of the host and viral genomes may functionally affect the biological behavior of HBV. These findings may impact public health given that millions of people worldwide are carriers of HBV. We also believe our assay will be a powerful tool to increase our understanding of the various types of DNA virus-associated tumorigenesis.</STUDY_ABSTRACT>
    </DESCRIPTOR>
    <GRANTS>
      <GRANT grant_id="23590964">
        <TITLE>Sequence analysis at HBV integrants and flanking host genomes</TITLE>
        <AGENCY abbr="JSPS KAKEN">Grants-in-Aid for Scientific Research</AGENCY>
      </GRANT>
    </GRANTS>
    <PUBLICATIONS>
      <PUBLICATION id="2034275" status="published">
        <DB_TYPE>PUBMED</DB_TYPE>
      </PUBLICATION>
      <PUBLICATION id="8138251" status="published">
        <DB_TYPE>PUBMED</DB_TYPE>
      </PUBLICATION>
      <PUBLICATION id="8666388" status="published">
        <DB_TYPE>PUBMED</DB_TYPE>
      </PUBLICATION>
    </PUBLICATIONS>
    <STUDY_LINKS>
      <STUDY_LINK>
        <URL_LINK>
          <LABEL>http://www.marianna-u.ac.jp/univ_en/index.html</LABEL>
          <URL>http://www.marianna-u.ac.jp/univ_en/index.html</URL>
        </URL_LINK>
      </STUDY_LINK>
    </STUDY_LINKS>
    <STUDY_ATTRIBUTES>
      <STUDY_ATTRIBUTE>
        <TAG>NBDC Number</TAG>
        <VALUE>hum0011</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Registration date</TAG>
        <VALUE>2015-01-13</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Submitting organization</TAG>
        <VALUE>St.Marianna University, School of Medicine</VALUE>
      </STUDY_ATTRIBUTE>
    </STUDY_ATTRIBUTES>
  </STUDY>
  <STUDY alias="JSUB000016_Study_0001" center_name="Individual" accession="JGAS000012">
    <IDENTIFIERS>
      <SECONDARY_ID>JGAS00000000012</SECONDARY_ID>
    </IDENTIFIERS>
    <DESCRIPTOR>
      <STUDY_TITLE>Genotype data from Nagahama cohort project</STUDY_TITLE>
      <STUDY_TYPES>
        <STUDY_TYPE existing_study_type="Cohort"/>
        <STUDY_TYPE existing_study_type="Population"/>
        <STUDY_TYPE existing_study_type="GWAS"/>
      </STUDY_TYPES>
      <STUDY_ABSTRACT>Genotype data with basic phenotypes (age and gender) for 3693 samples from Nagahama Cohort project are provided. Genotyping are performed by A)Human610-Quad?B)HumanOmni2.5-4?C)HumanOmni2.5-8?D)HumanOmni2.5S?E)HumanCoreExome?F)HumanExome BeadChip from Illumina Inc. 1708, 1017, 185, 112, 479 and 192 samples are genotyped by A only, B only, C only, A+B+E, B+D+F and C+D+F respectively.</STUDY_ABSTRACT>
    </DESCRIPTOR>
    <PUBLICATIONS>
      <PUBLICATION id="24919509" status="published">
        <DB_TYPE>PUBMED</DB_TYPE>
      </PUBLICATION>
    </PUBLICATIONS>
    <STUDY_LINKS>
      <STUDY_LINK>
        <URL_LINK>
          <LABEL>http://www.city.nagahama.shiga.jp/index.cfm/11,3709,96,558,html</LABEL>
          <URL>http://www.city.nagahama.shiga.jp/index.cfm/11,3709,96,558,html</URL>
        </URL_LINK>
      </STUDY_LINK>
      <STUDY_LINK>
        <URL_LINK>
          <LABEL>http://zeroji-club.com/0ji_kohot.html</LABEL>
          <URL>http://zeroji-club.com/0ji_kohot.html</URL>
        </URL_LINK>
      </STUDY_LINK>
    </STUDY_LINKS>
  </STUDY>
  <STUDY alias="JSUB000017_Study_0001" center_name="Individual" accession="JGAS000009">
    <IDENTIFIERS>
      <SECONDARY_ID>JGAS00000000009</SECONDARY_ID>
    </IDENTIFIERS>
    <DESCRIPTOR>
      <STUDY_TITLE>Whole exome sequence analysis in multiple system atrophy</STUDY_TITLE>
      <STUDY_TYPES>
        <STUDY_TYPE existing_study_type="Case-Control"/>
      </STUDY_TYPES>
      <STUDY_ABSTRACT>To identify a susceptible gene for multiple system atrophy, exome sequence analysis was conducted in 14 patients and 7 controls.</STUDY_ABSTRACT>
    </DESCRIPTOR>
  </STUDY>
  <STUDY alias="JSUB000018_Study_0001" center_name="Individual" accession="JGAS000011">
    <IDENTIFIERS>
      <SECONDARY_ID>JGAS00000000011</SECONDARY_ID>
    </IDENTIFIERS>
    <DESCRIPTOR>
      <STUDY_TITLE>Systematic identification of long non-coding RNAs potentially involved in gastrointestinal carncer</STUDY_TITLE>
      <STUDY_TYPES>
        <STUDY_TYPE existing_study_type="Transcriptome Sequencing"/>
        <STUDY_TYPE existing_study_type="Tumor vs. Matched-Normal"/>
      </STUDY_TYPES>
      <STUDY_ABSTRACT>Recent work has suggested various important functions and molecular mechanisms for long non-coding RNAs (lncRNAs) and they are also thought to play critical roles in cancer. However the importance of lncRNAs in cancer biology is still unclear. In this study, we aim to comprehensively identify novel lncRNAs that are critically involved in tumorigenesis and progression in gastrointestinal cancer.</STUDY_ABSTRACT>
    </DESCRIPTOR>
    <GRANTS>
      <GRANT grant_id="221S0003">
        <TITLE>Genome Science</TITLE>
        <AGENCY abbr="MEXT">Japanese Ministry of Education, Culture, Sports, Science and Technology</AGENCY>
      </GRANT>
    </GRANTS>
  </STUDY>
  <STUDY alias="JSUB000019_Study_0001" center_name="Individual" accession="JGAS000013">
    <IDENTIFIERS>
      <SECONDARY_ID>JGAS00000000013</SECONDARY_ID>
    </IDENTIFIERS>
    <DESCRIPTOR>
      <STUDY_TITLE>Whole exome sequence analysis in sporadic amyotrophic lateral sclerosis</STUDY_TITLE>
      <STUDY_TYPES>
        <STUDY_TYPE existing_study_type="Case Set"/>
      </STUDY_TYPES>
      <STUDY_ABSTRACT>To identify a susceptible gene for amyotrophic lateral sclerosis, exome sequence analysis was conducted in patients with amyotrophic lateral sclerosis and control subjects to perform whole genome association studies. In this data set, exome sequencing data of 11 patients with amyotrophic lateral sclerosis was included.</STUDY_ABSTRACT>
    </DESCRIPTOR>
  </STUDY>
  <STUDY alias="JSUB000020_Study_0001" center_name="Individual" accession="JGAS000014">
    <IDENTIFIERS>
      <SECONDARY_ID>JGAS00000000014</SECONDARY_ID>
    </IDENTIFIERS>
    <DESCRIPTOR>
      <STUDY_TITLE>Genetic analysis in monozygotic twins discordant for bipolar disorder</STUDY_TITLE>
      <STUDY_TYPES>
        <STUDY_TYPE existing_study_type="Control Set"/>
      </STUDY_TYPES>
      <STUDY_ABSTRACT>To identify genes relevant to bipolar disorder, an exome sequence analysis was conducted in 3 pairs of healthy monozygotic twins as control twins in this study. In addition to this data set, an exome sequence analysis was also conducted in several monozygotic twins discordant for bipolar disorder.</STUDY_ABSTRACT>
    </DESCRIPTOR>
  </STUDY>
  <STUDY alias="JSUB000021_Study_0001" center_name="Individual" accession="JGAS000017">
    <IDENTIFIERS>
      <SECONDARY_ID>JGAS00000000017</SECONDARY_ID>
    </IDENTIFIERS>
    <DESCRIPTOR>
      <STUDY_TITLE>Leukemic evolution of donor-derived cells harboring IDH2 and DNMT3A mutations after allogeneic stem cell transplantation</STUDY_TITLE>
      <STUDY_TYPES>
        <STUDY_TYPE existing_study_type="Exome Sequencing"/>
        <STUDY_TYPE existing_study_type="Case-Control"/>
      </STUDY_TYPES>
      <STUDY_ABSTRACT>An individual with acute myeloid leukemia (AML) received peripheral blood stem cell (PBSC) transplantation, but later experienced relapse. Whole-exome sequencing of bone marrow cells obtained from different stages of this patient as well as PBSC of the donor revealed that relapsed AML was not the regrowth of the original leukemic clones, but donor cell leukemia (DCL). Interestingly, some of the oncogenic mutations found in DCL were already present at a low frequency in the donor PBSC. Target deep sequencing of these genes indeed confirmed this observation, and revealed that the emergence of additional oncogenic mutations triggered leukemic evolution.</STUDY_ABSTRACT>
    </DESCRIPTOR>
    <STUDY_ATTRIBUTES>
      <STUDY_ATTRIBUTE>
        <TAG>NBDC Number</TAG>
        <VALUE>hum0022</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Registration date</TAG>
        <VALUE>2015-01-27</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Submitting organization</TAG>
        <VALUE>Department of Cellular Signaling, Graduate School of Medicine, The University of Tokyo</VALUE>
      </STUDY_ATTRIBUTE>
    </STUDY_ATTRIBUTES>
  </STUDY>
  <STUDY alias="JSUB000022_Study_0001" center_name="Individual" accession="JGAS000016">
    <IDENTIFIERS>
      <SECONDARY_ID>JGAS00000000016</SECONDARY_ID>
    </IDENTIFIERS>
    <DESCRIPTOR>
      <STUDY_TITLE>Genetic analysis in lifestyle-related disease, arteriosclerotic disease, and aging-related diseases.</STUDY_TITLE>
      <STUDY_TYPES>
        <STUDY_TYPE existing_study_type="Case Set"/>
      </STUDY_TYPES>
      <STUDY_ABSTRACT>Exome sequence analysis was conducted in patients with hypertension (Stage 3). Rare variants in candidate susceptible genes discovered by previous GWASs were prioritised and further analysed for an additional case-control association study.</STUDY_ABSTRACT>
    </DESCRIPTOR>
    <GRANTS>
      <GRANT grant_id="221">
        <TITLE>Genome Science</TITLE>
        <AGENCY abbr="MEXT">Japanese Ministry of Education, Culture, Sports, Science and Technology</AGENCY>
      </GRANT>
    </GRANTS>
    <STUDY_ATTRIBUTES>
      <STUDY_ATTRIBUTE>
        <TAG>NBDC Number</TAG>
        <VALUE>hum0023</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Registration date</TAG>
        <VALUE>2015-01-21</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Submitting organization</TAG>
        <VALUE>Department of Geriatric Medicine and Neurology, Graduate School of Medicine, Ehime University</VALUE>
      </STUDY_ATTRIBUTE>
    </STUDY_ATTRIBUTES>
  </STUDY>
  <STUDY alias="JSUB000025_Study_0001" center_name="Individual" accession="JGAS000023">
    <IDENTIFIERS>
      <SECONDARY_ID>JGAS00000000023</SECONDARY_ID>
    </IDENTIFIERS>
    <DESCRIPTOR>
      <STUDY_TITLE>Whole-exome sequencing of MDS and related myeloid neoplasms</STUDY_TITLE>
      <STUDY_TYPES>
        <STUDY_TYPE existing_study_type="Tumor vs. Matched-Normal"/>
      </STUDY_TYPES>
      <STUDY_ABSTRACT>Myelodysplastic syndromes(MDS) and related myeloid neoplasms (myelodysplasia) are heterogenous group of myeloid neoplasms characterized by deregulated blood cell production with evidence of myeloid dysplasia. Previously, frequent mutations in genes on RNA splicing machinery and DNA methylation pathway have been identified. However, comprehensive analysis of genetic alterations have not performed on a large cohort of these diseases. Therefore, in this study, we performed whole-exome sequencing of MDS and related myeloid neoplasms.</STUDY_ABSTRACT>
    </DESCRIPTOR>
    <GRANTS>
      <GRANT grant_id="23249052">
        <TITLE>Grants-in-Aid from the Ministry of Health, Labor and Welfare of Japan and KAKENHI</TITLE>
        <AGENCY abbr="MHLW, MEXT">Ministry of Health, Labor and Welfare of Japan, Ministry of Education, Culture, Sports, Science and Technology</AGENCY>
      </GRANT>
      <GRANT grant_id="22134006">
        <TITLE>Grants-in-Aid from the Ministry of Health, Labor and Welfare of Japan and KAKENHI</TITLE>
        <AGENCY abbr="MHLW, MEXT">Ministry of Health, Labor and Welfare of Japan, Ministry of Education, Culture, Sports, Science and Technology</AGENCY>
      </GRANT>
      <GRANT grant_id="21790907">
        <TITLE>Grants-in-Aid from the Ministry of Health, Labor and Welfare of Japan and KAKENHI</TITLE>
        <AGENCY abbr="MHLW, MEXT">Ministry of Health, Labor and Welfare of Japan, Ministry of Education, Culture, Sports, Science and Technology</AGENCY>
      </GRANT>
      <GRANT grant_id="08C46598a">
        <TITLE>the Industrial Technology Research Grant Program from the New Energy and Industrial Technology Development Organization (NEDO)</TITLE>
        <AGENCY abbr="METI">Ministry of Economy, Trade and Industry</AGENCY>
      </GRANT>
      <GRANT grant_id="">
        <TITLE>the project for development of innovative research on cancer therapies (p-direct)</TITLE>
        <AGENCY abbr="MEXT">Ministry of Education, Culture, Sports, Science and Technology</AGENCY>
      </GRANT>
    </GRANTS>
    <PUBLICATIONS>
      <PUBLICATION id="24056718" status="published">
        <DB_TYPE>PUBMED</DB_TYPE>
      </PUBLICATION>
      <PUBLICATION id="24220272" status="published">
        <DB_TYPE>PUBMED</DB_TYPE>
      </PUBLICATION>
    </PUBLICATIONS>
    <STUDY_LINKS>
      <STUDY_LINK>
        <URL_LINK>
          <LABEL>http://plaza.umin.ac.jp/kyoto_tumorpatho/</LABEL>
          <URL>http://plaza.umin.ac.jp/kyoto_tumorpatho/</URL>
        </URL_LINK>
      </STUDY_LINK>
    </STUDY_LINKS>
    <STUDY_ATTRIBUTES>
      <STUDY_ATTRIBUTE>
        <TAG>NBDC Number</TAG>
        <VALUE>hum0024</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Registration date</TAG>
        <VALUE>2015-04-10</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Submitting organization</TAG>
        <VALUE>Kyoto University</VALUE>
      </STUDY_ATTRIBUTE>
    </STUDY_ATTRIBUTES>
  </STUDY>
  <STUDY alias="JSUB000027_Study_0001" center_name="Individual" accession="JGAS000021">
    <IDENTIFIERS>
      <SECONDARY_ID>JGAS00000000021</SECONDARY_ID>
    </IDENTIFIERS>
    <DESCRIPTOR>
      <STUDY_TITLE>Genomics characterization of primary central nervous system lymphoma</STUDY_TITLE>
      <STUDY_TYPES>
        <STUDY_TYPE existing_study_type="Exome Sequencing"/>
        <STUDY_TYPE existing_study_type="Tumor vs. Matched-Normal"/>
      </STUDY_TYPES>
      <STUDY_ABSTRACT>Primary central nervous system lymphoma (PCNSL) is a rare malignancy confined to the central nervous system (CNS). Despite low tendency of systemic dissemination, its prognosis is poor with median overall survival of 2?4 years. Due to its rarity, knowledge of genomic alterations underling PCNSL pathogenesis is severely limited. Here we performed whole-exome sequencing on 44 PCNSL and paired normal specimens, revealing high penetrance of nonsynonymous somatic mutations in PIM1 (95.5%), BTG2 (88.6%) and MYD88 (81.8%). Interestingly we found oncogenic mutations in GRB2, and this effect was cancelled when transformed cells are treated with inhibitors to downstream kinases MAP2K1/2. Further, when tumor cells carries MYD88 mutations, the same mutations were also found at low frequency in peripheral blood mononuclear cells (PBMNC), implying that MYD88 mutation?positive precancerous cells originate outside CNS and develop to lymphoma with additional genetic hits that fit the CNS environment.</STUDY_ABSTRACT>
    </DESCRIPTOR>
    <PUBLICATIONS>
      <PUBLICATION id="26757737" status="published">
        <DB_TYPE>PUBMED</DB_TYPE>
      </PUBLICATION>
    </PUBLICATIONS>
    <STUDY_ATTRIBUTES>
      <STUDY_ATTRIBUTE>
        <TAG>NBDC Number</TAG>
        <VALUE>hum0017</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Registration date</TAG>
        <VALUE>2015-03-05</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Submitting organization</TAG>
        <VALUE>Department of Cellular Signaling, Graduate School of Medicine, The University of Tokyo</VALUE>
      </STUDY_ATTRIBUTE>
    </STUDY_ATTRIBUTES>
  </STUDY>
  <STUDY alias="JSUB000029_Study_0001" center_name="Individual" accession="JGAS000018">
    <IDENTIFIERS>
      <SECONDARY_ID>JGAS00000000018</SECONDARY_ID>
    </IDENTIFIERS>
    <DESCRIPTOR>
      <STUDY_TITLE>An imputation reference panel of HLA variants in Japanese</STUDY_TITLE>
      <STUDY_TYPES>
        <STUDY_TYPE existing_study_type="Control Set"/>
        <STUDY_TYPE existing_study_type="Population"/>
        <STUDY_TYPE existing_study_type="Cohort"/>
      </STUDY_TYPES>
      <STUDY_ABSTRACT>We constructed a human leukocyte antigen (HLA) imputation reference panel of Japanese ancestry, which includes genotype data of HLA alleles and single nucleotide polymorphisms (SNPs) in the major histocompatibility complex (MHC) region of 908 healthy Japanese controls.
  Variant locations are based on NCBI build 36.</STUDY_ABSTRACT>
    </DESCRIPTOR>
    <GRANTS>
      <GRANT grant_id="">
        <TITLE>Tailor-made Medical Treatment Program (BioBank Japan: BBJ)</TITLE>
        <AGENCY abbr="MEXT">Ministry of Education, Culture, Sports, Sciences and Technology of the Japanese government</AGENCY>
      </GRANT>
    </GRANTS>
    <PUBLICATIONS>
      <PUBLICATION id="23762245" status="published">
        <DB_TYPE>PUBMED</DB_TYPE>
      </PUBLICATION>
      <PUBLICATION id="26029868" status="published">
        <DB_TYPE>PUBMED</DB_TYPE>
      </PUBLICATION>
    </PUBLICATIONS>
    <STUDY_LINKS>
      <STUDY_LINK>
        <URL_LINK>
          <LABEL>http://www.broadinstitute.org/mpg/snp2hla/</LABEL>
          <URL>http://www.broadinstitute.org/mpg/snp2hla/</URL>
        </URL_LINK>
      </STUDY_LINK>
      <STUDY_LINK>
        <URL_LINK>
          <LABEL>http://biobankjp.org/english/index.html</LABEL>
          <URL>http://biobankjp.org/english/index.html</URL>
        </URL_LINK>
      </STUDY_LINK>
    </STUDY_LINKS>
    <STUDY_ATTRIBUTES>
      <STUDY_ATTRIBUTE>
        <TAG>NBDC Number</TAG>
        <VALUE>hum0028</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Registration date</TAG>
        <VALUE>2015-03-04</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Submitting organization</TAG>
        <VALUE>RIKEN</VALUE>
      </STUDY_ATTRIBUTE>
    </STUDY_ATTRIBUTES>
  </STUDY>
  <STUDY alias="JSUB000030_Study_0001" center_name="Individual" accession="JGAS000024">
    <IDENTIFIERS>
      <SECONDARY_ID>JGAS00000000024</SECONDARY_ID>
    </IDENTIFIERS>
    <DESCRIPTOR>
      <STUDY_TITLE>Identification of genetic polymorphism on aggressive periodontitis</STUDY_TITLE>
      <STUDY_TYPES>
        <STUDY_TYPE existing_study_type="Case Set"/>
      </STUDY_TYPES>
      <STUDY_ABSTRACT>Periodontitis is an inflammatory disease with loss of gingival tissue and alveolar bone. Aggressive periodontitis is rapidly progressive form of periodontitis in young people. It has been demonstrated that the susceptibility to AgP is influenced by genetic risk factors. However few were established as a risk factor for aggressive periodontitis. To identify genetic risk factors for aggressive periodontitis in Japanese population, we conducted the exome sequence of unrelated patients. </STUDY_ABSTRACT>
    </DESCRIPTOR>
    <STUDY_ATTRIBUTES>
      <STUDY_ATTRIBUTE>
        <TAG>NBDC Number</TAG>
        <VALUE>hum0027</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Registration date</TAG>
        <VALUE>2015-03-26</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Submitting organization</TAG>
        <VALUE>Department of periodontology, Osaka University Graduate School of Dentistry</VALUE>
      </STUDY_ATTRIBUTE>
    </STUDY_ATTRIBUTES>
  </STUDY>
  <STUDY alias="JSUB000031_Study_0001" center_name="Individual" accession="JGAS000022">
    <IDENTIFIERS>
      <SECONDARY_ID>JGAS00000000022</SECONDARY_ID>
    </IDENTIFIERS>
    <DESCRIPTOR>
      <STUDY_TITLE>Integrated copy number and expression analysis identifies profiles of whole-arm chromosomal alterations and subgroups with favorable outcome in ovarian clear cell carcinomas</STUDY_TITLE>
      <STUDY_TYPES>
        <STUDY_TYPE existing_study_type="Tumor vs. Matched-Normal"/>
        <STUDY_TYPE existing_study_type="Other" new_study_type="Cancer copy number analysis"/>
      </STUDY_TYPES>
      <STUDY_ABSTRACT>Ovarian clear cell carcinoma (CCC) is generally associated with chemoresistance and poor clinical outcome, even with early diagnosis; whereas high-grade serous carcinomas (SCs) and endometrioid carcinomas (ECs) are commonly chemosensitive at advanced stages. Although an integrated genomic analysis of SC has been performed, conclusive views on copy number and expression profiles for CCC are still limited. In this study, we performed single nucleotide polymorphism arrays in 57 (31 CCCs, 14 SCs, and 12 ECs) and expression microarrays in 55 epithelial ovarian cancers (25 CCCs, 16 SCs, and 14 ECs), and then evaluated PIK3CA mutations and ARID1A expression in CCCs. SNP array analysis classified 13% of CCCs into a cluster with high frequency and focal range of copy number alterations (CNAs), significantly lower than for SCs (93%, P &lt; 0.01) and ECs (50%, P = 0.017). The ratio of whole-arm to all CNAs was higher in CCCs (46.9%) than SCs (21.7%) (P &lt; 0.0001). SCs with loss of heterozygosity (LOH) of BRCA1 (85%) also had LOH of NF1 and TP53, and LOH of BRCA2 (62%) coexisted with LOH of RB1 and TP53. Microarray analysis classified CCCs into three clusters. One cluster (CCC-2, n = 10) showed more favorable prognosis than the others (CCC-1and CCC-3) (P = 0.041). Coexistent alterations of PIK3CA and ARID1A were more common in CCC-1 and CCC-3 (7/11, 64%) than in CCC-2 (0/10, 0%) (P &lt; 0.01). Being in cluster CCC-2 was an independent favorable prognostic factor in CCC. In conclusion, CCC was characterized by a high ratio of whole-arm CNAs; whereas CNAs in SC were mainly focal, but preferentially caused LOH of well-known tumor suppressor genes. As such, expression profiles might be useful for sub-classification of CCC, and might provide useful information on prognosis.</STUDY_ABSTRACT>
    </DESCRIPTOR>
    <STUDY_ATTRIBUTES>
      <STUDY_ATTRIBUTE>
        <TAG>NBDC Number</TAG>
        <VALUE>hum0030</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Registration date</TAG>
        <VALUE>2014-01-01</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Submitting organization</TAG>
        <VALUE>Department of Obstetrics and Gynecology, Faculty of Medicine, The University of Tokyo</VALUE>
      </STUDY_ATTRIBUTE>
    </STUDY_ATTRIBUTES>
  </STUDY>
  <STUDY alias="JSUB000033_Study_0001" center_name="Individual" accession="JGAS000026">
    <IDENTIFIERS>
      <SECONDARY_ID>JGAS00000000026</SECONDARY_ID>
    </IDENTIFIERS>
    <DESCRIPTOR>
      <STUDY_TITLE>Epigenome mapping in purified cells of the digestive and urogenital organs: Participation in International Human Epigenome Consortium (IHEC) (WGBS)</STUDY_TITLE>
      <STUDY_TYPES>
        <STUDY_TYPE existing_study_type="Control Set"/>
        <STUDY_TYPE existing_study_type="Case Set"/>
        <STUDY_TYPE existing_study_type="Other" new_study_type="Whole-genome bisulfite sequencing (WGBS)"/>
      </STUDY_TYPES>
      <STUDY_ABSTRACT>The aim of this study is to participate in International Human Epigenome Consortium (IHEC, http://ihec-epigenomes.org/), through disclosure of quality epigenome profiles of various normal cell lineages and diseased cells purified from surgically resected materials of multiple Japanese people.</STUDY_ABSTRACT>
    </DESCRIPTOR>
    <GRANTS>
      <GRANT grant_id="0">
        <TITLE>Core Research for Evolutional Science and Technology (CREST)</TITLE>
        <AGENCY abbr="AMED">Japan Agency for Medical Research and Development</AGENCY>
      </GRANT>
    </GRANTS>
    <PUBLICATIONS>
      <PUBLICATION id="24592273" status="published">
        <DB_TYPE>PUBMED</DB_TYPE>
      </PUBLICATION>
      <PUBLICATION id="25324297" status="published">
        <DB_TYPE>PUBMED</DB_TYPE>
      </PUBLICATION>
      <PUBLICATION id="22649061" status="published">
        <DB_TYPE>PUBMED</DB_TYPE>
      </PUBLICATION>
    </PUBLICATIONS>
    <STUDY_LINKS>
      <STUDY_LINK>
        <URL_LINK>
          <LABEL>http://crest-ihec.jp/</LABEL>
          <URL>http://crest-ihec.jp/</URL>
        </URL_LINK>
      </STUDY_LINK>
      <STUDY_LINK>
        <URL_LINK>
          <LABEL>http://ihec-epigenomes.org/</LABEL>
          <URL>http://ihec-epigenomes.org/</URL>
        </URL_LINK>
      </STUDY_LINK>
    </STUDY_LINKS>
    <STUDY_ATTRIBUTES>
      <STUDY_ATTRIBUTE>
        <TAG>NBDC Number</TAG>
        <VALUE>hum0032</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Registration date</TAG>
        <VALUE>2015-04-02</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Submitting organization</TAG>
        <VALUE>Division of Moleuclar Pathology, National Cancer Center Rsearch Institute</VALUE>
      </STUDY_ATTRIBUTE>
    </STUDY_ATTRIBUTES>
  </STUDY>
  <STUDY alias="JSUB000034_Study_0001" center_name="Individual" accession="JGAS000027">
    <IDENTIFIERS>
      <SECONDARY_ID>JGAS00000000027</SECONDARY_ID>
    </IDENTIFIERS>
    <DESCRIPTOR>
      <STUDY_TITLE>Epigenome mapping in purified cells of the digestive and urogenital organs: Participation in International Human Epigenome Consortium (IHEC) (ChIP-seq)</STUDY_TITLE>
      <STUDY_TYPES>
        <STUDY_TYPE existing_study_type="Control Set"/>
        <STUDY_TYPE existing_study_type="Case Set"/>
        <STUDY_TYPE existing_study_type="Other" new_study_type="Chromatin immunoprecipitation sequencing (ChIP-seq)"/>
      </STUDY_TYPES>
      <STUDY_ABSTRACT>The aim of this study is to participate in International Human Epigenome Consortium (IHEC, http://ihec-epigenomes.org/), through disclosure of quality epigenome profiles of various normal cell lineages and diseased cells purified from surgically resected materials of multiple Japanese people.</STUDY_ABSTRACT>
    </DESCRIPTOR>
    <GRANTS>
      <GRANT grant_id="0">
        <TITLE>Core Research for Evolutional Science and Technology (CREST)</TITLE>
        <AGENCY abbr="AMED">Japan Agency for Medical Research and Development</AGENCY>
      </GRANT>
    </GRANTS>
    <PUBLICATIONS>
      <PUBLICATION id="24592273" status="published">
        <DB_TYPE>PUBMED</DB_TYPE>
      </PUBLICATION>
    </PUBLICATIONS>
    <STUDY_LINKS>
      <STUDY_LINK>
        <URL_LINK>
          <LABEL>http://crest-ihec.jp/</LABEL>
          <URL>http://crest-ihec.jp/</URL>
        </URL_LINK>
      </STUDY_LINK>
      <STUDY_LINK>
        <URL_LINK>
          <LABEL>http://ihec-epigenomes.org/</LABEL>
          <URL>http://ihec-epigenomes.org/</URL>
        </URL_LINK>
      </STUDY_LINK>
    </STUDY_LINKS>
    <STUDY_ATTRIBUTES>
      <STUDY_ATTRIBUTE>
        <TAG>NBDC Number</TAG>
        <VALUE>hum0032</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Registration date</TAG>
        <VALUE>2015-04-02</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Submitting organization</TAG>
        <VALUE>Division of Moleuclar Pathology, National Cancer Center Rsearch Institute</VALUE>
      </STUDY_ATTRIBUTE>
    </STUDY_ATTRIBUTES>
  </STUDY>
  <STUDY alias="JSUB000035_Study_0001" center_name="Individual" accession="JGAS000028">
    <IDENTIFIERS>
      <SECONDARY_ID>JGAS00000000028</SECONDARY_ID>
    </IDENTIFIERS>
    <DESCRIPTOR>
      <STUDY_TITLE>Epigenome mapping in purified cells of the digestive and urogenital organs: Participation in International Human Epigenome Consortium (IHEC) (RNA-Seq)</STUDY_TITLE>
      <STUDY_TYPES>
        <STUDY_TYPE existing_study_type="Control Set"/>
        <STUDY_TYPE existing_study_type="Case Set"/>
        <STUDY_TYPE existing_study_type="Transcriptome Sequencing"/>
      </STUDY_TYPES>
      <STUDY_ABSTRACT>The aim of this study is to participate in International Human Epigenome Consortium (IHEC, http://ihec-epigenomes.org/), through disclosure of quality epigenome profiles of various normal cell lineages and diseased cells purified from surgically resected materials of multiple Japanese people.</STUDY_ABSTRACT>
    </DESCRIPTOR>
    <GRANTS>
      <GRANT grant_id="0">
        <TITLE>Core Research for Evolutional Science and Technology (CREST)</TITLE>
        <AGENCY abbr="AMED">Japan Agency for Medical Research and Development</AGENCY>
      </GRANT>
    </GRANTS>
    <PUBLICATIONS>
      <PUBLICATION id="24592273" status="published">
        <DB_TYPE>PUBMED</DB_TYPE>
      </PUBLICATION>
    </PUBLICATIONS>
    <STUDY_LINKS>
      <STUDY_LINK>
        <URL_LINK>
          <LABEL>http://crest-ihec.jp/</LABEL>
          <URL>http://crest-ihec.jp/</URL>
        </URL_LINK>
      </STUDY_LINK>
      <STUDY_LINK>
        <URL_LINK>
          <LABEL>http://ihec-epigenomes.org/</LABEL>
          <URL>http://ihec-epigenomes.org/</URL>
        </URL_LINK>
      </STUDY_LINK>
    </STUDY_LINKS>
    <STUDY_ATTRIBUTES>
      <STUDY_ATTRIBUTE>
        <TAG>NBDC Number</TAG>
        <VALUE>hum0032</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Registration date</TAG>
        <VALUE>2015-04-02</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Submitting organization</TAG>
        <VALUE>Division of Moleuclar Pathology, National Cancer Center Rsearch Institute</VALUE>
      </STUDY_ATTRIBUTE>
    </STUDY_ATTRIBUTES>
  </STUDY>
  <STUDY alias="JSUB000036_Study_0001" center_name="Individual" accession="JGAS000025">
    <IDENTIFIERS>
      <SECONDARY_ID>JGAS00000000025</SECONDARY_ID>
    </IDENTIFIERS>
    <DESCRIPTOR>
      <STUDY_TITLE>TEST1</STUDY_TITLE>
      <STUDY_TYPES>
        <STUDY_TYPE existing_study_type="Other" new_study_type="TEST1"/>
      </STUDY_TYPES>
      <STUDY_ABSTRACT>TEST1</STUDY_ABSTRACT>
      <RELATED_STUDIES>
        <RELATED_STUDY>
          <RELATED_LINK>
            <DB>sra</DB>
            <ID>DRA000000</ID>
            <LABEL>DRA000000</LABEL>
          </RELATED_LINK>
          <IS_PRIMARY>false</IS_PRIMARY>
        </RELATED_STUDY>
      </RELATED_STUDIES>
    </DESCRIPTOR>
    <STUDY_LINKS>
      <STUDY_LINK>
        <URL_LINK>
          <LABEL>DDBJ Center</LABEL>
          <URL>https://www.ddbj.nig.ac.jp</URL>
        </URL_LINK>
      </STUDY_LINK>
    </STUDY_LINKS>
    <STUDY_ATTRIBUTES>
      <STUDY_ATTRIBUTE>
        <TAG>NBDC Number</TAG>
        <VALUE/>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Registration date</TAG>
        <VALUE>2015-04-22</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Submitting organization</TAG>
        <VALUE>DDBJ</VALUE>
      </STUDY_ATTRIBUTE>
    </STUDY_ATTRIBUTES>
  </STUDY>
  <STUDY alias="JSUB000041_Study_0001" center_name="Individual" accession="JGAS000037">
    <IDENTIFIERS>
      <SECONDARY_ID>JGAS00000000037</SECONDARY_ID>
    </IDENTIFIERS>
    <DESCRIPTOR>
      <STUDY_TITLE>Development of molecular targeted therapy for small cell lung cancer by comprehensive genome analysis</STUDY_TITLE>
      <STUDY_TYPES>
        <STUDY_TYPE existing_study_type="Case Set"/>
        <STUDY_TYPE existing_study_type="Tumor vs. Matched-Normal"/>
        <STUDY_TYPE existing_study_type="Exome Sequencing"/>
      </STUDY_TYPES>
      <STUDY_ABSTRACT>Aims: Identifying new therapeutic targets of small cell lung cancer (SCLC), genome-wide mutation analysis has been performed.
  Methods: Genomic DNA was extracted from formalin-fixed or methanol-fixed tissue samples. 71 Mb of DNA fragments containing whole coding exons were concentrated using SureSelect Human All Exon V4+UTRs Kit (Agilent Technologies) followed by 100-bp paired end sequencing by HiSeq 2000 (Illumina).
  Participants/Materials: 51 of 1042 cases of pathologically diagnosed small seen lung cancer that were registered to National Cancer Hospital East Lung Cancer Database in 1992-2012, and which surgically resected or biopsy samples were suitable for DNA extraction for further analyses.</STUDY_ABSTRACT>
    </DESCRIPTOR>
    <GRANTS>
      <GRANT grant_id="24300346">
        <TITLE>Exploring therapeutic targets and investigating molecular carcinogenesis of small cell lung cancer by comprehensive genome analysis</TITLE>
        <AGENCY abbr="KAKENHI">Grants-in-Aid for Scientific Research, Ministry of Education, Culture, Sports , Science and Technology </AGENCY>
      </GRANT>
      <GRANT grant_id="26870876">
        <TITLE>Development of molecular targeted therapy for large cell neuroendocrine carcinoma by targeting genome sequencing</TITLE>
        <AGENCY abbr="KAKENHI">Grants-in-Aid for Scientific Research, Ministry of Education, Culture, Sports , Science and Technology </AGENCY>
      </GRANT>
      <GRANT grant_id="23">
        <TITLE>Development of the biostatistics and bioinformatics platforms for cancer research</TITLE>
        <AGENCY abbr="NCC">National Cancer Center</AGENCY>
      </GRANT>
    </GRANTS>
    <PUBLICATIONS>
      <PUBLICATION id="25122428" status="published">
        <DB_TYPE>PUBMED</DB_TYPE>
      </PUBLICATION>
    </PUBLICATIONS>
    <STUDY_ATTRIBUTES>
      <STUDY_ATTRIBUTE>
        <TAG>NBDC Number</TAG>
        <VALUE>hum0034</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Registration date</TAG>
        <VALUE>2014-01-01</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Submitting organization</TAG>
        <VALUE>National Cancer Center</VALUE>
      </STUDY_ATTRIBUTE>
    </STUDY_ATTRIBUTES>
  </STUDY>
  <STUDY alias="JSUB000042_Study_0001" center_name="Individual" accession="JGAS000036">
    <IDENTIFIERS>
      <SECONDARY_ID>JGAS00000000036</SECONDARY_ID>
    </IDENTIFIERS>
    <DESCRIPTOR>
      <STUDY_TITLE>Whole-exome sequencing of pediatric solid tumors</STUDY_TITLE>
      <STUDY_TYPES>
        <STUDY_TYPE existing_study_type="Tumor vs. Matched-Normal"/>
      </STUDY_TYPES>
      <STUDY_ABSTRACT>Pediatric solid tumors are rare, whose pathogenesis is poorly understood. To investigate the genetic basis of pediatric solid tumors, we performed whole exome sequencing in 16 rhabdmyosarcoma (RMS) cases and 7 pleuropulmonary blastoma (PPB) cases.
  </STUDY_ABSTRACT>
    </DESCRIPTOR>
    <GRANTS>
      <GRANT grant_id="157100000120">
        <TITLE>Investigation of novel molecular targets of intractable pediatric solid tumors using integrated genetic analysis</TITLE>
        <AGENCY abbr="P-DIRECT">The Project for Development of Innovative Research on Cancer Therapeutics (P-DIRECT) (886695).</AGENCY>
      </GRANT>
      <GRANT grant_id="26293242">
        <TITLE>Studies on clonal evolutions which regulate metastasis and relapse in pediatric solid tumors using spatiotemporal and comprehensive genome-wide analysis</TITLE>
        <AGENCY abbr="KAKENHI">KAKENHI of Japan Society of Promotion of Science; Research on Measures for Intractable Diseases, Health, and Labor Sciences Research Grants, Ministry of Health, Labor and Welfare; by Research on Health Sciences focusing on Drug Innovation</AGENCY>
      </GRANT>
    </GRANTS>
    <PUBLICATIONS>
      <PUBLICATION id="24675358" status="published">
        <DB_TYPE>PUBMED</DB_TYPE>
      </PUBLICATION>
      <PUBLICATION id="26138366" status="published">
        <DB_TYPE>PUBMED</DB_TYPE>
      </PUBLICATION>
    </PUBLICATIONS>
    <STUDY_ATTRIBUTES>
      <STUDY_ATTRIBUTE>
        <TAG>NBDC Number</TAG>
        <VALUE>hum0035</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Registration date</TAG>
        <VALUE>2015-09-03</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Submitting organization</TAG>
        <VALUE>Department of Pediatrics, The University of Tokyo</VALUE>
      </STUDY_ATTRIBUTE>
    </STUDY_ATTRIBUTES>
  </STUDY>
  <STUDY alias="JSUB000046_Study_0001" center_name="Individual" accession="JGAS000032">
    <IDENTIFIERS>
      <SECONDARY_ID>JGAS00000000032</SECONDARY_ID>
    </IDENTIFIERS>
    <DESCRIPTOR>
      <STUDY_TITLE>Effective screening strategy for deafness using a new-genetation sequencing platform: a consecutive analysis</STUDY_TITLE>
      <STUDY_TYPES>
        <STUDY_TYPE existing_study_type="Case Set"/>
      </STUDY_TYPES>
      <STUDY_ABSTRACT>The diagnosis of the genetic etiology of deafness contributes to the clinical management of patients. We performed the following four genetic tests in three stages for 52 consecutive deafness subjects in one facility. We used the Invade assay and Sanger sequencing for the GJB2 gene or SLC26A4 gene in the first stage test, TaqMan genotyping assay in second stage test, and targeted exon sequencing using the massively parallel DNA sequencing in third stage test. Overall, we identified the genetic cause in 40% (21/52) of patients. The diagnostic rates of the first-, second- and third-stage genetic testing were 17%(9/52), 9%(4/43) and 21% (8/39), respectively. The combination approach using these genetic tests appears to be useful as a diagnostic tool for deafness patients. We recommended that genetic testing for the screening of common mutations in deafness genes using the Invader assay or TaqMan genotyping assay be performed as the initial evaluation. For the remaining undiagnosed cases, targeted exon sequencing using MPS is clinically and economically beneficial. This data set was MPS reads data (fastq) for 39 sensorineural hearing loss patients.</STUDY_ABSTRACT>
    </DESCRIPTOR>
    <PUBLICATIONS>
      <PUBLICATION id="26763877" status="published">
        <DB_TYPE>PUBMED</DB_TYPE>
      </PUBLICATION>
    </PUBLICATIONS>
    <STUDY_ATTRIBUTES>
      <STUDY_ATTRIBUTE>
        <TAG>NBDC Number</TAG>
        <VALUE>hum0005</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Registration date</TAG>
        <VALUE>2015-07-27</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Submitting organization</TAG>
        <VALUE>Shinshu University School of Medicine</VALUE>
      </STUDY_ATTRIBUTE>
    </STUDY_ATTRIBUTES>
  </STUDY>
  <STUDY alias="JSUB000047_Study_0001" center_name="Individual" accession="JGAS000035">
    <IDENTIFIERS>
      <SECONDARY_ID>JGAS00000000035</SECONDARY_ID>
    </IDENTIFIERS>
    <DESCRIPTOR>
      <STUDY_TITLE>Searching for rare/low frequency variants in rheumatoid arthritis by exome sequencing</STUDY_TITLE>
      <STUDY_TYPES>
        <STUDY_TYPE existing_study_type="Exome Sequencing"/>
        <STUDY_TYPE existing_study_type="Case Set"/>
        <STUDY_TYPE existing_study_type="Control Set"/>
      </STUDY_TYPES>
      <STUDY_ABSTRACT>Rheumatoid arthritis (RA) is a multifactorial and systemic autoimmune disease and characterized by synovial inflammation and hyperplasia, autoantibody production, cartilage and bone destruction and systemic features including cardiovascular, pulmonary, psychological and skeletal disorders. Although the causality of RA is not completely understood, genetic factors contribute to the onset. About 60% of the RA risk is genetic. To identify causative- or susceptible- rare/low-frequency variants in RA, exome sequencing of 39 patients with RA was conducted. We also conducted genotyping of pooled healthy men and women exome-sequencing data.</STUDY_ABSTRACT>
    </DESCRIPTOR>
    <PUBLICATIONS>
      <PUBLICATION id="23364395" status="published">
        <DB_TYPE>PUBMED</DB_TYPE>
      </PUBLICATION>
      <PUBLICATION id="26016412" status="published">
        <DB_TYPE>PUBMED</DB_TYPE>
      </PUBLICATION>
    </PUBLICATIONS>
    <STUDY_ATTRIBUTES>
      <STUDY_ATTRIBUTE>
        <TAG>NBDC Number</TAG>
        <VALUE>hum0037</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Registration date</TAG>
        <VALUE>2014-01-01</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Submitting organization</TAG>
        <VALUE>Tokai University School of Medicine</VALUE>
      </STUDY_ATTRIBUTE>
    </STUDY_ATTRIBUTES>
  </STUDY>
  <STUDY alias="JSUB000048_Study_0001" center_name="Individual" accession="JGAS000041">
    <IDENTIFIERS>
      <SECONDARY_ID>JGAS00000000041</SECONDARY_ID>
    </IDENTIFIERS>
    <DESCRIPTOR>
      <STUDY_TITLE>Genetic analysis in an inherited cardiac arrhythmia</STUDY_TITLE>
      <STUDY_TYPES>
        <STUDY_TYPE existing_study_type="Case-Control"/>
        <STUDY_TYPE existing_study_type="Exome Sequencing"/>
      </STUDY_TYPES>
      <STUDY_ABSTRACT>To identify a causative gene for an inherited cardiac arrhythmia, exome sequence analysis was conducted in 6 patients and 5 controls.</STUDY_ABSTRACT>
    </DESCRIPTOR>
    <GRANTS>
      <GRANT grant_id="Grant-in-Aid for Scientific Research on Innovative Areas Grant Number 22136007">
        <TITLE>Molecular basis of cardiac channelopathies</TITLE>
        <AGENCY abbr="MEXT">Ministry of Education, Culture, Sports, Science and Technology</AGENCY>
      </GRANT>
    </GRANTS>
    <STUDY_ATTRIBUTES>
      <STUDY_ATTRIBUTE>
        <TAG>NBDC Number</TAG>
        <VALUE>hum0038</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Registration date</TAG>
        <VALUE>2015-10-15</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Submitting organization</TAG>
        <VALUE>Department of Molecular Physiology, Nagasaki University Graduate School of Biomedical Sciences </VALUE>
      </STUDY_ATTRIBUTE>
    </STUDY_ATTRIBUTES>
  </STUDY>
  <STUDY alias="JSUB000050_Study_0001" center_name="Individual" accession="JGAS000039">
    <IDENTIFIERS>
      <SECONDARY_ID>JGAS00000000039</SECONDARY_ID>
    </IDENTIFIERS>
    <DESCRIPTOR>
      <STUDY_TITLE>Analysis of TKI resistant mechanism for gastrointstinal stromal tumor</STUDY_TITLE>
      <STUDY_TYPES>
        <STUDY_TYPE existing_study_type="Exome Sequencing"/>
      </STUDY_TYPES>
      <STUDY_ABSTRACT>Gastrointestinal stromal tumors are the most common mesenchymal tumor of the digestive tract and the proliferation is driven by gain-of-function mutations in KIT. Despite its proven benefits, half of the patients treated with imatinib develop disease progression within 2 years due to secondary resistance mutations in the KIT kinase domains. To characterize the changes associated with imatinib resistance, we performed genomic and transcriptomic analyses of four resistant cell lines and one cell line briefly exposed to imatinib. We also performed exome sequencing of drug-resistant clinical samples. </STUDY_ABSTRACT>
    </DESCRIPTOR>
    <STUDY_ATTRIBUTES>
      <STUDY_ATTRIBUTE>
        <TAG>NBDC Number</TAG>
        <VALUE>hum0039</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Registration date</TAG>
        <VALUE>2015-10-13</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Submitting organization</TAG>
        <VALUE>Osaka unversity graduate school of medicine</VALUE>
      </STUDY_ATTRIBUTE>
    </STUDY_ATTRIBUTES>
  </STUDY>
  <STUDY alias="JSUB000051_Study_0001" center_name="Individual" accession="JGAS000038">
    <IDENTIFIERS>
      <SECONDARY_ID>JGAS00000000038</SECONDARY_ID>
    </IDENTIFIERS>
    <DESCRIPTOR>
      <STUDY_TITLE>Parent-of-origin dependent DNA methylation and gene expression in the human placenta</STUDY_TITLE>
      <STUDY_TYPES>
        <STUDY_TYPE existing_study_type="Whole Genome Sequencing"/>
        <STUDY_TYPE existing_study_type="Exome Sequencing"/>
        <STUDY_TYPE existing_study_type="Transcriptome Sequencing"/>
        <STUDY_TYPE existing_study_type="Other" new_study_type="Bisulfite Sequencing"/>
      </STUDY_TYPES>
      <STUDY_ABSTRACT>DNA methylation is globally reprogrammed after fertilization and the parental genomes have similar DNA methylation profiles after implantation except at the germline differentially methylated regions (gDMRs). We, and others, have previously shown that there are a large number of transient gDMRs in human blastocysts, whose differential methylation is lost in embryonic tissues after implantation. In this study we employed genome-wide allelic DNA methylation analyses of highly purified trophoblast cells from human placentas. ~40% of the transient-in-embryo gDMRs maintained their parent-of-origin-dependent biased allelic methylation. RNA sequencing-based allelic expression analyses revealed that some of the placental-specific gDMRs were associated with novel imprinted genes. This approach identified the first examples of X-linked gDMRs specific to the placenta. These findings highlight the unique regulation of allelic DNA methylation in the human placenta, which is important for understanding normal placental development and the pathogenesis of pregnancy complications.</STUDY_ABSTRACT>
    </DESCRIPTOR>
    <STUDY_ATTRIBUTES>
      <STUDY_ATTRIBUTE>
        <TAG>NBDC Number</TAG>
        <VALUE>hum0040</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Registration date</TAG>
        <VALUE>2015-09-17</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Submitting organization</TAG>
        <VALUE>Department of Informative Genetics, Environment and Genome Research Center, Tohoku University Graduate School of Medicine</VALUE>
      </STUDY_ATTRIBUTE>
    </STUDY_ATTRIBUTES>
  </STUDY>
  <STUDY alias="JSUB000053_Study_0001" center_name="Individual" accession="JGAS000040">
    <IDENTIFIERS>
      <SECONDARY_ID>JGAS00000000040</SECONDARY_ID>
    </IDENTIFIERS>
    <DESCRIPTOR>
      <STUDY_TITLE>Identification of genetic polymorphism on aggressive periodontitis</STUDY_TITLE>
      <STUDY_TYPES>
        <STUDY_TYPE existing_study_type="Case Set"/>
      </STUDY_TYPES>
      <STUDY_ABSTRACT>Periodontitis is an inflammatory disease with loss of gingival tissue and alveolar bone. Aggressive periodontitis is rapidly progressive form of periodontitis in young people. It has been demonstrated that the susceptibility to AgP is influenced by genetic risk factors. However few were established as a risk factor for aggressive periodontitis. To identify genetic risk factors for aggressive periodontitis in Japanese population, we conducted the exome sequence of unrelated patients. </STUDY_ABSTRACT>
    </DESCRIPTOR>
    <STUDY_ATTRIBUTES>
      <STUDY_ATTRIBUTE>
        <TAG>NBDC Number</TAG>
        <VALUE>hum0027</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Registration date</TAG>
        <VALUE>2015-10-15</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Submitting organization</TAG>
        <VALUE>Department of periodontology, Osaka University Graduate School of Dentistry</VALUE>
      </STUDY_ATTRIBUTE>
    </STUDY_ATTRIBUTES>
  </STUDY>
  <STUDY alias="JSUB000055_Study_0001" center_name="Individual" accession="JGAS000042">
    <IDENTIFIERS>
      <SECONDARY_ID>JGAS00000000042</SECONDARY_ID>
    </IDENTIFIERS>
    <DESCRIPTOR>
      <STUDY_TITLE>Constructing database of magnetic resonance imaging of the brain and the ancillary clinical information for multisite collaboration studies: a dataset from normal individuals</STUDY_TITLE>
      <STUDY_TYPES>
        <STUDY_TYPE existing_study_type="Case-Control"/>
      </STUDY_TYPES>
      <STUDY_ABSTRACT>Previously there was no neuroimaging database available for research community that incorporated a large Japanese sample of healthy people and patients with neuropsychiatric disorders. Establishing such a database will enable large-scale, neuroimaging-based investigations on pathophysiology of neuropsychiatric disorders by simply using the large data pool or by combining it with investigators' own data sets.</STUDY_ABSTRACT>
    </DESCRIPTOR>
    <GRANTS>
      <GRANT grant_id="MEXT KAKENHI Grant Number 221S0003">
        <TITLE>Comprehensive Brain Science Network</TITLE>
        <AGENCY abbr="MEXT">The Ministry of Education,Culture,Sports,Science and Technology</AGENCY>
      </GRANT>
      <GRANT grant_id="">
        <TITLE>Study on integration of the human brain related diseases imaging data</TITLE>
        <AGENCY abbr="JST">Japan Science and Technology Agency</AGENCY>
      </GRANT>
    </GRANTS>
    <PUBLICATIONS>
      <PUBLICATION id="0" status="published">
        <DB_TYPE>PUBMED</DB_TYPE>
      </PUBLICATION>
    </PUBLICATIONS>
    <STUDY_LINKS>
      <STUDY_LINK>
        <URL_LINK>
          <LABEL>http://npsy.umin.jp/index.html</LABEL>
          <URL>http://npsy.umin.jp/index.html</URL>
        </URL_LINK>
      </STUDY_LINK>
      <STUDY_LINK>
        <URL_LINK>
          <LABEL>http://cbsn-mri.umin.jp</LABEL>
          <URL>http://cbsn-mri.umin.jp</URL>
        </URL_LINK>
      </STUDY_LINK>
    </STUDY_LINKS>
    <STUDY_ATTRIBUTES>
      <STUDY_ATTRIBUTE>
        <TAG>NBDC Number</TAG>
        <VALUE>hum0031</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Registration date</TAG>
        <VALUE>2015-11-09</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Submitting organization</TAG>
        <VALUE>Department of Neuropsychiatry, Graduate School of Medicine, the University of Tokyo</VALUE>
      </STUDY_ATTRIBUTE>
    </STUDY_ATTRIBUTES>
  </STUDY>
  <STUDY alias="JSUB000056_Study_0001" center_name="Individual" accession="JGAS000043">
    <IDENTIFIERS>
      <SECONDARY_ID>JGAS00000000043</SECONDARY_ID>
    </IDENTIFIERS>
    <DESCRIPTOR>
      <STUDY_TITLE>Constructing database of magnetic resonance imaging of the brain and the ancillary clinical information for multisite collaboration studies: a dataset from Schizophrenia individuals</STUDY_TITLE>
      <STUDY_TYPES>
        <STUDY_TYPE existing_study_type="Case-Control"/>
      </STUDY_TYPES>
      <STUDY_ABSTRACT>Previously there was no neuroimaging database available for research community that incorporated a large Japanese sample of healthy people and patients with neuropsychiatric disorders. Establishing such a database will enable large-scale, neuroimaging-based investigations on pathophysiology of neuropsychiatric disorders by simply using the large data pool or by combining it with investigators' own data sets.</STUDY_ABSTRACT>
    </DESCRIPTOR>
    <GRANTS>
      <GRANT grant_id="MEXT KAKENHI Grant Number 221S0003">
        <TITLE>Comprehensive Brain Science Network</TITLE>
        <AGENCY abbr="MEXT">The Ministry of Education,Culture,Sports,Science and Technology</AGENCY>
      </GRANT>
      <GRANT grant_id="">
        <TITLE>Study on integration of the human brain related diseases imaging data</TITLE>
        <AGENCY abbr="JST">Japan Science and Technology Agency</AGENCY>
      </GRANT>
    </GRANTS>
    <PUBLICATIONS>
      <PUBLICATION id="0" status="published">
        <DB_TYPE>PUBMED</DB_TYPE>
      </PUBLICATION>
    </PUBLICATIONS>
    <STUDY_LINKS>
      <STUDY_LINK>
        <URL_LINK>
          <LABEL>http://npsy.umin.jp/index.html</LABEL>
          <URL>http://npsy.umin.jp/index.html</URL>
        </URL_LINK>
      </STUDY_LINK>
      <STUDY_LINK>
        <URL_LINK>
          <LABEL>http://cbsn-mri.umin.jp</LABEL>
          <URL>http://cbsn-mri.umin.jp</URL>
        </URL_LINK>
      </STUDY_LINK>
    </STUDY_LINKS>
    <STUDY_ATTRIBUTES>
      <STUDY_ATTRIBUTE>
        <TAG>NBDC Number</TAG>
        <VALUE>hum0031</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Registration date</TAG>
        <VALUE>2015-11-09</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Submitting organization</TAG>
        <VALUE>Department of Neuropsychiatry, Graduate School of Medicine, the University of Tokyo</VALUE>
      </STUDY_ATTRIBUTE>
    </STUDY_ATTRIBUTES>
  </STUDY>
  <STUDY alias="JSUB000057_Study_0001" center_name="Individual" accession="JGAS000044">
    <IDENTIFIERS>
      <SECONDARY_ID>JGAS00000000044</SECONDARY_ID>
    </IDENTIFIERS>
    <DESCRIPTOR>
      <STUDY_TITLE>Constructing database of magnetic resonance imaging of the brain and the ancillary clinical information for multisite collaboration studies: a dataset from Depression individuals</STUDY_TITLE>
      <STUDY_TYPES>
        <STUDY_TYPE existing_study_type="Case-Control"/>
      </STUDY_TYPES>
      <STUDY_ABSTRACT>Previously there was no neuroimaging database available for research community that incorporated a large Japanese sample of healthy people and patients with neuropsychiatric disorders. Establishing such a database will enable large-scale, neuroimaging-based investigations on pathophysiology of neuropsychiatric disorders by simply using the large data pool or by combining it with investigators' own data sets.</STUDY_ABSTRACT>
    </DESCRIPTOR>
    <GRANTS>
      <GRANT grant_id="MEXT KAKENHI Grant Number 221S0003">
        <TITLE>Comprehensive Brain Science Network</TITLE>
        <AGENCY abbr="MEXT">The Ministry of Education,Culture,Sports,Science and Technology</AGENCY>
      </GRANT>
      <GRANT grant_id="">
        <TITLE>Study on integration of the human brain related diseases imaging data</TITLE>
        <AGENCY abbr="JST">Japan Science and Technology Agency</AGENCY>
      </GRANT>
    </GRANTS>
    <PUBLICATIONS>
      <PUBLICATION id="0" status="published">
        <DB_TYPE>PUBMED</DB_TYPE>
      </PUBLICATION>
    </PUBLICATIONS>
    <STUDY_LINKS>
      <STUDY_LINK>
        <URL_LINK>
          <LABEL>http://npsy.umin.jp/index.html</LABEL>
          <URL>http://npsy.umin.jp/index.html</URL>
        </URL_LINK>
      </STUDY_LINK>
      <STUDY_LINK>
        <URL_LINK>
          <LABEL>http://cbsn-mri.umin.jp</LABEL>
          <URL>http://cbsn-mri.umin.jp</URL>
        </URL_LINK>
      </STUDY_LINK>
    </STUDY_LINKS>
    <STUDY_ATTRIBUTES>
      <STUDY_ATTRIBUTE>
        <TAG>NBDC Number</TAG>
        <VALUE>hum0031</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Registration date</TAG>
        <VALUE>2015-11-09</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Submitting organization</TAG>
        <VALUE>Department of Neuropsychiatry, Graduate School of Medicine, the University of Tokyo</VALUE>
      </STUDY_ATTRIBUTE>
    </STUDY_ATTRIBUTES>
  </STUDY>
  <STUDY alias="JSUB000058_Study_0001" center_name="Individual" accession="JGAS000045">
    <IDENTIFIERS>
      <SECONDARY_ID>JGAS00000000045</SECONDARY_ID>
    </IDENTIFIERS>
    <DESCRIPTOR>
      <STUDY_TITLE>Constructing database of magnetic resonance imaging of the brain and the ancillary clinical information for multisite collaboration studies: a dataset from Bipolar disorder individuals</STUDY_TITLE>
      <STUDY_TYPES>
        <STUDY_TYPE existing_study_type="Case-Control"/>
      </STUDY_TYPES>
      <STUDY_ABSTRACT>Previously there was no neuroimaging database available for research community that incorporated a large Japanese sample of healthy people and patients with neuropsychiatric disorders. Establishing such a database will enable large-scale, neuroimaging-based investigations on pathophysiology of neuropsychiatric disorders by simply using the large data pool or by combining it with investigators' own data sets.</STUDY_ABSTRACT>
    </DESCRIPTOR>
    <GRANTS>
      <GRANT grant_id="MEXT KAKENHI Grant Number 221S0003">
        <TITLE>Comprehensive Brain Science Network</TITLE>
        <AGENCY abbr="MEXT">The Ministry of Education,Culture,Sports,Science and Technology</AGENCY>
      </GRANT>
      <GRANT grant_id="">
        <TITLE>Study on integration of the human brain related diseases imaging data</TITLE>
        <AGENCY abbr="JST">Japan Science and Technology Agency</AGENCY>
      </GRANT>
    </GRANTS>
    <PUBLICATIONS>
      <PUBLICATION id="0" status="published">
        <DB_TYPE>PUBMED</DB_TYPE>
      </PUBLICATION>
    </PUBLICATIONS>
    <STUDY_LINKS>
      <STUDY_LINK>
        <URL_LINK>
          <LABEL>http://npsy.umin.jp/index.html</LABEL>
          <URL>http://npsy.umin.jp/index.html</URL>
        </URL_LINK>
      </STUDY_LINK>
      <STUDY_LINK>
        <URL_LINK>
          <LABEL>http://cbsn-mri.umin.jp</LABEL>
          <URL>http://cbsn-mri.umin.jp</URL>
        </URL_LINK>
      </STUDY_LINK>
    </STUDY_LINKS>
    <STUDY_ATTRIBUTES>
      <STUDY_ATTRIBUTE>
        <TAG>NBDC Number</TAG>
        <VALUE>hum0031</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Registration date</TAG>
        <VALUE>2015-11-09</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Submitting organization</TAG>
        <VALUE>Department of Neuropsychiatry, Graduate School of Medicine, the University of Tokyo</VALUE>
      </STUDY_ATTRIBUTE>
    </STUDY_ATTRIBUTES>
  </STUDY>
  <STUDY alias="JSUB000059_Study_0001" center_name="Individual" accession="JGAS000052">
    <IDENTIFIERS>
      <SECONDARY_ID>JGAS00000000052</SECONDARY_ID>
    </IDENTIFIERS>
    <DESCRIPTOR>
      <STUDY_TITLE>Research of factors related to diagnosis, progression, prognosis and treatment of hepato-biliary-pancreatic malignancies</STUDY_TITLE>
      <STUDY_TYPES>
        <STUDY_TYPE existing_study_type="Tumor vs. Matched-Normal"/>
        <STUDY_TYPE existing_study_type="Exome Sequencing"/>
      </STUDY_TYPES>
      <STUDY_ABSTRACT>Advanced cancers with metastasis and/or recurrence are usually resistant and refractory to treatment. In our studies, whole exome sequencing analysis, comprehensive epigenetic analysis and genome-wide expression analysis were performed using cancerous and non-cancerous tissues derived from multicentric cohort study of hepatocellular carcinoma (HCC). The aim of the studies is identification of the refractoriness-related deriver genes for application to novel molecular targeted therapy and preventive medicine. The studies are intended for refractory HCC. High frequency of the tumor recurrence even after curative resection is one of the major difficulties in the treatment of HCC. According to our previous studies, not the recurrence itself, but the recurrence pattern has critical effects on prognosis of the patient with HCC. Then, we analyzed the cancerous and non-cancerous tissues of primary HCC on the point of the recurrence patterns in accordance with or without Milan criteria. The materials were obtained from thirty three patients underwent curative hepatectomy for HCC at Department of Hepato-Biliary-Pancreatic Surgery, Tokyo Medical and Dental University Hospital.  Written informed consent from these patients, as well as the institutional review board approved was obtained. The determination of the refractory HCC group (16 cases) was based on the point of the recurrence patterns in accordance with Milan criteria for the recurrent tumor (solitary &lt;5cm, or up to 3 nodules &lt;3 cm, without major vascular invasion or distant metastasis) that has been proposed as the useful criteria of the liver transplantation for HCC. The cellular DNA was extracted from the cancerous and non-cancerous tissues of primary HCC by the phenol-chloroform method.  After SNP certification using Genome-Wide Human SNP Array 6.0 (Affymetrix), whole exome sequencing was performed at the Cancer Institute of JFCR, as the support infrastructure. Exome sequencing was performed using HiSeq 2000 (Illumina), and the obtained reads were mapped to the human reference genome (hg19) using BWA software. GATK software was used for local realignment base call recalibration. Single nucleotide variants (SNVs) and indels were analyzed by MuTect and SomaticIndelDetector, as well as visual confirmation by IGV software.</STUDY_ABSTRACT>
    </DESCRIPTOR>
    <STUDY_ATTRIBUTES>
      <STUDY_ATTRIBUTE>
        <TAG>NBDC Number</TAG>
        <VALUE>hum0041</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>NBDC website</TAG>
        <VALUE>http://humandbs.biosciencedbc.jp/hum0041</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Registration date</TAG>
        <VALUE>2016-01-01</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Submitting organization</TAG>
        <VALUE>Tokyo Medical and Dental University</VALUE>
      </STUDY_ATTRIBUTE>
    </STUDY_ATTRIBUTES>
  </STUDY>
  <STUDY alias="JSUB000061_Study_0001" center_name="Individual" accession="JGAS000047">
    <IDENTIFIERS>
      <SECONDARY_ID>JGAS00000000047</SECONDARY_ID>
    </IDENTIFIERS>
    <DESCRIPTOR>
      <STUDY_TITLE>Transcriptome analysis of adolescents and young adults with Acute Lymphoblastic Leukemia</STUDY_TITLE>
      <STUDY_TYPES>
        <STUDY_TYPE existing_study_type="Transcriptome Sequencing"/>
      </STUDY_TYPES>
      <STUDY_ABSTRACT>The primary purpose of the research is identification of novel chromosome translocations in adolescents and young adults (AYA) with Acute Lymphoblastic Leukemia (ALL). We searched for novel chromosome translocations in 99 philadelphia-chromosome negative ALL cases (including 76 AYA cases) by RNA-seq using next-generation sequencers, and have discovered some novel chromosome translocations.
        </STUDY_ABSTRACT>
    </DESCRIPTOR>
    <PUBLICATIONS>
      <PUBLICATION id="27019113" status="published">
        <DB_TYPE>PUBMED</DB_TYPE>
      </PUBLICATION>
    </PUBLICATIONS>
    <STUDY_ATTRIBUTES>
      <STUDY_ATTRIBUTE>
        <TAG>NBDC Number</TAG>
        <VALUE>hum0045</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Registration date</TAG>
        <VALUE>2015-12-01</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Submitting organization</TAG>
        <VALUE>Department of Cellular Signaling, Graduate School of Medicine, The University of Tokyo</VALUE>
      </STUDY_ATTRIBUTE>
    </STUDY_ATTRIBUTES>
  </STUDY>
  <STUDY alias="JSUB000064_Study_0001" center_name="Individual" accession="JGAS000046">
    <IDENTIFIERS>
      <SECONDARY_ID>JGAS00000000046</SECONDARY_ID>
    </IDENTIFIERS>
    <DESCRIPTOR>
      <STUDY_TITLE>Genome-wide copy number analysis of neuroblastoma</STUDY_TITLE>
      <STUDY_TYPES>
        <STUDY_TYPE existing_study_type="Other" new_study_type="SNP array analysis"/>
        <STUDY_TYPE existing_study_type="Case Set"/>
      </STUDY_TYPES>
      <STUDY_ABSTRACT>Neuroblastoma is the most common extracranial solid tumor in childhood. Despite the improvement of risk-stratified therapies, overall survival rate of high-risk group is still as low as 40-50%. To investigate genome-wide copy number profiles of neuroblastoma, we performed SNP array analysis and PCR-based amplicon deep sequencing of neuroblastoma-related genes in 522 neuroblastoma samples.</STUDY_ABSTRACT>
    </DESCRIPTOR>
    <PUBLICATIONS>
      <PUBLICATION id="10.18632/oncotarget.22495" status="published">
        <DB_TYPE>DOI</DB_TYPE>
      </PUBLICATION>
    </PUBLICATIONS>
    <STUDY_ATTRIBUTES>
      <STUDY_ATTRIBUTE>
        <TAG>NBDC Number</TAG>
        <VALUE>hum0035</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Registration date</TAG>
        <VALUE>2015-12-21</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Submitting organization</TAG>
        <VALUE>Department of Pediatrics, Graduate School of Medicine, The University of Tokyo</VALUE>
      </STUDY_ATTRIBUTE>
    </STUDY_ATTRIBUTES>
  </STUDY>
  <STUDY alias="JSUB000068_Study_0001" center_name="Individual" accession="JGAS000051">
    <IDENTIFIERS>
      <SECONDARY_ID>JGAS00000000051</SECONDARY_ID>
    </IDENTIFIERS>
    <DESCRIPTOR>
      <STUDY_TITLE>Japanese Alzheimer's disease neuroimaging initiative</STUDY_TITLE>
      <STUDY_TYPES>
        <STUDY_TYPE existing_study_type="Cohort"/>
        <STUDY_TYPE existing_study_type="Longitudinal"/>
      </STUDY_TYPES>
      <STUDY_ABSTRACT>Japanese ADNI aims to establish imaging and biofluid markers that can predict and monitor the progression of changes in the brains of elderly individuals with AD, mild cognitive impairment (MCI) or normal cognition, and eventually be used as a surrogate markers for the clinical trials of DMDs for AD. </STUDY_ABSTRACT>
    </DESCRIPTOR>
    <GRANTS>
      <GRANT grant_id="20100000001577">
        <TITLE>Research Project for the Development of a Systematic Method for the Assessment of Alzheimer's Disease</TITLE>
        <AGENCY abbr="NEDO">New Energy and Industrial Technology Development Organization</AGENCY>
      </GRANT>
      <GRANT grant_id="H19-Dementia Research-024">
        <TITLE>Multisite longitudinal study for the evaluation of clinical manifestation and progression of Alzheimer disease: J-ADNI core study</TITLE>
        <AGENCY abbr="MHLW">Ministry of Health, Labour and Welfare</AGENCY>
      </GRANT>
      <GRANT grant_id="H22-Dementia Research-019">
        <TITLE>J-ADNI core study: analysis and application of imaging biomarkers and establishment of clinical study network.</TITLE>
        <AGENCY abbr="MHLW">Ministry of Health, Labour and Welfare</AGENCY>
      </GRANT>
      <GRANT grant_id="">
        <TITLE>Study on integration of the human brain related diseases imaging data</TITLE>
        <AGENCY abbr="JST">Japan Science and Technology Agency</AGENCY>
      </GRANT>
    </GRANTS>
    <STUDY_ATTRIBUTES>
      <STUDY_ATTRIBUTE>
        <TAG>NBDC Number</TAG>
        <VALUE>hum0043</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Registration date</TAG>
        <VALUE>2016-01-29</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Submitting organization</TAG>
        <VALUE>Department of Neuropathology, Graduate School of Medicine, the University of Tokyo</VALUE>
      </STUDY_ATTRIBUTE>
    </STUDY_ATTRIBUTES>
  </STUDY>
  <STUDY alias="JSUB000071_Study_0001" center_name="Individual" accession="JGAS000053">
    <IDENTIFIERS>
      <SECONDARY_ID>JGAS00000000053</SECONDARY_ID>
    </IDENTIFIERS>
    <DESCRIPTOR>
      <STUDY_TITLE>Transcriptome analysis of Hepatitis B for drug discovery and clinical applications</STUDY_TITLE>
      <STUDY_TYPES>
        <STUDY_TYPE existing_study_type="Transcriptome Sequencing"/>
        <STUDY_TYPE existing_study_type="Other" new_study_type="CAGE"/>
      </STUDY_TYPES>
      <STUDY_ABSTRACT>We analyzed blood transcriptome of HBV positive untreated patients (men) using the CAGE technology.</STUDY_ABSTRACT>
    </DESCRIPTOR>
    <STUDY_ATTRIBUTES>
      <STUDY_ATTRIBUTE>
        <TAG>NBDC Number</TAG>
        <VALUE>hum0050</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Registration date</TAG>
        <VALUE>2016-03-07</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Submitting organization</TAG>
        <VALUE>The Jikei University School of Medicine</VALUE>
      </STUDY_ATTRIBUTE>
    </STUDY_ATTRIBUTES>
  </STUDY>
  <STUDY alias="JSUB000073_Study_0001" center_name="Individual" accession="JGAS000062">
    <IDENTIFIERS>
      <SECONDARY_ID>JGAS00000000062</SECONDARY_ID>
    </IDENTIFIERS>
    <DESCRIPTOR>
      <STUDY_TITLE>Identification of new molecular targets with profiling of malignant mesothelioma</STUDY_TITLE>
      <STUDY_TYPES>
        <STUDY_TYPE existing_study_type="Exome Sequencing"/>
        <STUDY_TYPE existing_study_type="Tumor vs. Matched-Normal"/>
      </STUDY_TYPES>
      <STUDY_ABSTRACT>Aims: Malignant mesothelioma which is associated with asbestos exposure is highly aggressive and refractory to conventional therapeutic modalities. The aim of this study is identification of new targets for molecular target therapy by next generation sequencing and application of the genomic data to new diagnostic and therapeutic strategies for malignant mesothelioma patients.
  Methods: We extracted genomic DNAs from surgical specimens or established mesothelioma cell lines from Japanese malignant mesothelioma patients. We also extracted control DNAs from peripheral blood of the same patients. We performed whole exome sequencing using these DNAs.</STUDY_ABSTRACT>
    </DESCRIPTOR>
    <GRANTS>
      <GRANT grant_id="">
        <TITLE>Identification of new molecular targets with profiling of malignant mesothelioma / Development of therapeutic modalities against intractable cancers via identification of new therapeutic targets with molecular profiling / P-DIRECT: Project for Development of Innovative Research on Cancer Therapeutics</TITLE>
        <AGENCY abbr="MEXT">Ministry of Education, Culture, Sports, Science and Technology</AGENCY>
      </GRANT>
      <GRANT grant_id="">
        <TITLE>Identification of new molecular targets with profiling of malignant mesothelioma / Development of therapeutic modalities against intractable cancers via identification of new therapeutic targets with molecular profiling / P-DIRECT: Project for Development of Innovative Research on Cancer Therapeutics</TITLE>
        <AGENCY abbr="AMED">Japan Agency for Medical Research and Development</AGENCY>
      </GRANT>
    </GRANTS>
    <STUDY_LINKS>
      <STUDY_LINK>
        <URL_LINK>
          <LABEL>http://www.pref.aichi.jp/cancer-center/english/ri/01division/03molecular/index.html</LABEL>
          <URL>http://www.pref.aichi.jp/cancer-center/english/ri/01division/03molecular/index.html</URL>
        </URL_LINK>
      </STUDY_LINK>
    </STUDY_LINKS>
    <STUDY_ATTRIBUTES>
      <STUDY_ATTRIBUTE>
        <TAG>NBDC Number</TAG>
        <VALUE>hum0053</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Registration date</TAG>
        <VALUE>2016-07-08</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Submitting organization</TAG>
        <VALUE>Hyogo College of Medicine, Division of Respiratory Medicine</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Principal Investigator</TAG>
        <VALUE>Takashi Nakano</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Molecular Data Type</TAG>
        <VALUE>Exome sequencing</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Platform</TAG>
        <VALUE>HiSeq 2000</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Vendor</TAG>
        <VALUE>Illumina</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>List</TAG>
        <VALUE/>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Primary Phenotype</TAG>
        <VALUE>Malignant mesothelioma</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Disease Type</TAG>
        <VALUE>Neoplasms</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Cancer Type</TAG>
        <VALUE>Mesothelioma</VALUE>
      </STUDY_ATTRIBUTE>
    </STUDY_ATTRIBUTES>
  </STUDY>
  <STUDY alias="JSUB000077_Study_0001" center_name="Individual" accession="JGAS000059">
    <IDENTIFIERS>
      <SECONDARY_ID>JGAS00000000059</SECONDARY_ID>
    </IDENTIFIERS>
    <DESCRIPTOR>
      <STUDY_TITLE>Genetic and epigentic analysis of non-alcoholic fatty liver disease. Methylation analysis of nonalcoholic fatty liver.</STUDY_TITLE>
      <STUDY_TYPES>
        <STUDY_TYPE existing_study_type="Control Set"/>
        <STUDY_TYPE existing_study_type="Case Set"/>
        <STUDY_TYPE existing_study_type="Transcriptome Sequencing"/>
        <STUDY_TYPE existing_study_type="Other" new_study_type="Illumina Infinium HumanMethylation450 BeadChip"/>
      </STUDY_TYPES>
      <STUDY_ABSTRACT>The aim of this study is to elucidate the mRNA expression related to the development and/or progression of non-alcoholic fatty liver disease. We performed genome-wide methylation analysis and determined the differentially methylated CpGs between mild and advanced nonalcoholic fatty liver disease.</STUDY_ABSTRACT>
    </DESCRIPTOR>
    <GRANTS>
      <GRANT grant_id="221">
        <TITLE>Genome Science</TITLE>
        <AGENCY abbr="MEXT">Japanese Ministry of Education, Culture, Sports, Science and Technology</AGENCY>
      </GRANT>
      <GRANT grant_id="25461343">
        <TITLE>Kiban C</TITLE>
        <AGENCY abbr="MEXT">Japanese Ministry of Education, Culture, Sports, Science and Technology</AGENCY>
      </GRANT>
      <GRANT grant_id="JSPS KAKENHI Grant Number 25461343">
        <TITLE>Genetic predisposition and environmental factor retrieval of ectopic fat accumulation and their verification in prospective follow-up survey</TITLE>
        <AGENCY abbr="JSPS">Japan Society for the Promotion of Science</AGENCY>
      </GRANT>
      <GRANT grant_id="JSPS KAKENHI Grant Number 16K09781">
        <TITLE>Elucidation of pathology and development of diagnosis method of nonalcoholic fatty liver disease by using genomic, and epigenomic analysis</TITLE>
        <AGENCY abbr="JSPS">Japan Society for the Promotion of Science</AGENCY>
      </GRANT>
      <GRANT grant_id="JSPS KAKENHI Grant Number 26460999">
        <TITLE>Analysis of genetic predisposition and environmental factors related to the onset and progression of nonalcoholic fatty liver disease</TITLE>
        <AGENCY abbr="JSPS">Japan Society for the Promotion of Science</AGENCY>
      </GRANT>
    </GRANTS>
    <PUBLICATIONS>
      <PUBLICATION id="28219123" status="published">
        <DB_TYPE>PUBMED</DB_TYPE>
      </PUBLICATION>
      <PUBLICATION id="29059699" status="published">
        <DB_TYPE>PUBMED</DB_TYPE>
      </PUBLICATION>
    </PUBLICATIONS>
    <STUDY_ATTRIBUTES>
      <STUDY_ATTRIBUTE>
        <TAG>NBDC Number</TAG>
        <VALUE>hum0055</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Registration date</TAG>
        <VALUE>2016-06-02</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Submitting organization</TAG>
        <VALUE>Department of Medical Innovation, Osaka University Hospital</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Principal Investigator</TAG>
        <VALUE>Kikuko Hotta</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Primary Phenotype</TAG>
        <VALUE>non-alcoholic fatty liver disease</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Platform</TAG>
        <VALUE>Illumina HiSeq 2500</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Platform</TAG>
        <VALUE>Infinium HumanMethylation450 BeadChip</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Vendor</TAG>
        <VALUE>Illumina </VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>List</TAG>
        <VALUE/>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Disease</TAG>
        <VALUE>Nonalcoholic fatty liver disease</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Tissue</TAG>
        <VALUE>Liver</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Analysis</TAG>
        <VALUE>Genomic DNA methylation</VALUE>
      </STUDY_ATTRIBUTE>
    </STUDY_ATTRIBUTES>
  </STUDY>
  <STUDY alias="JSUB000079_Study_0001" center_name="Individual" accession="JGAS000091">
    <IDENTIFIERS>
      <SECONDARY_ID>JGAS00000000091</SECONDARY_ID>
    </IDENTIFIERS>
    <DESCRIPTOR>
      <STUDY_TITLE>Identification of genetic mutations characteristic for recurrence and metastasis of colon and rectal cancer.</STUDY_TITLE>
      <STUDY_TYPES>
        <STUDY_TYPE existing_study_type="Tumor vs. Matched-Normal"/>
      </STUDY_TYPES>
      <STUDY_ABSTRACT>We collected the cancerous tissues of the primary and recurrence tumors from the same patient with recurrent / metastatic colorectal cancer, and the purpose of this study is to find the characteristics of recurrent / metastatic colorectal cancers by carrying out a "molecular profiling", mainly the exome sequence analysis of these tissues.</STUDY_ABSTRACT>
    </DESCRIPTOR>
    <STUDY_ATTRIBUTES>
      <STUDY_ATTRIBUTE>
        <TAG>NBDC Number</TAG>
        <VALUE>hum0058</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Registration date</TAG>
        <VALUE>2016-11-15</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Submitting organization</TAG>
        <VALUE>The Cancer Institute Hospital of JFCR     </VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Principal Investigator</TAG>
        <VALUE>Toshiharu Yamaguchi</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Molecular Data Type</TAG>
        <VALUE>Whole Exome Sequencing</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Platform</TAG>
        <VALUE>Hiseq 2000</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Vendor</TAG>
        <VALUE>Illumina</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>List</TAG>
        <VALUE/>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Primary Phenotype</TAG>
        <VALUE>Cancer</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Disease Type</TAG>
        <VALUE>Neoplasms</VALUE>
      </STUDY_ATTRIBUTE>
    </STUDY_ATTRIBUTES>
  </STUDY>
  <STUDY alias="JSUB000080_Study_0001" center_name="Individual" accession="JGAS000087">
    <IDENTIFIERS>
      <SECONDARY_ID>JGAS00000000087</SECONDARY_ID>
    </IDENTIFIERS>
    <DESCRIPTOR>
      <STUDY_TITLE>Identification of genetic mutations characteristic for recurrence and metastasis of lymphoma.</STUDY_TITLE>
      <STUDY_TYPES>
        <STUDY_TYPE existing_study_type="Tumor vs. Matched-Normal"/>
      </STUDY_TYPES>
      <STUDY_ABSTRACT>We collected the cancerous tissues of the primary and recurrence tumors from the same patient with recurrent B cell lymphoma, and the purpose of this study is to find the characteristics of recurrent B cell lymphoma by carrying out a "molecular profiling", mainly the exome sequence analysis of these tissues.</STUDY_ABSTRACT>
    </DESCRIPTOR>
    <STUDY_ATTRIBUTES>
      <STUDY_ATTRIBUTE>
        <TAG>NBDC Number</TAG>
        <VALUE>hum0134</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Registration date</TAG>
        <VALUE>2016-11-15</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Submitting organization</TAG>
        <VALUE>The Cancer Institute Hospital of JFCR</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Principal Investigator</TAG>
        <VALUE>Toshiharu Yamaguchi</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Molecular Data Type</TAG>
        <VALUE>Whole Exome Sequencing</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Platform</TAG>
        <VALUE>Hiseq 2000</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Vendor</TAG>
        <VALUE>Illumina</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>List</TAG>
        <VALUE/>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Primary Phenotype</TAG>
        <VALUE>Cancer</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Disease Type</TAG>
        <VALUE>Neoplasms</VALUE>
      </STUDY_ATTRIBUTE>
    </STUDY_ATTRIBUTES>
  </STUDY>
  <STUDY alias="JSUB000081_Study_0001" center_name="Individual" accession="JGAS000086">
    <IDENTIFIERS>
      <SECONDARY_ID>JGAS00000000086</SECONDARY_ID>
    </IDENTIFIERS>
    <DESCRIPTOR>
      <STUDY_TITLE>Identification of genetic mutations characteristic for recurrence and metastasis of gastric cancer.</STUDY_TITLE>
      <STUDY_TYPES>
        <STUDY_TYPE existing_study_type="Tumor vs. Matched-Normal"/>
      </STUDY_TYPES>
      <STUDY_ABSTRACT>We collected the cancerous tissues of the primary and recurrence tumors from the same patient with recurrent / metastatic gastric cancer, and the purpose of this study is to find the characteristics of recurrent / metastatic gastric cancers by carrying out a "molecular profiling", mainly the exome sequence analysis of these tissues.</STUDY_ABSTRACT>
    </DESCRIPTOR>
    <STUDY_ATTRIBUTES>
      <STUDY_ATTRIBUTE>
        <TAG>NBDC Number</TAG>
        <VALUE>hum0133</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Registration date</TAG>
        <VALUE>2016-11-15</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Submitting organization</TAG>
        <VALUE>The Cancer Institute Hospital of JFCR</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Principal Investigator</TAG>
        <VALUE>Toshiharu Yamaguchi</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Molecular Data Type</TAG>
        <VALUE>Whole Exome Sequencing</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Platform</TAG>
        <VALUE>Hiseq 2000</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Vendor</TAG>
        <VALUE>Illumina</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>List</TAG>
        <VALUE/>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Primary Phenotype</TAG>
        <VALUE>Cancer</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Disease Type</TAG>
        <VALUE>Neoplasms</VALUE>
      </STUDY_ATTRIBUTE>
    </STUDY_ATTRIBUTES>
  </STUDY>
  <STUDY alias="JSUB000082_Study_0001" center_name="Individual" accession="JGAS000104">
    <IDENTIFIERS>
      <SECONDARY_ID>JGAS00000000104</SECONDARY_ID>
    </IDENTIFIERS>
    <DESCRIPTOR>
      <STUDY_TITLE>Identification of genetic mutations characteristic for recurrence of serous ovarian cancer.</STUDY_TITLE>
      <STUDY_TYPES>
        <STUDY_TYPE existing_study_type="Tumor vs. Matched-Normal"/>
      </STUDY_TYPES>
      <STUDY_ABSTRACT>Establishment of novel therapeutic strategy to overcome intractable cancer by molecular profiling of serous ovarian cancer</STUDY_ABSTRACT>
    </DESCRIPTOR>
    <STUDY_ATTRIBUTES>
      <STUDY_ATTRIBUTE>
        <TAG>NBDC Number</TAG>
        <VALUE>hum0059</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Registration date</TAG>
        <VALUE>2017-04-06</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Submitting organization</TAG>
        <VALUE>The Cancer Institute Hospital of JFCR</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Principal Investigator</TAG>
        <VALUE>Kazuyoshi Kato</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Molecular Data Type</TAG>
        <VALUE>Whole Exome Sequencing</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Platform</TAG>
        <VALUE>Hiseq 2000</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Vendor</TAG>
        <VALUE>Illumina</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>List</TAG>
        <VALUE/>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Primary Phenotype</TAG>
        <VALUE>Ovarian Cancer</VALUE>
      </STUDY_ATTRIBUTE>
    </STUDY_ATTRIBUTES>
  </STUDY>
  <STUDY alias="JSUB000083_Study_0001" center_name="Individual" accession="JGAS000075">
    <IDENTIFIERS>
      <SECONDARY_ID>JGAS00000000075</SECONDARY_ID>
    </IDENTIFIERS>
    <DESCRIPTOR>
      <STUDY_TITLE>Intractable Cancer Therapy Development through a New Target Identification by Molecular Profiling</STUDY_TITLE>
      <STUDY_TYPES>
        <STUDY_TYPE existing_study_type="Tumor vs. Matched-Normal"/>
        <STUDY_TYPE existing_study_type="Exome Sequencing"/>
      </STUDY_TYPES>
      <STUDY_ABSTRACT>We collected the cancerous tissues of the primary and recurrence tumors from the same patient with recurrent / metastatic breast cancer, and the purpose of this study is to find the characteristics of recurrent / metastatic breast cancers by carrying out a "molecular profiling", mainly the exome sequence analysis of these tissues.</STUDY_ABSTRACT>
    </DESCRIPTOR>
    <STUDY_ATTRIBUTES>
      <STUDY_ATTRIBUTE>
        <TAG>NBDC Number</TAG>
        <VALUE>hum0060</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Registration date</TAG>
        <VALUE>2016-09-08</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Submitting organization</TAG>
        <VALUE>Medical Research Institute, Tokyo Medical and Dental University</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Principal Investigator</TAG>
        <VALUE>Yoshio Miki</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Molecular Data Type</TAG>
        <VALUE>Exome Sequencing</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Platform</TAG>
        <VALUE>Hiseq 2000</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Vendor</TAG>
        <VALUE>Illumina</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>List</TAG>
        <VALUE/>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Primary Phenotype</TAG>
        <VALUE>Breast Cancer</VALUE>
      </STUDY_ATTRIBUTE>
    </STUDY_ATTRIBUTES>
  </STUDY>
  <STUDY alias="JSUB000084_Study_0001" center_name="Individual" accession="JGAS000057">
    <IDENTIFIERS>
      <SECONDARY_ID>JGAS00000000057</SECONDARY_ID>
    </IDENTIFIERS>
    <DESCRIPTOR>
      <STUDY_TITLE>Homozygous inactivation of CHEK2 is linked to a familial case of multiple primary lung cancer with accompanying cancers in other organs</STUDY_TITLE>
      <STUDY_TYPES>
        <STUDY_TYPE existing_study_type="Case Set"/>
        <STUDY_TYPE existing_study_type="Exome Sequencing"/>
        <STUDY_TYPE existing_study_type="Other" new_study_type="SNP genotyping"/>
      </STUDY_TYPES>
      <STUDY_ABSTRACT>In clinical practice, there are a number of cancer patients with clear family histories, but not belonging to existing familial malignancies. Recent advances in genomic technologies have enhanced the possibility of identifying causative genes in such cases. Two siblings, an elder sister and a younger brother, were found to have multiple primary lung cancers at the age of 60. The former subsequently developed breast cancer, and had a history of myoma uteri. The latter had initially developed prostate cancer at the age of 59, and had a history of colon cancer. SNP genotyping revealed that approximately 10% of the genomes were homozygous in both patients. Exome sequencing revealed non-synonymous mutations in four genes in the runs of homozygosity: CHEK2, FCGRT, INPP5J, and SFI1. Evolutionary conservation of primary protein structures suggested the functional importance of the CHEK2 mutation, R474C. This mutation altered the tertiary structure of CHK2 by disrupting the salt bridge between R474 and E394. No such structural changes were observed with the other three mutated genes. Subsequent cell-based transfection analysis revealed that CHK2 R474C was unstable and scarcely activated. We concluded that CHEK2 is a causative gene in this case of familial cancer. Although homozygous inactivation of CHEK2 in mice led to cancers in multiple organs, accumulation of additional human cases is needed to establish its pathogenic role in humans. </STUDY_ABSTRACT>
    </DESCRIPTOR>
    <GRANTS>
      <GRANT grant_id="25430180">
        <TITLE>Grant-in-Aid for Scientific Research (C)</TITLE>
        <AGENCY abbr="JSPS">Japan Society for The Promotion of Science</AGENCY>
      </GRANT>
    </GRANTS>
    <PUBLICATIONS>
      <PUBLICATION id="27900359" status="published">
        <DB_TYPE>PUBMED</DB_TYPE>
      </PUBLICATION>
    </PUBLICATIONS>
    <STUDY_ATTRIBUTES>
      <STUDY_ATTRIBUTE>
        <TAG>NBDC Number</TAG>
        <VALUE>hum0061</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Registration date</TAG>
        <VALUE>2016-05-25</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Submitting organization</TAG>
        <VALUE>Osaka Medical Center for Cancer and Cardiovascular Diseases</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Principal Investigator</TAG>
        <VALUE>Kikuya Kato</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Molecular Data Type</TAG>
        <VALUE>Whole Exome Sequencing</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Platform</TAG>
        <VALUE>HiSeq 2000</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Vendor</TAG>
        <VALUE>Illumina</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>List</TAG>
        <VALUE/>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Molecular Data Type</TAG>
        <VALUE>SNP Array</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Platform</TAG>
        <VALUE>Omni1-Quad</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Vendor</TAG>
        <VALUE>Illumina</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>List</TAG>
        <VALUE/>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Primary Phenotype</TAG>
        <VALUE>Cancer</VALUE>
      </STUDY_ATTRIBUTE>
    </STUDY_ATTRIBUTES>
  </STUDY>
  <STUDY alias="JSUB000102_Study_0001" center_name="Individual" accession="JGAS000061">
    <IDENTIFIERS>
      <SECONDARY_ID>JGAS00000000061</SECONDARY_ID>
    </IDENTIFIERS>
    <DESCRIPTOR>
      <STUDY_TITLE>Geriatric Oncology Database of genotypes and methylation, gene expression, clinical data, and survey results on psychosocial and physical conditions in Japanese elderly cancer patients to establish truly effective treatment strategy</STUDY_TITLE>
      <STUDY_TYPES>
        <STUDY_TYPE existing_study_type="Case Set"/>
        <STUDY_TYPE existing_study_type="Control Set"/>
      </STUDY_TYPES>
      <STUDY_ABSTRACT>Owing to the advent of super-aged society, cancer mortality in Japan is forecasted to become an all-time high. The management of elderly patients with cancer is a serious health issue and the need for specific care guidelines for this population is critical in Japan. The significant individual differences in comorbidity, physical and mental functioning, and social problems among aging individuals are obstacles to the progress. The response to cancer treatment varies significantly among patients, even in the same stage of the same type of cancer. Older aged patients are still less likely to be offered participation in clinical trials, thus the number of clinical evidences is limited. The molecular mechanisms regulating the physiological process of ageing and senescence, and cancer are far from understood. To establish a truly effective treatment algorithm, we attempted to develop a geriatric oncology database for genotypes and methylation, gene expression, clinical data, and survey results on psychosocial and physical conditions in Japanese elderly cancer patients in this retrospective study. The genomic analysis was performed in 62, 106, and 173 cases, respectively for gastric, colon and lung cancers. The clinical data and survey results on psychosocial and physical conditions were collected from 166, 313, and 344 patients respectively for gastric, colon and lung cancers, and also collected from 357, 49, and 300 benign cases respectively for cardiovascular disorder, respiratory dysfunction, diabetes and nephropathy as the analysis control.
  </STUDY_ABSTRACT>
    </DESCRIPTOR>
    <STUDY_ATTRIBUTES>
      <STUDY_ATTRIBUTE>
        <TAG>NBDC Number</TAG>
        <VALUE>hum0064</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Registration date</TAG>
        <VALUE>2016-07-12</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Submitting organization</TAG>
        <VALUE>Gunma University</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Principal Investigator</TAG>
        <VALUE>Masahiko Nishiyama</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Molecular Data Type</TAG>
        <VALUE>Gene expression (cDNA microarray)</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Platform</TAG>
        <VALUE>G2565BA</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Vendor</TAG>
        <VALUE>Agilent</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>List</TAG>
        <VALUE/>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Molecular Data Type</TAG>
        <VALUE>Gene expression (qPCR)</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Platform</TAG>
        <VALUE>LightCycler480</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Vendor</TAG>
        <VALUE>Roche</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>List</TAG>
        <VALUE/>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Molecular Data Type</TAG>
        <VALUE>Genotyping</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Platform</TAG>
        <VALUE>LightCycler480</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Vendor</TAG>
        <VALUE>Roche</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>List</TAG>
        <VALUE/>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Molecular Data Type</TAG>
        <VALUE>Genotyping</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Platform</TAG>
        <VALUE>Genetic Analyzer 3130</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Vendor</TAG>
        <VALUE>ABI</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>List</TAG>
        <VALUE/>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Primary Phenotype</TAG>
        <VALUE>Cancer</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Phenotype</TAG>
        <VALUE>Cardiovascular disorder</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Phenotype</TAG>
        <VALUE>Respiratory dysfunction</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Phenotype</TAG>
        <VALUE>Nephropathy</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Phenotype</TAG>
        <VALUE>Diabetes</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Study Inclusion/Exclusion Criteria</TAG>
        <VALUE>Cancer case
  1) Patients with definite diagnosis of colorectal, gastric, and lung cancer.
  2) Patients who had received cancer treatment between September 2002 to June 2006.
  3) Patients?40 years old.
  4) Patients with claer records of age, gender, stage, prognosis, and therapeutic response.
  5) Patients who agreed enroll to this research project with written informed consent in case of genomic analysys.
  Benigh case (as the analysis control)
  1) Patients with definite diagnosis of cardiovascular disorder, respiratory dysfunction, diabetes and nephropathy.
  2) Patients who had no histrory of cancer. And patinets with cancer who achieved complete remission before September 2002.
  3) Patients who had received treatments for cardiovascular disorder, respiratory dysfunction, diabetes or nephropathy between September 2002 to June 2006.
  4) Patients &gt;= 40 years old.
  5) Patients with claer records of age, gender, stage, prognosis, and therapeutic response.</VALUE>
      </STUDY_ATTRIBUTE>
    </STUDY_ATTRIBUTES>
  </STUDY>
  <STUDY alias="JSUB000103_Study_0001" center_name="Individual" accession="JGAS000089">
    <IDENTIFIERS>
      <SECONDARY_ID>JGAS00000000089</SECONDARY_ID>
    </IDENTIFIERS>
    <DESCRIPTOR>
      <STUDY_TITLE>Project for Development of Innovative Research on Cancer Therapeutics;Shuttle system between petient-derived xenograft and ex vivo culture for innovative platform of evaluating drug sensitivity.</STUDY_TITLE>
      <STUDY_TYPES>
        <STUDY_TYPE existing_study_type="Tumor vs. Matched-Normal"/>
      </STUDY_TYPES>
      <STUDY_ABSTRACT>We developed CTOS (cancer tissue-originated spheroid) panel covering diversity among patients for colorectal cancer, lung cancer and cervical small cell carcinoma.
  We then carried out exome sequence analysis of tumor tissues, cell lines and CTOS derived from patients to validate qualitative changes in preparation, culture, cell line, transplantation and passage of CTOS pathologically, biochemically, molecular biologically.</STUDY_ABSTRACT>
    </DESCRIPTOR>
    <STUDY_ATTRIBUTES>
      <STUDY_ATTRIBUTE>
        <TAG>NBDC Number</TAG>
        <VALUE>hum0065</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Registration date</TAG>
        <VALUE>2016-11-15</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Submitting organization</TAG>
        <VALUE>Osaka Medical Center for Cancer and Cardiovascular Diseases</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Principal Investigator</TAG>
        <VALUE>Masahiro Inoue</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Molecular Data Type</TAG>
        <VALUE>Whole Exome Sequencing</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Platform</TAG>
        <VALUE>Hiseq 2000</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Vendor</TAG>
        <VALUE>Illumina</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>List</TAG>
        <VALUE/>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Primary Phenotype</TAG>
        <VALUE>Cancer</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Disease Type</TAG>
        <VALUE>Neoplasms</VALUE>
      </STUDY_ATTRIBUTE>
    </STUDY_ATTRIBUTES>
  </STUDY>
  <STUDY alias="JSUB000105_Study_0001" center_name="Individual" accession="JGAS000060">
    <IDENTIFIERS>
      <SECONDARY_ID>JGAS00000000060</SECONDARY_ID>
    </IDENTIFIERS>
    <DESCRIPTOR>
      <STUDY_TITLE>Investigating genomic intratumor heterogeneity in colorectal carcinoma</STUDY_TITLE>
      <STUDY_TYPES>
        <STUDY_TYPE existing_study_type="Case-Control"/>
        <STUDY_TYPE existing_study_type="Case Set"/>
        <STUDY_TYPE existing_study_type="Tumor vs. Matched-Normal"/>
      </STUDY_TYPES>
      <STUDY_ABSTRACT>To investigateintertumor heterogeneity of colorecatal carcinoma, we profiled the genome and epigenome in multiple regions within each of nine colorectal tumors.</STUDY_ABSTRACT>
    </DESCRIPTOR>
    <GRANTS>
      <GRANT grant_id="25861199">
        <TITLE>CREST</TITLE>
        <AGENCY abbr="JST">Japan Science and Technology</AGENCY>
      </GRANT>
      <GRANT grant_id="">
        <TITLE>Supercomputational Life Science</TITLE>
        <AGENCY abbr="">The MEXT Strategic Programs on Innovative
  Research</AGENCY>
      </GRANT>
    </GRANTS>
    <PUBLICATIONS>
      <PUBLICATION id="26890883" status="published">
        <DB_TYPE>PUBMED</DB_TYPE>
      </PUBLICATION>
    </PUBLICATIONS>
    <STUDY_ATTRIBUTES>
      <STUDY_ATTRIBUTE>
        <TAG>NBDC Number</TAG>
        <VALUE>hum0066</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Registration date</TAG>
        <VALUE>2016-07-08</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Submitting organization</TAG>
        <VALUE>Kyushu University</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Principal Investigator</TAG>
        <VALUE>Uchi Ryutaro</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Molecular Data Type</TAG>
        <VALUE>Whole Exome Sequencing</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Platform</TAG>
        <VALUE>Hiseq2000</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Vendor</TAG>
        <VALUE>Illumina</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>List</TAG>
        <VALUE/>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Primary Phenotype</TAG>
        <VALUE>Cancer</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Phenotype</TAG>
        <VALUE>Colorectal Carcinoma</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Study Inclusion/Exclusion Criteria</TAG>
        <VALUE>Patients who underwent radical resection of primary and/or liver metastatic tumors at Kyushu University Beppu Hospital, Kyushu University Hospital and Osaka University Hospital.</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Disease Type</TAG>
        <VALUE>Neoplasms</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Disease Type</TAG>
        <VALUE>Colorectal Carcinoma</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Methods</TAG>
        <VALUE>Exome sequencing</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Sampling</TAG>
        <VALUE>Multiregional samplig</VALUE>
      </STUDY_ATTRIBUTE>
    </STUDY_ATTRIBUTES>
  </STUDY>
  <STUDY alias="JSUB000108_Study_0001" center_name="Individual" accession="JGAS000076">
    <IDENTIFIERS>
      <SECONDARY_ID>JGAS00000000076</SECONDARY_ID>
    </IDENTIFIERS>
    <DESCRIPTOR>
      <STUDY_TITLE>Project for Development of Innovative Research on Cancer Therapeutics; Identifiying the predictive factors for response to chemoherapy in ovarian cancer</STUDY_TITLE>
      <STUDY_TYPES>
        <STUDY_TYPE existing_study_type="Tumor vs. Matched-Normal"/>
      </STUDY_TYPES>
      <STUDY_ABSTRACT>To identify novel predictive biomarkers of response to chemotherapy for clear cell carcinoma of the ovary</STUDY_ABSTRACT>
    </DESCRIPTOR>
    <STUDY_ATTRIBUTES>
      <STUDY_ATTRIBUTE>
        <TAG>NBDC Number</TAG>
        <VALUE>hum0067</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Registration date</TAG>
        <VALUE>2016-09-27</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Submitting organization</TAG>
        <VALUE>Department of Obstetrics and Gynecology, Iwate Medical University School of Medicine</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Principal Investigator</TAG>
        <VALUE>Toru Sugiyama</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Molecular Data Type</TAG>
        <VALUE>Exome Sequencing</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Platform</TAG>
        <VALUE>Hiseq 2000</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Vendor</TAG>
        <VALUE>Illumina</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>List</TAG>
        <VALUE/>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Primary Phenotype</TAG>
        <VALUE>Clear Cell Carcinoma of the Ovary</VALUE>
      </STUDY_ATTRIBUTE>
    </STUDY_ATTRIBUTES>
  </STUDY>
  <STUDY alias="JSUB000109_Study_0001" center_name="Individual" accession="JGAS000115">
    <IDENTIFIERS>
      <SECONDARY_ID>JGAS00000000115</SECONDARY_ID>
    </IDENTIFIERS>
    <DESCRIPTOR>
      <STUDY_TITLE>BHD-associated kidney cancer</STUDY_TITLE>
      <STUDY_TYPES>
        <STUDY_TYPE existing_study_type="Tumor vs. Matched-Normal"/>
      </STUDY_TYPES>
      <STUDY_ABSTRACT>Background
  Birt-Hogg-Dub? (BHD) syndrome is a hereditary kidney cancer syndrome, which predisposes patients to develop kidney cancer, cutaneous fibrofolliculomas and pulmonary cysts. The responsible gene, FLCN is a tumor suppressor for kidney cancer which plays an important role for energy homeostasis through the regulation of mitochondrial oxidative metabolism. However, how FLCN-deficiency leads to renal tumorigenesis is unclear.
  Results
  Whole-exome sequencing analysis of BHD-associated kidney cancer revealed that copy number variations (CNV) of BHD-associated kidney cancer are considerably different from those already reported in sporadic cases. Somatic mutation analysis revealed BHD-associated kidney cancer has quite few common mutations in specific genes; however, chromatin remodeling genes in total were frequently mutated in BHD-associated kidney cancer (17/29 tumors, 59%). Metabolite analysis revealed that glycolysis, pentose phosphate pathway and lipid metabolism were upregulated whereas the rate of beta oxydation and TCA cycle is decreased in BHD-associated kidney cancer compared to normal adjacent kidney.
  Conclusions
  BHD-associated kidney cancer displays a unique molecular characteristics which is totally different from that of sporadic kidney cancer, providing the mechanistic insight into tumorigenesis under FLCN deficiency as well as the foundation for the development of novel therapeutics for kidney cancer.</STUDY_ABSTRACT>
    </DESCRIPTOR>
    <GRANTS>
      <GRANT grant_id="0">
        <TITLE>Project for Development of Innovative Research on Cancer Therapeutics (P-DIRECT)</TITLE>
        <AGENCY abbr="MECSST, JP">Ministry of Education, Culture, Sports, Science and Technology, Japan</AGENCY>
      </GRANT>
    </GRANTS>
    <STUDY_LINKS>
      <STUDY_LINK>
        <URL_LINK>
          <LABEL>http://www-user.yokohama-cu.ac.jp/~urology/wp/</LABEL>
          <URL>http://www-user.yokohama-cu.ac.jp/~urology/wp/</URL>
        </URL_LINK>
      </STUDY_LINK>
      <STUDY_LINK>
        <URL_LINK>
          <LABEL>https://www.bhd-net.jp/</LABEL>
          <URL>https://www.bhd-net.jp/</URL>
        </URL_LINK>
      </STUDY_LINK>
    </STUDY_LINKS>
    <STUDY_ATTRIBUTES>
      <STUDY_ATTRIBUTE>
        <TAG>NBDC Number</TAG>
        <VALUE>hum0070</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Registration date</TAG>
        <VALUE>2017-08-18</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Submitting organization</TAG>
        <VALUE>Yokohama City University</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Principal Investigator</TAG>
        <VALUE>Masahiro Yao</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Molecular Data Type</TAG>
        <VALUE>Whole Exome Sequencing</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Platform</TAG>
        <VALUE>HiSeq 2000/2500</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Vendor</TAG>
        <VALUE>Illumina</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>List</TAG>
        <VALUE/>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Primary Phenotype</TAG>
        <VALUE>Cancer</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Study Inclusion/Exclusion Criteria</TAG>
        <VALUE>BHD syndrome</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Disease Type</TAG>
        <VALUE>Neoplasms</VALUE>
      </STUDY_ATTRIBUTE>
    </STUDY_ATTRIBUTES>
  </STUDY>
  <STUDY alias="JSUB000110_Study_0001" center_name="Individual" accession="JGAS000065">
    <IDENTIFIERS>
      <SECONDARY_ID>JGAS00000000065</SECONDARY_ID>
    </IDENTIFIERS>
    <DESCRIPTOR>
      <STUDY_TITLE>Sequencing cancer mutations in various types of lung cancer using the long-read, portable sequencer</STUDY_TITLE>
      <STUDY_TYPES>
        <STUDY_TYPE existing_study_type="Case Set"/>
        <STUDY_TYPE existing_study_type="Exome Sequencing"/>
      </STUDY_TYPES>
      <STUDY_ABSTRACT>In this study, we used a long-read and portable sequencer MinION to identify cancer mutations in lung adenocarcinoma cells. We performed cDNA amplicon sequencing for various types of mutations such as point mutations in EGFR and KRAS and oncogenic fusion transcripts in ALK and RET. Using the long reads of MinION, we also conducted mutation phasing of EGFR TKI-sensitive and resistant mutations, which would provide useful information to next thrapeutic approaches for cancers. We applied this method to identify mutation genotypes of eight clinical samples from Japanese lung adenocarcinomas. This method could provide new sequencing-based diagnostic approaches for lung cancers. Additinally we also performed cancer mutation identification of risk-dependent unique samples. Usual interstitial pneumonia (UIP) is a risk factor for lung carcinogenesis. This study was performed to characterize mutagenesis and mutational target genes underlying lung carcinogenesis in patients with UIP.We performed whole exome sequencing of lung adenocarcinoma with usual interstitial pneumonia.</STUDY_ABSTRACT>
    </DESCRIPTOR>
    <PUBLICATIONS>
      <PUBLICATION id="29117310" status="published">
        <DB_TYPE>PUBMED</DB_TYPE>
      </PUBLICATION>
    </PUBLICATIONS>
    <STUDY_ATTRIBUTES>
      <STUDY_ATTRIBUTE>
        <TAG>NBDC Number</TAG>
        <VALUE>hum0068</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Registration date</TAG>
        <VALUE>2016-08-16</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Submitting organization</TAG>
        <VALUE>National Cancer Center Research Institute</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Principal Investigator</TAG>
        <VALUE>Takashi Kono</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Molecular Data Type</TAG>
        <VALUE>Amplicon Sequencing</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Molecular Data Type</TAG>
        <VALUE>Whole exome sequencing</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Platform</TAG>
        <VALUE>MinION</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Platform</TAG>
        <VALUE>HiSeq2000</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Vendor</TAG>
        <VALUE>Oxford nanopore</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Vendor</TAG>
        <VALUE>Illumina</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>List</TAG>
        <VALUE/>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Primary Phenotype</TAG>
        <VALUE>Lung Cancer (HP:0100526)</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Phenotype</TAG>
        <VALUE>Usual interstitial pneumonia (HP:0031950)</VALUE>
      </STUDY_ATTRIBUTE>
    </STUDY_ATTRIBUTES>
  </STUDY>
  <STUDY alias="JSUB000111_Study_0001" center_name="Individual" accession="JGAS000064">
    <IDENTIFIERS>
      <SECONDARY_ID>JGAS00000000064</SECONDARY_ID>
    </IDENTIFIERS>
    <DESCRIPTOR>
      <STUDY_TITLE>RNA expression profiling of neuromuscular diseases and viral diseases</STUDY_TITLE>
      <STUDY_TYPES>
        <STUDY_TYPE existing_study_type="Transcriptome Sequencing"/>
      </STUDY_TYPES>
      <STUDY_ABSTRACT>MicroRNAs (miRNAs), particularly those found in human body fluids, have been suggested as potential biomarkers. Among various body fluids, the cerebrospinal fluid (CSF) shows promise as a profiling target for diagnosis and monitoring of neurological diseases. However, relevant genome-scale studies are limited and no studies have profiled exosomal miRNAs in CSF. Therefore, we conducted a next-generation sequencing-based survey of small RNAs in the exosomal and non-exosomal (supernatant) fractions of healthy human CSF as well as serum in each donor. Our data provided the first landscape of small RNAs in CSF exosome.</STUDY_ABSTRACT>
    </DESCRIPTOR>
    <PUBLICATIONS>
      <PUBLICATION id="27780738" status="published">
        <DB_TYPE>PUBMED</DB_TYPE>
      </PUBLICATION>
    </PUBLICATIONS>
    <STUDY_LINKS>
      <STUDY_LINK>
        <URL_LINK>
          <LABEL>http://www.tmd.ac.jp/med/nuro/index.html</LABEL>
          <URL>http://www.tmd.ac.jp/med/nuro/index.html</URL>
        </URL_LINK>
      </STUDY_LINK>
    </STUDY_LINKS>
    <STUDY_ATTRIBUTES>
      <STUDY_ATTRIBUTE>
        <TAG>NBDC Number</TAG>
        <VALUE>hum0069</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Registration date</TAG>
        <VALUE>2016-08-16</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Submitting organization</TAG>
        <VALUE>Tokyo Medical and Dental University</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Principal Investigator</TAG>
        <VALUE>Takanori Yokota</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Molecular Data Type</TAG>
        <VALUE>Small RNA sequencing</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Platform</TAG>
        <VALUE>HiSeq 2500</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Vendor</TAG>
        <VALUE>Illumina</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>List</TAG>
        <VALUE/>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Primary Phenotype</TAG>
        <VALUE>Healthy donors</VALUE>
      </STUDY_ATTRIBUTE>
    </STUDY_ATTRIBUTES>
  </STUDY>
  <STUDY alias="JSUB000118_Study_0001" center_name="Individual" accession="JGAS000070">
    <IDENTIFIERS>
      <SECONDARY_ID>JGAS00000000070</SECONDARY_ID>
    </IDENTIFIERS>
    <DESCRIPTOR>
      <STUDY_TITLE>CAGE analysis for non-small cell lung carcinoma</STUDY_TITLE>
      <STUDY_TYPES>
        <STUDY_TYPE existing_study_type="Transcriptome Sequencing"/>
      </STUDY_TYPES>
      <STUDY_ABSTRACT>Targeted therapies based on the molecular and histological features of cancer types are becoming standard practice. The most effective regimen in lung cancers is different between squamous cell carcinoma (SCC) and adenocarcinoma (AD). Therefore a precise diagnosis is crucial, but this has been difficult, particularly for poorly differentiated SCC (PDSCC) and AD without a lepidic growth component (non-lepidic AD). Biomarkers enabling a precise diagnosis are therefore urgently needed.
  To achieve this goal, we performed CAGE (Cap Analysis of Gene Expression) to quantify promoter activities on 97 frozen tissues from surgically resected lung cancers (22 SCC and 75 AD). The result was followed up by by immunohistochemical analysis (IHC) in an independent group. </STUDY_ABSTRACT>
    </DESCRIPTOR>
    <GRANTS>
      <GRANT grant_id="">
        <TITLE>Grant-in-Aid for Scientific Research (C )</TITLE>
        <AGENCY abbr="MEXT">Ministry of Education, Culture, Sports, Science and Technology</AGENCY>
      </GRANT>
      <GRANT grant_id="">
        <TITLE>Research Grant for RIKEN Omics Science Center</TITLE>
        <AGENCY abbr="MEXT">Ministry of Education, Culture, Sports, Science and Technology</AGENCY>
      </GRANT>
      <GRANT grant_id="">
        <TITLE>Research Grant to RIKEN Preventive Medicine and Diagnosis Innovation Program</TITLE>
        <AGENCY abbr="MEXT">Ministry of Education, Culture, Sports, Science and Technology</AGENCY>
      </GRANT>
    </GRANTS>
    <STUDY_ATTRIBUTES>
      <STUDY_ATTRIBUTE>
        <TAG>NBDC Number</TAG>
        <VALUE>hum0083</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Registration date</TAG>
        <VALUE>2016-09-16</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Submitting organization</TAG>
        <VALUE>RIKEN Preventive Medicine and Diagnosis Innovation Program</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Principal Investigator</TAG>
        <VALUE>Yoshihide Hayashizaki</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Molecular Data Type</TAG>
        <VALUE>Transcriptome (Cap Analysis Of Gene Expression)</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Platform</TAG>
        <VALUE>HiSeq2500</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Vendor</TAG>
        <VALUE>Illumina</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>List</TAG>
        <VALUE/>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Primary Phenotype</TAG>
        <VALUE>Non-small cell lung carcinoma</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Disease Type</TAG>
        <VALUE>Respiratory Tract Diseases</VALUE>
      </STUDY_ATTRIBUTE>
    </STUDY_ATTRIBUTES>
  </STUDY>
  <STUDY alias="JSUB000119_Study_0001" center_name="Individual" accession="JGAS000071">
    <IDENTIFIERS>
      <SECONDARY_ID>JGAS00000000071</SECONDARY_ID>
    </IDENTIFIERS>
    <DESCRIPTOR>
      <STUDY_TITLE>Association study between NLRP1?3/CARD8 SNPs and outcomes of unrelated bone marrow transplantation</STUDY_TITLE>
      <STUDY_TYPES>
        <STUDY_TYPE existing_study_type="Other" new_study_type="Retrospective study"/>
        <STUDY_TYPE existing_study_type="Other" new_study_type="Survival analysis"/>
      </STUDY_TYPES>
      <STUDY_ABSTRACT>We examined the associations between inflammasome genes and outcomes of hematopoietic stem cell transplantation. We retrospectively genotyped two NLRP3 SNPs and one SNP each from NLRP1, NLRP2, and CARD8 in 999 Japanese donor?recipient pairs who underwent unrelated bone marrow transplantation matched at least at HLA-A, -B, and -DRB1 from October 2006 to April 2009 through the Japan Marrow Donor Program (JMDP).</STUDY_ABSTRACT>
    </DESCRIPTOR>
    <GRANTS>
      <GRANT grant_id="26460802">
        <TITLE>KAKENHI</TITLE>
        <AGENCY abbr="JSPS">The Japan Society for the Promotion of Science</AGENCY>
      </GRANT>
      <GRANT grant_id="25860408">
        <TITLE>KAKENHI</TITLE>
        <AGENCY abbr="JSPS">The Japan Society for the Promotion of Science</AGENCY>
      </GRANT>
      <GRANT grant_id="">
        <TITLE>The 53rd Academic Award</TITLE>
        <AGENCY abbr="">Ube Industries Research Foundation</AGENCY>
      </GRANT>
    </GRANTS>
    <STUDY_ATTRIBUTES>
      <STUDY_ATTRIBUTE>
        <TAG>NBDC Number</TAG>
        <VALUE>hum0084</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Registration date</TAG>
        <VALUE>2016-09-21</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Submitting organization</TAG>
        <VALUE>Yamaguchi University Graduate School of Medicine</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Principal Investigator</TAG>
        <VALUE>Tsuyoshi Tanabe</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Molecular Data Type</TAG>
        <VALUE>TaqMan SNP Genotyping Assays</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Platform</TAG>
        <VALUE>7900HT and ViiA 7</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Vendor</TAG>
        <VALUE>Applied Biosystems</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>List</TAG>
        <VALUE/>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Molecular Data Type</TAG>
        <VALUE>PCR direct Sanger sequencing</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Platform</TAG>
        <VALUE>3730xl</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Vendor</TAG>
        <VALUE>Applied Biosystems</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>List</TAG>
        <VALUE/>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Primary Phenotype</TAG>
        <VALUE>Outcomes of bone marrow transplantation</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Disease Type</TAG>
        <VALUE>Immune System Diseases</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Disease Type</TAG>
        <VALUE>Hemic and Lymphatic Diseases</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Outcome of bone marrow transplantation</TAG>
        <VALUE>Grade 2?4 acute graft-versus-host disease</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Outcome of bone marrow transplantation</TAG>
        <VALUE>Grade 3?4 acute graft-versus-host disease</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Outcome of bone marrow transplantation</TAG>
        <VALUE>Chronic graft-versus-host disease</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Outcome of bone marrow transplantation</TAG>
        <VALUE>Mortality</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Outcome of bone marrow transplantation</TAG>
        <VALUE>Relapse</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Outcome of bone marrow transplantation</TAG>
        <VALUE>Neutrophil engraftment</VALUE>
      </STUDY_ATTRIBUTE>
    </STUDY_ATTRIBUTES>
  </STUDY>
  <STUDY alias="JSUB000120_Study_0001" center_name="Individual" accession="JGAS000120">
    <IDENTIFIERS>
      <SECONDARY_ID>JGAS00000000120</SECONDARY_ID>
    </IDENTIFIERS>
    <DESCRIPTOR>
      <STUDY_TITLE>419 Japanese healthy control</STUDY_TITLE>
      <STUDY_TYPES>
        <STUDY_TYPE existing_study_type="Control Set"/>
      </STUDY_TYPES>
      <STUDY_ABSTRACT>Genotypes of 419 Japanese healthy individuals genotyped by using of SNP arrays (Genome-Wide Human SNP Array 6.0 and Axiom Genome-Wide ASI 1 Array). CEL files and CHP files are included in this data set.</STUDY_ABSTRACT>
    </DESCRIPTOR>
    <STUDY_ATTRIBUTES>
      <STUDY_ATTRIBUTE>
        <TAG>NBDC Number</TAG>
        <VALUE>hum0082</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Registration date</TAG>
        <VALUE>2017-09-21</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Submitting organization</TAG>
        <VALUE>University of Tokyo</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Principal Investigator</TAG>
        <VALUE>Katsushi Tokunaga</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Molecular Data Type</TAG>
        <VALUE>SNP array</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Platform</TAG>
        <VALUE>Genome-Wide Human SNP Array 6.0</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Vendor</TAG>
        <VALUE>Affymetrix</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>List</TAG>
        <VALUE/>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Molecular Data Type</TAG>
        <VALUE>SNP array</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Platform</TAG>
        <VALUE>Axiom Genome-Wide ASI 1 Array</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Vendor</TAG>
        <VALUE>Affymetrix</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>List</TAG>
        <VALUE/>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Primary Phenotype</TAG>
        <VALUE>Japanese healthy individuals</VALUE>
      </STUDY_ATTRIBUTE>
    </STUDY_ATTRIBUTES>
  </STUDY>
  <STUDY alias="JSUB000122_Study_0001" center_name="Individual" accession="JGAS000073">
    <IDENTIFIERS>
      <SECONDARY_ID>JGAS00000000073</SECONDARY_ID>
    </IDENTIFIERS>
    <DESCRIPTOR>
      <STUDY_TITLE>Epigenomic analysis of the human placenta and endometrium constituting the fetal-maternal interface</STUDY_TITLE>
      <STUDY_TYPES>
        <STUDY_TYPE existing_study_type="Transcriptome Sequencing"/>
        <STUDY_TYPE existing_study_type="Other" new_study_type="Bisulfite Sequencing, Chip-seq"/>
      </STUDY_TYPES>
      <STUDY_ABSTRACT>This study aims to determine the reference epigenomes of the human placenta and endometrium, which constitute the fetal-meternal interface, for future use in studies of human diseases associated with reproduction and development. In the placenta, we focus on cytotrophoblast and syncytiotrophoblast cells (both at first trimester and at term) and, in the endometrium, we focus on epithelial cells (at the follicular and secretory phases) and stroma cells. These reference epigenomic data will be of valuable resource in studying disease-associated differences in epigenomic modification in the reproductive system.</STUDY_ABSTRACT>
    </DESCRIPTOR>
    <GRANTS>
      <GRANT grant_id="">
        <TITLE>Core Research for Evolutional Science and Technology (CREST)</TITLE>
        <AGENCY abbr="AMED">Japan Agency for Medical Research and Development</AGENCY>
      </GRANT>
    </GRANTS>
    <STUDY_LINKS>
      <STUDY_LINK>
        <URL_LINK>
          <LABEL>http://ihec-epigenomes.net/</LABEL>
          <URL>http://ihec-epigenomes.net/</URL>
        </URL_LINK>
      </STUDY_LINK>
      <STUDY_LINK>
        <URL_LINK>
          <LABEL>http://crest-ihec.jp/english/index.html</LABEL>
          <URL>http://crest-ihec.jp/english/index.html</URL>
        </URL_LINK>
      </STUDY_LINK>
    </STUDY_LINKS>
    <STUDY_ATTRIBUTES>
      <STUDY_ATTRIBUTE>
        <TAG>NBDC Number</TAG>
        <VALUE>hum0086</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Registration date</TAG>
        <VALUE>2016-09-28</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Submitting organization</TAG>
        <VALUE>Medical Institute of Bioregulation, Kyushu University</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Principal Investigator</TAG>
        <VALUE>Hiroyuki Sasaki</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Molecular Data Type</TAG>
        <VALUE>Transcriptome Sequencing</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Platform</TAG>
        <VALUE>HiSeq 2500</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Vendor</TAG>
        <VALUE>Illumina</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>List</TAG>
        <VALUE/>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Molecular Data Type</TAG>
        <VALUE>Bisulfite Sequencing</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Platform</TAG>
        <VALUE>HiSeq 2500</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Vendor</TAG>
        <VALUE>Illumina</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>List</TAG>
        <VALUE/>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Molecular Data Type</TAG>
        <VALUE>ChIP-seq</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Platform</TAG>
        <VALUE>HiSeq 2500</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Vendor</TAG>
        <VALUE>Illumina</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>List</TAG>
        <VALUE/>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Primary Phenotype</TAG>
        <VALUE>Normal/none</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Project</TAG>
        <VALUE>International Human Epigenome Consortium (IHEC)</VALUE>
      </STUDY_ATTRIBUTE>
    </STUDY_ATTRIBUTES>
  </STUDY>
  <STUDY alias="JSUB000123_Study_0001" center_name="Individual" accession="JGAS000108">
    <IDENTIFIERS>
      <SECONDARY_ID>JGAS00000000108</SECONDARY_ID>
    </IDENTIFIERS>
    <DESCRIPTOR>
      <STUDY_TITLE>Genomic DNA analysis for malignant mesothelioma from the patients of Japan and USA.</STUDY_TITLE>
      <STUDY_TYPES>
        <STUDY_TYPE existing_study_type="Tumor vs. Matched-Normal"/>
      </STUDY_TYPES>
      <STUDY_ABSTRACT>Malignant mesotheliomas (MMs) are highly aggressive adult malignancies and exposure to asbestos is the major factor involved in MM pathogenesis. It is desirable for a better understanding of the molecular pathogenesis of MM will lead to more specific and effective targeted therapies. In addition it is reported that germline mutation in a specific gene (ex. BAP1) associates familial MMs, and new candidate markers to determine a subject?s predisposition to MM and for early detection need to be identified. Analysis of genomic DNA from MM tumors and reference peripheral blood from Japan and USA are ongoing to find the common genomic characters beyond race. </STUDY_ABSTRACT>
    </DESCRIPTOR>
    <GRANTS>
      <GRANT grant_id="0">
        <TITLE>Analysis of genome rearrangements in chr3p21 of cancers caused by environmental carcinogens, including malignant mesothelioma.</TITLE>
        <AGENCY abbr="MEXT">Ministry of Education, Culture, Sports, Science and Technology</AGENCY>
      </GRANT>
      <GRANT grant_id="0">
        <TITLE>Finding of the predisposition genes to malignant mesothelioma.</TITLE>
        <AGENCY abbr="MEXT">Ministry of Education, Culture, Sports, Science and Technology</AGENCY>
      </GRANT>
    </GRANTS>
    <PUBLICATIONS>
      <PUBLICATION id="27834213" status="published">
        <DB_TYPE>PUBMED</DB_TYPE>
      </PUBLICATION>
    </PUBLICATIONS>
    <STUDY_ATTRIBUTES>
      <STUDY_ATTRIBUTE>
        <TAG>NBDC Number</TAG>
        <VALUE>hum0085</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Registration date</TAG>
        <VALUE>2016-12-05</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Submitting organization</TAG>
        <VALUE>Department of Genetics, Hyogo College of Medicine</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Principal Investigator</TAG>
        <VALUE>Masaki Ohmuraya</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Molecular Data Type</TAG>
        <VALUE>Target Capture Sequencing</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Platform</TAG>
        <VALUE>MiSeq</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Vendor</TAG>
        <VALUE>Illumina</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>List</TAG>
        <VALUE/>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Molecular Data Type</TAG>
        <VALUE>Whole Genome Sequencing</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Platform</TAG>
        <VALUE>HiSeq X Ten</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Vendor</TAG>
        <VALUE>Illumina</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>List</TAG>
        <VALUE/>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Primary Phenotype</TAG>
        <VALUE>Cancer</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Phenotype</TAG>
        <VALUE>Malignant mesothelioma</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>disease</TAG>
        <VALUE>malignant mesothelioma</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>chromosome</TAG>
        <VALUE>chr3p21</VALUE>
      </STUDY_ATTRIBUTE>
    </STUDY_ATTRIBUTES>
  </STUDY>
  <STUDY alias="JSUB000125_Study_0001" center_name="Individual" accession="JGAS000077">
    <IDENTIFIERS>
      <SECONDARY_ID>JGAS00000000077</SECONDARY_ID>
    </IDENTIFIERS>
    <DESCRIPTOR>
      <STUDY_TITLE>RNA-seq analysis of BMP-stimulated glioma initiating cells</STUDY_TITLE>
      <STUDY_TYPES>
        <STUDY_TYPE existing_study_type="Transcriptome Sequencing"/>
      </STUDY_TYPES>
      <STUDY_ABSTRACT>Bone morphogenetic protein (BMP) signaling has been shown to suppress progression of glioblastoma by promoting astrocytic differentiation; however, roles of BMP signaling in cell proliferation and apoptosis of glioblastoma cells remains to be elucidated. We here performed RNA-seq analysis of glioma initiating cells to identify transcriptional target(s) of BMP.</STUDY_ABSTRACT>
    </DESCRIPTOR>
    <GRANTS>
      <GRANT grant_id="22112002">
        <TITLE>Effects of TGF-beta family on cancer microenvironment and strategies for cancer therapy</TITLE>
        <AGENCY abbr="MEXT">Ministry of Education, Culture, Sports, and Technology of Japan</AGENCY>
      </GRANT>
      <GRANT grant_id="24390070">
        <TITLE>Roles of BMP signaling in maintenance of cell stemness</TITLE>
        <AGENCY abbr="JSPS">Japan Society for the Promotion of Science</AGENCY>
      </GRANT>
      <GRANT grant_id="15H05774">
        <TITLE>Transcriptional regulation by TGF-beta signaling and its relation to progression of cancer</TITLE>
        <AGENCY abbr="JSPS">Japan Society for the Promotion of Science</AGENCY>
      </GRANT>
      <GRANT grant_id="201220012">
        <TITLE>Grants-in-Aid for Scientific Research</TITLE>
        <AGENCY abbr="">Ministry of Health, Labour and Welfare of Japan</AGENCY>
      </GRANT>
      <GRANT grant_id="">
        <TITLE>Core-to-Core Program Cooperative International Framework in TGF-beta Family Signaling</TITLE>
        <AGENCY abbr="JSPS">Japan Society for the Promotion of Science</AGENCY>
      </GRANT>
      <GRANT grant_id="19K16735">
        <TITLE>EphA6 tyrosine kinase as a potential biomarker for BMP-based therapy in adult glioblastoma</TITLE>
        <AGENCY abbr="JSPS">Japan Society for the Promotion of Science</AGENCY>
      </GRANT>
      <GRANT grant_id="17H06326">
        <TITLE>Molecular mechanisms of cell differentiation and diversity by TGF-beta family members</TITLE>
        <AGENCY abbr="JSPS">Japan Society for the Promotion of Science</AGENCY>
      </GRANT>
    </GRANTS>
    <PUBLICATIONS>
      <PUBLICATION id="28459464" status="published">
        <DB_TYPE>PUBMED</DB_TYPE>
      </PUBLICATION>
      <PUBLICATION id="31483918" status="published">
        <DB_TYPE>PUBMED</DB_TYPE>
      </PUBLICATION>
    </PUBLICATIONS>
    <STUDY_ATTRIBUTES>
      <STUDY_ATTRIBUTE>
        <TAG>NBDC Number</TAG>
        <VALUE>hum0088</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Registration date</TAG>
        <VALUE>2016-10-28</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Submitting organization</TAG>
        <VALUE>University of Tokyo</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Principal Investigator</TAG>
        <VALUE>Kohei Miyazono</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Molecular Data Type</TAG>
        <VALUE>RNA Sequencing</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Platform</TAG>
        <VALUE>Genome Analyzer IIx</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Vendor</TAG>
        <VALUE>Illumina</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>List</TAG>
        <VALUE/>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Molecular Data Type</TAG>
        <VALUE>RNA Sequencing</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Platform</TAG>
        <VALUE>Ion Proton</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Vendor</TAG>
        <VALUE>Thermo Fisher Scientific</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>List</TAG>
        <VALUE/>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Primary Phenotype</TAG>
        <VALUE>Cancer</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Disease Type</TAG>
        <VALUE>Neoplasms</VALUE>
      </STUDY_ATTRIBUTE>
    </STUDY_ATTRIBUTES>
  </STUDY>
  <STUDY alias="JSUB000129_Study_0001" center_name="Individual" accession="JGAS000078">
    <IDENTIFIERS>
      <SECONDARY_ID>JGAS00000000078</SECONDARY_ID>
    </IDENTIFIERS>
    <DESCRIPTOR>
      <STUDY_TITLE>Standard epigenome mapping in human epithelial cells of the digestive and urogenital organs [BS-Seq ]</STUDY_TITLE>
      <STUDY_TYPES>
        <STUDY_TYPE existing_study_type="Control Set"/>
        <STUDY_TYPE existing_study_type="Other" new_study_type="Epigenome"/>
      </STUDY_TYPES>
      <STUDY_ABSTRACT>The aim of this study is to participate in International Human Epigenome Consortium (http://ihec-epigenomes.org/), through disclosure of quality reference epigenome profiles in normal and diseased cells obtained from multiple Japanese people. </STUDY_ABSTRACT>
    </DESCRIPTOR>
    <STUDY_ATTRIBUTES>
      <STUDY_ATTRIBUTE>
        <TAG>NBDC Number</TAG>
        <VALUE>hum0090</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Registration date</TAG>
        <VALUE>2016-11-11</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Submitting organization</TAG>
        <VALUE>Division of Moleuclar Pathology, National Cancer Center Rsearch Institute</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Principal Investigator</TAG>
        <VALUE>Yae Kanai</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Primary Phenotype</TAG>
        <VALUE/>
      </STUDY_ATTRIBUTE>
    </STUDY_ATTRIBUTES>
  </STUDY>
  <STUDY alias="JSUB000130_Study_0001" center_name="Individual" accession="JGAS000079">
    <IDENTIFIERS>
      <SECONDARY_ID>JGAS00000000079</SECONDARY_ID>
    </IDENTIFIERS>
    <DESCRIPTOR>
      <STUDY_TITLE>Standard epigenome mapping in human epithelial cells of the digestive and urogenital organs [ ChIP-Seq ]</STUDY_TITLE>
      <STUDY_TYPES>
        <STUDY_TYPE existing_study_type="Control Set"/>
        <STUDY_TYPE existing_study_type="Other" new_study_type="Epigenome"/>
      </STUDY_TYPES>
      <STUDY_ABSTRACT>The aim of this study is to participate in International Human Epigenome Consortium (http://ihec-epigenomes.org/), through disclosure of quality reference epigenome profiles in normal and diseased cells obtained from multiple Japanese people. </STUDY_ABSTRACT>
    </DESCRIPTOR>
    <STUDY_ATTRIBUTES>
      <STUDY_ATTRIBUTE>
        <TAG>NBDC Number</TAG>
        <VALUE>hum0090</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Registration date</TAG>
        <VALUE>2016-11-11</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Submitting organization</TAG>
        <VALUE>Division of Moleuclar Pathology, National Cancer Center Rsearch Institute</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Principal Investigator</TAG>
        <VALUE>Yae Kanai</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Primary Phenotype</TAG>
        <VALUE/>
      </STUDY_ATTRIBUTE>
    </STUDY_ATTRIBUTES>
  </STUDY>
  <STUDY alias="JSUB000131_Study_0001" center_name="Individual" accession="JGAS000080">
    <IDENTIFIERS>
      <SECONDARY_ID>JGAS00000000080</SECONDARY_ID>
    </IDENTIFIERS>
    <DESCRIPTOR>
      <STUDY_TITLE>Standard epigenome mapping in human epithelial cells of the digestive and urogenital organs [RNA-Seq ]</STUDY_TITLE>
      <STUDY_TYPES>
        <STUDY_TYPE existing_study_type="Control Set"/>
        <STUDY_TYPE existing_study_type="Transcriptome Sequencing"/>
      </STUDY_TYPES>
      <STUDY_ABSTRACT>The aim of this study is to participate in International Human Epigenome Consortium (http://ihec-epigenomes.org/), through disclosure of quality reference epigenome profiles in normal and diseased cells obtained from multiple Japanese people. </STUDY_ABSTRACT>
    </DESCRIPTOR>
    <STUDY_ATTRIBUTES>
      <STUDY_ATTRIBUTE>
        <TAG>NBDC Number</TAG>
        <VALUE>hum0090</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Registration date</TAG>
        <VALUE>2016-11-11</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Submitting organization</TAG>
        <VALUE>Division of Moleuclar Pathology, National Cancer Center Rsearch Institute</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Principal Investigator</TAG>
        <VALUE>Yae Kanai</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Primary Phenotype</TAG>
        <VALUE/>
      </STUDY_ATTRIBUTE>
    </STUDY_ATTRIBUTES>
  </STUDY>
  <STUDY alias="JSUB000142_Study_0001" center_name="Individual" accession="JGAS000095">
    <IDENTIFIERS>
      <SECONDARY_ID>JGAS00000000095</SECONDARY_ID>
    </IDENTIFIERS>
    <DESCRIPTOR>
      <STUDY_TITLE>High-coverage whole-genome sequencing reveals structural variations in triple-negative breast cancer</STUDY_TITLE>
      <STUDY_TYPES>
        <STUDY_TYPE existing_study_type="Whole Genome Sequencing"/>
        <STUDY_TYPE existing_study_type="Exome Sequencing"/>
        <STUDY_TYPE existing_study_type="Transcriptome Sequencing"/>
      </STUDY_TYPES>
      <STUDY_ABSTRACT>Triple-negative breast cancer (TNBC) cells do not express estrogen receptors, progesterone receptors or human epidermal growth factor receptor 2 (HER2). Currently, apart from poly ADP-ribose polymerase (PARP) inhibitors, there are few effective therapeutic options for this cancer type. Here, we present a comprehensive characterization of genetic alterations in TNBC via high-coverage whole-genome sequencing along with transcriptomic and whole-exome sequencing. Silencing of BRCA1 gene impaired the homologous recombination (HR) pathway in a subset of TNBC, which exhibited similar phenotypes with tumors with BRCA1 mutations; they harbored many structural variations (SVs) with relative enrichment for tandem duplication. Clonal analysis suggested that TP53 mutations and methylation of CpG dinucleotides in the BRCA1 promoter were the early events of carcinogenesis. SVs were associated with driver oncogenic events such as amplification of MYC, NOTCH2 or NOTCH3 and impacted tumor suppressor genes including RB1, PTEN and KMT2C. We also identified a variety of oncogenes that could transform 3T3 mouse fibroblast cells, suggesting that individual TNBC tumors may undergo a unique driver event that can be targetable. Thus, we revealed several features of TNBC that had important clinical implications.</STUDY_ABSTRACT>
    </DESCRIPTOR>
    <STUDY_ATTRIBUTES>
      <STUDY_ATTRIBUTE>
        <TAG>NBDC Number</TAG>
        <VALUE>hum0094</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Registration date</TAG>
        <VALUE>2017-02-22</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Submitting organization</TAG>
        <VALUE>Department of Celluar Signaling, Graduate School of Medicine, The University of Tokyo</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Principal Investigator</TAG>
        <VALUE>Hiroyuki Mano</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Molecular Data Type</TAG>
        <VALUE>Whole Genome Sequencing</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Platform</TAG>
        <VALUE>HiSeq2000/2500</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Vendor</TAG>
        <VALUE>Illumina</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>List</TAG>
        <VALUE/>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Molecular Data Type</TAG>
        <VALUE>Whole Exome Sequencing</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Platform</TAG>
        <VALUE>HiSeq2000/2500</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Vendor</TAG>
        <VALUE>Illumina</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>List</TAG>
        <VALUE/>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Molecular Data Type</TAG>
        <VALUE>RNA Sequencing</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Platform</TAG>
        <VALUE>HiSeq2000/2500</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Vendor</TAG>
        <VALUE>Illumina</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>List</TAG>
        <VALUE/>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Primary Phenotype</TAG>
        <VALUE>Triple negative breast cancer</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Disease</TAG>
        <VALUE>Triple negative breast cancer</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Sequencing method</TAG>
        <VALUE>Whole genome sequencing</VALUE>
      </STUDY_ATTRIBUTE>
    </STUDY_ATTRIBUTES>
  </STUDY>
  <STUDY alias="JSUB000143_Study_0001" center_name="Individual" accession="JGAS000092">
    <IDENTIFIERS>
      <SECONDARY_ID>JGAS00000000092</SECONDARY_ID>
    </IDENTIFIERS>
    <DESCRIPTOR>
      <STUDY_TITLE>intratumor heterogeneity in colorectal adenoma and carcinoma</STUDY_TITLE>
      <STUDY_TYPES>
        <STUDY_TYPE existing_study_type="Tumor vs. Matched-Normal"/>
      </STUDY_TYPES>
      <STUDY_ABSTRACT>To investigate intratumor heterogeneity in precancerous lesions of colorectal cancers (PCRCs), we performed whole-exome sequencing of 53 tumor and 10 matched-normal samples from 10 laterally spreading tumors in the colon and rectum, which were histologically diagnosed as adenoma with/without adenocarcinoma.</STUDY_ABSTRACT>
    </DESCRIPTOR>
    <PUBLICATIONS>
      <PUBLICATION id="30038269" status="published">
        <DB_TYPE>PUBMED</DB_TYPE>
      </PUBLICATION>
    </PUBLICATIONS>
    <STUDY_ATTRIBUTES>
      <STUDY_ATTRIBUTE>
        <TAG>NBDC Number</TAG>
        <VALUE>hum0095</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Registration date</TAG>
        <VALUE>2017-02-07</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Submitting organization</TAG>
        <VALUE>Depertment of Surgery, Kyshu University Beppu Hospital</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Principal Investigator</TAG>
        <VALUE>Koshi Mimori</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Molecular Data Type</TAG>
        <VALUE>Whole Exome Sequencing</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Platform</TAG>
        <VALUE>Hiseq2500</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Vendor</TAG>
        <VALUE>Illumina</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>List</TAG>
        <VALUE/>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Primary Phenotype</TAG>
        <VALUE>cancer/colorectal cancer</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Disease Type</TAG>
        <VALUE>Neoplasms</VALUE>
      </STUDY_ATTRIBUTE>
    </STUDY_ATTRIBUTES>
  </STUDY>
  <STUDY alias="JSUB000145_Study_0001" center_name="Individual" accession="JGAS000090">
    <IDENTIFIERS>
      <SECONDARY_ID>JGAS00000000090</SECONDARY_ID>
    </IDENTIFIERS>
    <DESCRIPTOR>
      <STUDY_TITLE>Whole transcriptome sequencing of pediatric T-cell acute lymphoblastic leukemia</STUDY_TITLE>
      <STUDY_TYPES>
        <STUDY_TYPE existing_study_type="Transcriptome Sequencing"/>
      </STUDY_TYPES>
      <STUDY_ABSTRACT>Pediatric T-cell acute lymphoblastic leukemia (T-ALL) is rare and its pathogenesis is poorly understood. To investigate molecular basis of pediatric T-ALL, we performed whole transcriptome sequencing in 123 cases of pediatric T-ALL.</STUDY_ABSTRACT>
    </DESCRIPTOR>
    <PUBLICATIONS>
      <PUBLICATION id="28671687" status="published">
        <DB_TYPE>PUBMED</DB_TYPE>
      </PUBLICATION>
    </PUBLICATIONS>
    <STUDY_ATTRIBUTES>
      <STUDY_ATTRIBUTE>
        <TAG>NBDC Number</TAG>
        <VALUE>hum0096</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Registration date</TAG>
        <VALUE>2017-01-19</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Submitting organization</TAG>
        <VALUE>Department of Pediatrics, The University of Tokyo</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Principal Investigator</TAG>
        <VALUE>Junko Takita</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Molecular Data Type</TAG>
        <VALUE>Whole transcriptome sequencing</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Platform</TAG>
        <VALUE>Hiseq 2500</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Vendor</TAG>
        <VALUE>Illumina</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>List</TAG>
        <VALUE/>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Primary Phenotype</TAG>
        <VALUE>T-ALL</VALUE>
      </STUDY_ATTRIBUTE>
    </STUDY_ATTRIBUTES>
  </STUDY>
  <STUDY alias="JSUB000146_Study_0001" center_name="Individual" accession="JGAS000094">
    <IDENTIFIERS>
      <SECONDARY_ID>JGAS00000000094</SECONDARY_ID>
    </IDENTIFIERS>
    <DESCRIPTOR>
      <STUDY_TITLE>The elucidation of molecular mechanisms of hematopoietic stem cells focusing on paroxysmal nocturnal hemoglobinuria (PNH)-type cells</STUDY_TITLE>
      <STUDY_TYPES>
        <STUDY_TYPE existing_study_type="Tumor vs. Matched-Normal"/>
      </STUDY_TYPES>
      <STUDY_ABSTRACT> To elucidate the pathogenicity of aplastic anemia, we conducted exome seqence analysis in 5 patients with aplastic anemia with uniparental disomy in 6p. </STUDY_ABSTRACT>
    </DESCRIPTOR>
    <PUBLICATIONS>
      <PUBLICATION id="29720492" status="published">
        <DB_TYPE>PUBMED</DB_TYPE>
      </PUBLICATION>
    </PUBLICATIONS>
    <STUDY_ATTRIBUTES>
      <STUDY_ATTRIBUTE>
        <TAG>NBDC Number</TAG>
        <VALUE>hum0097</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Registration date</TAG>
        <VALUE>2017-01-24</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Submitting organization</TAG>
        <VALUE>Clinical Laboratory Science, Division of Health Sciences, Kanazawa University Graduate School of Medical Science</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Principal Investigator</TAG>
        <VALUE>Takamasa Katagiri</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Molecular Data Type</TAG>
        <VALUE>Whole Exome Sequencing</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Platform</TAG>
        <VALUE>HiSeq 2500</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Vendor</TAG>
        <VALUE>Illumina</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>List</TAG>
        <VALUE/>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Primary Phenotype</TAG>
        <VALUE>Aplastic Anemia</VALUE>
      </STUDY_ATTRIBUTE>
    </STUDY_ATTRIBUTES>
  </STUDY>
  <STUDY alias="JSUB000148_Study_0001" center_name="Individual" accession="JGAS000085">
    <IDENTIFIERS>
      <SECONDARY_ID>JGAS00000000085</SECONDARY_ID>
    </IDENTIFIERS>
    <DESCRIPTOR>
      <STUDY_TITLE>Expression quantitative trait loci analysis using human immune cells in a Japanese population</STUDY_TITLE>
      <STUDY_TYPES>
        <STUDY_TYPE existing_study_type="Other" new_study_type="Expression quantitative trait loci analysis"/>
      </STUDY_TYPES>
      <STUDY_ABSTRACT>Recent evidence suggests that a substantial portion of complex disease risk alleles modify gene expression in a cell-specific manner. Therefore, it is reasonable to expect that cell-specific expression quantitative trait loci (eQTL) analysis can identify the candidate causal mechanisms of complex diseases (an eQTL is a variant whose polymorphism affects gene expression). We fractionated peripheral blood from 105 healthy Japanese volunteers into five major immune cell subsets (CD4&lt;sup&gt;+&lt;/sup&gt; T cells, CD8&lt;sup&gt;+&lt;/sup&gt; T cells, B cells, NK cells, and monocytes). We quantified gene and exon expression by RNA sequencing, and tested associations with neighboring common variants (MAF ? 0.05).</STUDY_ABSTRACT>
    </DESCRIPTOR>
    <STUDY_ATTRIBUTES>
      <STUDY_ATTRIBUTE>
        <TAG>NBDC Number</TAG>
        <VALUE>hum0099</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Registration date</TAG>
        <VALUE>2017-02-03</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Submitting organization</TAG>
        <VALUE>RIKEN Center for Integrative Medical Sciences</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Principal Investigator</TAG>
        <VALUE>Kazuyoshi Ishigaki</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Molecular Data Type</TAG>
        <VALUE>RNA-sequencing</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Platform</TAG>
        <VALUE>TruSeq Stranded mRNA Library Prep Kits, Hiseq 2500</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Vendor</TAG>
        <VALUE>Illumina</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>List</TAG>
        <VALUE/>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Primary Phenotype</TAG>
        <VALUE>complex disease</VALUE>
      </STUDY_ATTRIBUTE>
    </STUDY_ATTRIBUTES>
  </STUDY>
  <STUDY alias="JSUB000150_Study_0001" center_name="Individual" accession="JGAS000098">
    <IDENTIFIERS>
      <SECONDARY_ID>JGAS00000000098</SECONDARY_ID>
    </IDENTIFIERS>
    <DESCRIPTOR>
      <STUDY_TITLE>Targeted exome sequencing identify compound heterozygous TYK2 mutations in patients with primary immunodeficiency who developed EBV-associated lymphoma</STUDY_TITLE>
      <STUDY_TYPES>
        <STUDY_TYPE existing_study_type="Family"/>
      </STUDY_TYPES>
      <STUDY_ABSTRACT>In this study, we evaluated 2 siblings with primary immunodeficiency who developed EBV-associated lymphoma. Immunophenotyping of PBMCs revealed that both patients had significant T cell lymphopenia characterized by low na?ve CD4+ T cell counts. To identify the causative genetic mutations in the patients, we performed targeted exome sequencing using the Illumina MiSeq on the patients and their parents. The results showed a novel compound heterozygous mutations in the gene encoding tyrosine kinase 2 (TYK2) in the patients. </STUDY_ABSTRACT>
    </DESCRIPTOR>
    <PUBLICATIONS>
      <PUBLICATION id="29725107" status="published">
        <DB_TYPE>PUBMED</DB_TYPE>
      </PUBLICATION>
    </PUBLICATIONS>
    <STUDY_ATTRIBUTES>
      <STUDY_ATTRIBUTE>
        <TAG>NBDC Number</TAG>
        <VALUE>hum0101</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Registration date</TAG>
        <VALUE>2017-04-02</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Submitting organization</TAG>
        <VALUE>National Hospital Organization Nagoya Medical Center</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Principal Investigator</TAG>
        <VALUE>Yasumasa Iwatani</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Molecular Data Type</TAG>
        <VALUE>Targeted exome sequencing</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Platform</TAG>
        <VALUE>Miseq</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Vendor</TAG>
        <VALUE>Illumina</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>List</TAG>
        <VALUE/>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Primary Phenotype</TAG>
        <VALUE>Lymphoma</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Phenotype</TAG>
        <VALUE>Lymphopenia</VALUE>
      </STUDY_ATTRIBUTE>
    </STUDY_ATTRIBUTES>
  </STUDY>
  <STUDY alias="JSUB000152_Study_0001" center_name="Individual" accession="JGAS000088">
    <IDENTIFIERS>
      <SECONDARY_ID>JGAS00000000088</SECONDARY_ID>
    </IDENTIFIERS>
    <DESCRIPTOR>
      <STUDY_TITLE>Genome-wide integrative analysis of pediatric pancreatoblastoma</STUDY_TITLE>
      <STUDY_TYPES>
        <STUDY_TYPE existing_study_type="Exome Sequencing"/>
        <STUDY_TYPE existing_study_type="Transcriptome Sequencing"/>
        <STUDY_TYPE existing_study_type="Other" new_study_type="SNP array"/>
        <STUDY_TYPE existing_study_type="Other" new_study_type="Methylation array"/>
      </STUDY_TYPES>
      <STUDY_ABSTRACT>Pancreatoblastoma is the most common pancreatic malignancy of young children, but its molecular pathogenesis remains poorly understood. To understand the molecular pathogenesis of pancreatoblastoma, we comprehensively analysed the whole exome sequencing, RNA sequencing, SNP array, and methylation array data of pancreatoblastoma.</STUDY_ABSTRACT>
    </DESCRIPTOR>
    <PUBLICATIONS>
      <PUBLICATION id="29233928" status="published">
        <DB_TYPE>PUBMED</DB_TYPE>
      </PUBLICATION>
    </PUBLICATIONS>
    <STUDY_ATTRIBUTES>
      <STUDY_ATTRIBUTE>
        <TAG>NBDC Number</TAG>
        <VALUE>hum0035</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Registration date</TAG>
        <VALUE>2017-02-22</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Submitting organization</TAG>
        <VALUE>Department of Pediatrics, The University of Tokyo</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Principal Investigator</TAG>
        <VALUE>Junko Takita</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Molecular Data Type</TAG>
        <VALUE>Exome Sequencing</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Platform</TAG>
        <VALUE>Hiseq 2500</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Vendor</TAG>
        <VALUE>Illumina</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>List</TAG>
        <VALUE/>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Molecular Data Type</TAG>
        <VALUE>Transcriptome Sequencing</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Platform</TAG>
        <VALUE>Hiseq 2500</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Vendor</TAG>
        <VALUE>Illumina</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>List</TAG>
        <VALUE/>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Molecular Data Type</TAG>
        <VALUE>SNP array</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Platform</TAG>
        <VALUE>Cytoscan HD</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Vendor</TAG>
        <VALUE>Affymetrix</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>List</TAG>
        <VALUE/>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Molecular Data Type</TAG>
        <VALUE>Methylation array</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Platform</TAG>
        <VALUE>Infinium MethylationEPIC</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Vendor</TAG>
        <VALUE>Illumina</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>List</TAG>
        <VALUE/>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Primary Phenotype</TAG>
        <VALUE>Pancreatoblastoma</VALUE>
      </STUDY_ATTRIBUTE>
    </STUDY_ATTRIBUTES>
  </STUDY>
  <STUDY alias="JSUB000155_Study_0001" center_name="Individual" accession="JGAS000109">
    <IDENTIFIERS>
      <SECONDARY_ID>JGAS00000000109</SECONDARY_ID>
    </IDENTIFIERS>
    <DESCRIPTOR>
      <STUDY_TITLE>Genome sequencing of biliary tract cancers</STUDY_TITLE>
      <STUDY_TYPES>
        <STUDY_TYPE existing_study_type="Whole Genome Sequencing"/>
        <STUDY_TYPE existing_study_type="Exome Sequencing"/>
      </STUDY_TYPES>
      <STUDY_ABSTRACT>Biliary tract cancers (BTCs) are clinically and pathologically heterogeneous with poor response to treatments. Genomic profiling can offer a clearer understanding of their carcinogenesis, classification and treatment strategy. We performed genome sequencing analyses for a large scale samples of BTCs to investigate their somatic and germline driver events and characterize their genomic landscape.</STUDY_ABSTRACT>
    </DESCRIPTOR>
    <PUBLICATIONS>
      <PUBLICATION id="29360550" status="published">
        <DB_TYPE>PUBMED</DB_TYPE>
      </PUBLICATION>
    </PUBLICATIONS>
    <STUDY_ATTRIBUTES>
      <STUDY_ATTRIBUTE>
        <TAG>NBDC Number</TAG>
        <VALUE>hum0103</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Registration date</TAG>
        <VALUE>2017-05-11</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Submitting organization</TAG>
        <VALUE>RIKEN Center for Integrative Medical Sciences</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Principal Investigator</TAG>
        <VALUE>Hidewaki Nakagawa</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Molecular Data Type</TAG>
        <VALUE>Whole Genome Sequencing</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Platform</TAG>
        <VALUE>HiSeq2000, HiSeq2500</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Vendor</TAG>
        <VALUE>Illumina</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>List</TAG>
        <VALUE/>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Molecular Data Type</TAG>
        <VALUE>Exome Sequencing</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Platform</TAG>
        <VALUE>HiSeq2000, HiSeq2500</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Vendor</TAG>
        <VALUE>Illumina</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>List</TAG>
        <VALUE/>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Primary Phenotype</TAG>
        <VALUE>Biliary tract cancer</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Disease Type</TAG>
        <VALUE>Neoplasms</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Disease Type</TAG>
        <VALUE>Digestive System Diseases</VALUE>
      </STUDY_ATTRIBUTE>
    </STUDY_ATTRIBUTES>
  </STUDY>
  <STUDY alias="JSUB000157_Study_0001" center_name="Individual" accession="JGAS000096">
    <IDENTIFIERS>
      <SECONDARY_ID>JGAS00000000096</SECONDARY_ID>
    </IDENTIFIERS>
    <DESCRIPTOR>
      <STUDY_TITLE>WGS analysis of a glioma initiating cell line</STUDY_TITLE>
      <STUDY_TYPES>
        <STUDY_TYPE existing_study_type="Whole Genome Sequencing"/>
      </STUDY_TYPES>
      <STUDY_ABSTRACT>We here obtained whole-genome sequencing data to analyze transcription factor binding sequences and somatic mutations found in our RNA-seq analysis of glioma initiating cells. </STUDY_ABSTRACT>
    </DESCRIPTOR>
    <GRANTS>
      <GRANT grant_id="22112002">
        <TITLE>Grants-in-Aid for Scientific Research</TITLE>
        <AGENCY abbr="MEXT">Ministry of Education, Culture, Sports, and Technology of Japan</AGENCY>
      </GRANT>
      <GRANT grant_id="24390070">
        <TITLE>Grants-in-Aid for Scientific Research (B)</TITLE>
        <AGENCY abbr="JSPS">Japan Society for the Promotion of Science</AGENCY>
      </GRANT>
      <GRANT grant_id="15">
        <TITLE>Grants-in-Aid for Scientific Research (S)</TITLE>
        <AGENCY abbr="JSPS">Japan Society for the Promotion of Science</AGENCY>
      </GRANT>
      <GRANT grant_id="201220012">
        <TITLE>Grants-in-Aid for Scientific Research</TITLE>
        <AGENCY abbr="">Ministry of Health, Labour and Welfare of Japan</AGENCY>
      </GRANT>
      <GRANT grant_id="">
        <TITLE>Core-to-Core Program ?Cooperative International Framework in TGF-beta Family Signaling?</TITLE>
        <AGENCY abbr="JSPS">Japan Society for the Promotion of Science</AGENCY>
      </GRANT>
    </GRANTS>
    <PUBLICATIONS>
      <PUBLICATION id="29193056" status="published">
        <DB_TYPE>PUBMED</DB_TYPE>
      </PUBLICATION>
    </PUBLICATIONS>
    <STUDY_ATTRIBUTES>
      <STUDY_ATTRIBUTE>
        <TAG>NBDC Number</TAG>
        <VALUE>hum0088</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Registration date</TAG>
        <VALUE>2017-03-01</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Submitting organization</TAG>
        <VALUE>University of Tokyo</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Principal Investigator</TAG>
        <VALUE>Kohei Miyazono</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Molecular Data Type</TAG>
        <VALUE>Whole Genome Sequencing</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Platform</TAG>
        <VALUE>Ion Proton</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Vendor</TAG>
        <VALUE>Thermo Fisher Scientific</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>List</TAG>
        <VALUE/>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Primary Phenotype</TAG>
        <VALUE>Cancer</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Disease Type</TAG>
        <VALUE>Neoplasms</VALUE>
      </STUDY_ATTRIBUTE>
    </STUDY_ATTRIBUTES>
  </STUDY>
  <STUDY alias="JSUB000160_Study_0001" center_name="Individual" accession="JGAS000093">
    <IDENTIFIERS>
      <SECONDARY_ID>JGAS00000000093</SECONDARY_ID>
    </IDENTIFIERS>
    <DESCRIPTOR>
      <STUDY_TITLE>POU4F3 mutation screening in Japanese hearing loss patients.</STUDY_TITLE>
      <STUDY_TYPES>
        <STUDY_TYPE existing_study_type="Case Set"/>
      </STUDY_TYPES>
      <STUDY_ABSTRACT>A variant in a transcription factor gene, POU4F3, is responsible for autosomal dominant nonsyndromic hereditary hearing loss, DFNA15. To date, 14 variants, including a whole deletion of POU4F3, have been reported to cause HL in various ethnic groups. In the present study, genetic screening for POU4F3 variants was carried out for a large series of Japanese hearing loss (HL) patients to clarify the prevalence and clinical characteristics of DFNA15 in the Japanese population. Massively parallel DNA sequencing of 68 target candidate genes was utilized in 2,549 unrelated Japanese HL patients (probands) to identify genomic variations responsible for HL. The detailed clinical features in patients with POU4F3 variants were collected from medical charts and analyzed. Novel 12 POU4F3 likely pathogenic variants (six missense variants, three frameshift variants, and three nonsense variants) were successfully identified in 15 probands (2.5%) among 602 families exhibiting autosomal dominant HL, whereas no variants were detected in the other 1,947 probands with autosomal recessive or inheritance pattern unknown HL. To obtain the audiovestibular configuration of the patients harboring POU4F3 variants, we collected audiograms and vestibular symptoms of the probands and their affected family members. Audiovestibular phenotypes in a total of 24 individuals from the 15 families possessing variants were characterized by progressive HL, with a large variation in the onset age and severity with or without vestibular symptoms observed. Pure-tone audiograms indicated the most prevalent configuration as mid-frequency HL type followed by high-frequency HL type, with asymmetry observed in approximately 20% of affected individuals. Analysis of the relationship between age and pure-tone average suggested that individuals with truncating variants showed earlier onset and slower progression of HL than did those with non-truncating variants. The present study showed that variants in POU4F3 were a common cause of autosomal dominant HL.</STUDY_ABSTRACT>
    </DESCRIPTOR>
    <STUDY_ATTRIBUTES>
      <STUDY_ATTRIBUTE>
        <TAG>NBDC Number</TAG>
        <VALUE>hum0005</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Registration date</TAG>
        <VALUE>2017-03-16</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Submitting organization</TAG>
        <VALUE>Shinshu University School of Medicine</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Principal Investigator</TAG>
        <VALUE>Shin-ichi Usami</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Molecular Data Type</TAG>
        <VALUE>Target resequencing</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Platform</TAG>
        <VALUE>Ion PGM, Ion Proton</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Vendor</TAG>
        <VALUE>Thermo Fisher Scientific</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>List</TAG>
        <VALUE/>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Primary Phenotype</TAG>
        <VALUE>Nonsyndromic hearing loss</VALUE>
      </STUDY_ATTRIBUTE>
    </STUDY_ATTRIBUTES>
  </STUDY>
  <STUDY alias="JSUB000163_Study_0001" center_name="Individual" accession="JGAS000099">
    <IDENTIFIERS>
      <SECONDARY_ID>JGAS00000000099</SECONDARY_ID>
    </IDENTIFIERS>
    <DESCRIPTOR>
      <STUDY_TITLE>mutation analysys of Gorlin syndrome</STUDY_TITLE>
      <STUDY_TYPES>
        <STUDY_TYPE existing_study_type="Exome Sequencing"/>
      </STUDY_TYPES>
      <STUDY_ABSTRACT>Gorlin syndrome is a genetic disorder of autosomal dominant inheritance that predisposes the affected individual to a variety of disorders that are attributed largely to heterozygous germline patched1 (PTCH1) mutations. PTCH1 is a hedgehog (Hh) receptor as well as a repressor, mutation of which leads to constitutive activation of Hh pathway. Hh pathway encompasses a wide variety of cellular signaling cascades, which involve several molecules; however, no associated genotype?phenotype correlations have been reported. Recently, mutations in Suppressor of fused homolog (SUFU) or PTCH2 were reported in patients with Gorlin syndrome. These facts suggest that multi-layered mutations in Hh pathway may contribute to the development of Gorlin syndrome. We demonstrated multiple mutations of Hh-related genes in addition to PTCH1, which possibly act in an additive or multiplicative manner and lead to Gorlin syndrome. High-throughput sequencing was performed to analyze exome sequences in four unrelated Gorlin syndrome patient genomes. Mutations in PTCH1 gene were detected in all four patients. Specific nucleotide variations or frameshift variations of PTCH1 were identified along with the inferred amino acid changes in all patients. We further filtered 84 different genes which are closely related to Hh signaling. Fifty three of these had enough coverage of over ?30. The sequencing results were filtered and compared to reduce the number of sequence variants identified in each of the affected individuals. We discovered three genes, PTCH2, BOC, and WNT9b, with mutations with a predicted functional impact assessed by MutationTaster2 or PolyPhen-2 (Polymorphism Phenotyping v2) analysis. It is noticeable that PTCH2 and BOC are Hh receptor molecules. No significant mutations were observed in SUFU. Multi-layered mutations in Hh pathway may change the activation level of the Hh signals, which may explain the wide phenotypic variability of Gorlin syndrome. </STUDY_ABSTRACT>
    </DESCRIPTOR>
    <GRANTS>
      <GRANT grant_id="16">
        <TITLE>Elucidation of the pathological mechanism of Gorlin syndrome with patient-specific iPS cells</TITLE>
        <AGENCY abbr="KAKEN">Grant-in-Aid for Scientific Research</AGENCY>
      </GRANT>
    </GRANTS>
    <PUBLICATIONS>
      <PUBLICATION id="28915250" status="published">
        <DB_TYPE>PUBMED</DB_TYPE>
      </PUBLICATION>
    </PUBLICATIONS>
    <STUDY_ATTRIBUTES>
      <STUDY_ATTRIBUTE>
        <TAG>NBDC Number</TAG>
        <VALUE>hum0107</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Registration date</TAG>
        <VALUE>2017-04-04</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Submitting organization</TAG>
        <VALUE>Tokyo Dental collage</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Principal Investigator</TAG>
        <VALUE>Toshifumi Azuma</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Molecular Data Type</TAG>
        <VALUE>exome sequencing</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Platform</TAG>
        <VALUE>Hiseq 2000,Hiseq 4000</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Vendor</TAG>
        <VALUE>Illumina</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>List</TAG>
        <VALUE/>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Primary Phenotype</TAG>
        <VALUE>OMIM #109400 Basal cell nevus syndrome</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Disease</TAG>
        <VALUE>Basal cell nevus syndrome</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Disease</TAG>
        <VALUE>Gorlin syndrome</VALUE>
      </STUDY_ATTRIBUTE>
    </STUDY_ATTRIBUTES>
  </STUDY>
  <STUDY alias="JSUB000164_Study_0001" center_name="Individual" accession="JGAS000105">
    <IDENTIFIERS>
      <SECONDARY_ID>JGAS00000000105</SECONDARY_ID>
    </IDENTIFIERS>
    <DESCRIPTOR>
      <STUDY_TITLE>High-coverage whole exome sequence in non-TRU-type lung adenocarcinomas</STUDY_TITLE>
      <STUDY_TYPES>
        <STUDY_TYPE existing_study_type="Exome Sequencing"/>
        <STUDY_TYPE existing_study_type="Transcriptome Sequencing"/>
      </STUDY_TYPES>
      <STUDY_ABSTRACT> In order to elucidate the key genetic events in non-TRU-type lung cancer, we selected 43 non-TRU-type lung adenocarcinomas and performed a whole exome sequence and RNA-seq analysis using a next-generation sequencer. The results of the analysis identified mutations in TP53, KRAS and NKX2-1 as the top three significantly mutated genes, while the EGFR mutation was rare in this cohort. Eight NKX2-1 mutations (5 frameshift, 2 nonsense, and one missense) were identified, with one case harboring two distinct NKX2-1 mutations (missense and frameshift). All NKX2-1 mutants were transcriptionally inactive in reporter assays. Histologically, invasive mucinous adenocarcinomas accounted for most of the NKX2-1 mutations (5 cases), while 1 enteric and 1 acinar adenocarcinoma harbored the NKX2-1 mutation. </STUDY_ABSTRACT>
    </DESCRIPTOR>
    <PUBLICATIONS>
      <PUBLICATION id="28677170" status="published">
        <DB_TYPE>PUBMED</DB_TYPE>
      </PUBLICATION>
    </PUBLICATIONS>
    <STUDY_ATTRIBUTES>
      <STUDY_ATTRIBUTE>
        <TAG>NBDC Number</TAG>
        <VALUE>hum0094</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Registration date</TAG>
        <VALUE>2017-05-18</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Submitting organization</TAG>
        <VALUE>Department of Celluar Signaling, Graduate School of Medicine, The University of Tokyo</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Principal Investigator</TAG>
        <VALUE>Hiroyuki Mano</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Molecular Data Type</TAG>
        <VALUE>Whole Exome Sequencing</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Platform</TAG>
        <VALUE>HiSeq2500</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Vendor</TAG>
        <VALUE>Illumina</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>List</TAG>
        <VALUE/>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Molecular Data Type</TAG>
        <VALUE>RNA Sequencing</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Platform</TAG>
        <VALUE>HiSeq2500</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Vendor</TAG>
        <VALUE>Illumina</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>List</TAG>
        <VALUE/>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Primary Phenotype</TAG>
        <VALUE>adenocarcinoma/Non small cell lung cancer</VALUE>
      </STUDY_ATTRIBUTE>
    </STUDY_ATTRIBUTES>
  </STUDY>
  <STUDY alias="JSUB000165_Study_0001" center_name="Individual" accession="JGAS000111">
    <IDENTIFIERS>
      <SECONDARY_ID>JGAS00000000111</SECONDARY_ID>
    </IDENTIFIERS>
    <DESCRIPTOR>
      <STUDY_TITLE>Searching for DNA methylation sites associated with panic disorder</STUDY_TITLE>
      <STUDY_TYPES>
        <STUDY_TYPE existing_study_type="Case-Control"/>
        <STUDY_TYPE existing_study_type="Other" new_study_type="genome-wide DNA mehtylation analysis"/>
      </STUDY_TYPES>
      <STUDY_ABSTRACT>This study aimed to identify whole-genome DNA methylation profile of panic disoeder and to search DNA methylation sites associated with the disease</STUDY_ABSTRACT>
    </DESCRIPTOR>
    <STUDY_ATTRIBUTES>
      <STUDY_ATTRIBUTE>
        <TAG>NBDC Number</TAG>
        <VALUE>hum0108</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Registration date</TAG>
        <VALUE>2017-06-20</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Submitting organization</TAG>
        <VALUE>The University of Tokyo</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Principal Investigator</TAG>
        <VALUE>Katsushi Tokunaga</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Molecular Data Type</TAG>
        <VALUE>genome-wide DNA mehtylation analysis</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Platform</TAG>
        <VALUE>HumanMethlyation450K</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Vendor</TAG>
        <VALUE>Illumina</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>List</TAG>
        <VALUE/>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Primary Phenotype</TAG>
        <VALUE>Panic disorder</VALUE>
      </STUDY_ATTRIBUTE>
    </STUDY_ATTRIBUTES>
  </STUDY>
  <STUDY alias="JSUB000167_Study_0001" center_name="Individual" accession="JGAS000113">
    <IDENTIFIERS>
      <SECONDARY_ID>JGAS00000000113</SECONDARY_ID>
    </IDENTIFIERS>
    <DESCRIPTOR>
      <STUDY_TITLE>Comprehensive genomic analysis of colorectal cancer with microsatellite instability</STUDY_TITLE>
      <STUDY_TYPES>
        <STUDY_TYPE existing_study_type="Exome Sequencing"/>
        <STUDY_TYPE existing_study_type="Transcriptome Sequencing"/>
      </STUDY_TYPES>
      <STUDY_ABSTRACT>Microsatellite instability-high (MSI-H) colorectal cancers (CRCs) account for 10?15% of all CRCs. MSI-H CRC is characterized by a large number of somatic insertions/deletions (indels) resulting from either mutations within or the silencing of genes involved in the DNA mismatch repair (MMR) system. A subset of MSI-H CRCs is associated with Lynch syndrome (LS), which is caused by germline MMR gene mutations, leading to hereditary cancer predisposition. Other than frequent somatic mutations in BRAF, the transformation mechanisms underlying MSI-H CRC are largely unknown. Here, genomic DNA from 149 MSI-H CRC specimens was analyzed using whole-exome sequencing, and 93 of these samples were subjected to genome-wide DNA methylation analysis. Furthermore, transcriptome sequencing was conducted on 111 samples. Genomic/epigenomic analyses identified three subgroups within our cohort: (1) MSI-H CRCs with silenced MLH1 that share frequent indels, a specific mutation/copy number alteration profile and promoter DNA methylation; (2) LS-associated MSI-H CRCs with MMR genes containing germline mutations; and (3) the remaining MSI-H CRCs with frequent somatic disruptive mutations of MLH1 or MSH2. Unexpectedly, only the first group was found to frequently carry fusion-type protein kinases (15% of this group and 9.9% of all MSI-H CRCs) that are promising therapeutic targets. Thus, MSI-H CRCs can be classified into three subgroups with distinctive genomic as well as epigenomic statuses, probably reflecting the oncogenic processes of these cancers. Fusion-type kinases are enriched in MSI-H CRCs, shedding new light on potential treatment strategies.</STUDY_ABSTRACT>
    </DESCRIPTOR>
    <PUBLICATIONS>
      <PUBLICATION id="30279230" status="published">
        <DB_TYPE>PUBMED</DB_TYPE>
      </PUBLICATION>
    </PUBLICATIONS>
    <STUDY_ATTRIBUTES>
      <STUDY_ATTRIBUTE>
        <TAG>NBDC Number</TAG>
        <VALUE>hum0094</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Registration date</TAG>
        <VALUE>2017-06-15</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Submitting organization</TAG>
        <VALUE>Department of Celluar Signaling, Graduate School of Medicine, The University of Tokyo</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Principal Investigator</TAG>
        <VALUE>Hiroyuki Mano</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Molecular Data Type</TAG>
        <VALUE>Whole Exome Sequencing</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Platform</TAG>
        <VALUE>HiSeq2000/2500</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Vendor</TAG>
        <VALUE>Illumina</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>List</TAG>
        <VALUE/>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Molecular Data Type</TAG>
        <VALUE>RNA Sequencing</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Platform</TAG>
        <VALUE>HiSeq2000/2500</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Vendor</TAG>
        <VALUE>Illumina</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>List</TAG>
        <VALUE/>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Molecular Data Type</TAG>
        <VALUE>DNA Microarray</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Platform</TAG>
        <VALUE>iScan system</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Vendor</TAG>
        <VALUE>Illumina</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>List</TAG>
        <VALUE/>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Primary Phenotype</TAG>
        <VALUE>Colon cancer</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Phenotype</TAG>
        <VALUE>Hereditary nonpolyposis colorectal carcinoma</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Phenotype</TAG>
        <VALUE>Neoplasm of the rectum</VALUE>
      </STUDY_ATTRIBUTE>
    </STUDY_ATTRIBUTES>
  </STUDY>
  <STUDY alias="JSUB000168_Study_0001" center_name="Individual" accession="JGAS000101">
    <IDENTIFIERS>
      <SECONDARY_ID>JGAS00000000101</SECONDARY_ID>
    </IDENTIFIERS>
    <DESCRIPTOR>
      <STUDY_TITLE>GWAS for atrial fibrillation in the Japanese population</STUDY_TITLE>
      <STUDY_TYPES>
        <STUDY_TYPE existing_study_type="Case-Control"/>
      </STUDY_TYPES>
      <STUDY_ABSTRACT>We performed a genome-wide association study (GWAS) that utilized 8,180 atrial fibrillation cases and 28,612 controls and followed up in an additional 3,120 cases and 125,064 controls in the Japanese population.  We replicated previously reported loci and identified six novel loci.  Five of the six novel loci were specifically associated with atrial fibrillation in the Japanese population after comparing our data to individuals of European ancestry, suggesting there might be different susceptibility genetic factors across ancestries.  Our study has discovered variants in genes HAND2, KCND3 and NEBL that are relevant to atrial fibrillation susceptibility.  The involvement of PPFIA4 and SH3PXD2A in axon guidance also suggested its role in the disease pathogenesis. Our findings may contribute to a better understanding of atrial fibrillation susceptibility and pathogenesis.</STUDY_ABSTRACT>
    </DESCRIPTOR>
    <PUBLICATIONS>
      <PUBLICATION id="28416822" status="published">
        <DB_TYPE>PUBMED</DB_TYPE>
      </PUBLICATION>
    </PUBLICATIONS>
    <STUDY_ATTRIBUTES>
      <STUDY_ATTRIBUTE>
        <TAG>NBDC Number</TAG>
        <VALUE>hum0014</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Registration date</TAG>
        <VALUE>2017-04-14</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Submitting organization</TAG>
        <VALUE>RIKEN Center For Integrative Medical Sciences</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Principal Investigator</TAG>
        <VALUE>Michiaki Kubo</VALUE>
      </STUDY_ATTRIBUTE>
    </STUDY_ATTRIBUTES>
  </STUDY>
  <STUDY alias="JSUB000171_Study_0001" center_name="Individual" accession="JGAS000106">
    <IDENTIFIERS>
      <SECONDARY_ID>JGAS00000000106</SECONDARY_ID>
    </IDENTIFIERS>
    <DESCRIPTOR>
      <STUDY_TITLE>Molecular analysis of diffuse cerebellar gliomas</STUDY_TITLE>
      <STUDY_TYPES>
        <STUDY_TYPE existing_study_type="Tumor vs. Matched-Normal"/>
        <STUDY_TYPE existing_study_type="Exome Sequencing"/>
        <STUDY_TYPE existing_study_type="Transcriptome Sequencing"/>
        <STUDY_TYPE existing_study_type="Other" new_study_type="DNA methylation array"/>
      </STUDY_TYPES>
      <STUDY_ABSTRACT>Among diffuse gliomas, oligodendrogliomas show relatively better prognosis, respond well to radiotherapy and chemotherapy, and seldom progress to very aggressive tumors. To elucidate the genetic and epigenetic background for such behavior and tumor evolution during tumor relapse, we comparatively analyzed 12 pairs of primary and recurrent oligodendrogliomas with 1p/19q-codeletion. Initial treatment for these patients was mostly chemotherapy alone. Temozolomide was used for 3, and procarbazine, nimustine and vincristine (PAV chemotherapy) were used for 7 patients. World Health Organization histological grade at recurrence was mostly stable; it was increased in 2, the same in 9, and decreased in 1 cases. Whole-exome sequencing demonstrated that the rate of shared mutation between the primary and recurrent tumors was relatively low, ranging from 3.2-57.9% (average, 33.3%), indicating a branched evolutionary pattern. The trunk alterations that existed throughout the course were restricted to IDH1 mutation, 1p/19q-codeletion, and TERT promoter mutation, and mutation of the known candidate tumor suppressor genes CIC and FUBP1 were not consistently observed between primary and recurrent tumors. Multiple sampling from different regions within a tumor showed marked intratumoral heterogeneity. Notably, in general, the number of mutations was not significantly different after recurrence, remaining under 100, and no hypermutator phenotype was observed. FUBP1 mutation, loss of chr. 9p21, and TCF12 mutation were among a few recurrent de novo alterations that were found at recurrence, indicating that these events were clonally selected at recurrence but were not enough to enhance malignancy. Genome-wide methylation status, measured by Illumina 450 K arrays, was stable between recurrence and the primary tumor. In summary, although oligodendroglioma displays marked mutational heterogeneity, histological malignant transformation accompanying events such as considerable increase in mutation number and epigenetic profile change were not observed at recurrence, indicating that noticeable temporal and spatial genetic heterogeneity in oligodendrogliomas does not result in rapid tumor progression.</STUDY_ABSTRACT>
    </DESCRIPTOR>
    <GRANTS>
      <GRANT grant_id="">
        <TITLE>Identification of new molecular targets with profiling of malignant mesothelioma / Development of therapeutic modalities against intractable cancers via identification of new therapeutic targets with molecular profiling / P-DIRECT: Project for Development of Innovative Research on Cancer Therapeutics</TITLE>
        <AGENCY abbr="MEXT">Ministry of Education, Culture, Sports, Science and Technology</AGENCY>
      </GRANT>
      <GRANT grant_id="">
        <TITLE>Identification of new molecular targets with profiling of malignant mesothelioma / Development of therapeutic modalities against intractable cancers via identification of new therapeutic targets with molecular profiling / P-DIRECT: Project for Development of Innovative Research on Cancer Therapeutics</TITLE>
        <AGENCY abbr="AMED">Japan Agency for Medical Research and Development</AGENCY>
      </GRANT>
    </GRANTS>
    <PUBLICATIONS>
      <PUBLICATION id="28852847" status="published">
        <DB_TYPE>PUBMED</DB_TYPE>
      </PUBLICATION>
      <PUBLICATION id="24336570" status="published">
        <DB_TYPE>PUBMED</DB_TYPE>
      </PUBLICATION>
      <PUBLICATION id="28270234" status="published">
        <DB_TYPE>PUBMED</DB_TYPE>
      </PUBLICATION>
    </PUBLICATIONS>
    <STUDY_ATTRIBUTES>
      <STUDY_ATTRIBUTE>
        <TAG>NBDC Number</TAG>
        <VALUE>hum0006</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Registration date</TAG>
        <VALUE>2017-06-02</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Submitting organization</TAG>
        <VALUE>Department of Neurosurgery, The University of Tokyo</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Principal Investigator</TAG>
        <VALUE>Nobuhito Saito</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Molecular Data Type</TAG>
        <VALUE>Exome sequencing</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Platform</TAG>
        <VALUE>HiSeq 2000</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Vendor</TAG>
        <VALUE>Illumina</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>List</TAG>
        <VALUE/>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Molecular Data Type</TAG>
        <VALUE>Transcriptome profiling by high-throughput sequencing</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Platform</TAG>
        <VALUE>HiSeq 2000</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Vendor</TAG>
        <VALUE>Illumina</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>List</TAG>
        <VALUE/>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Molecular Data Type</TAG>
        <VALUE>Methylation profiling by array</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Platform</TAG>
        <VALUE>Infinium HumanMethylation450 BeadChip</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Vendor</TAG>
        <VALUE>Illumina</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>List</TAG>
        <VALUE/>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Primary Phenotype</TAG>
        <VALUE>Glioma</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Disease Type</TAG>
        <VALUE>Neoplasms</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Cancer Type</TAG>
        <VALUE>Glioma</VALUE>
      </STUDY_ATTRIBUTE>
    </STUDY_ATTRIBUTES>
  </STUDY>
  <STUDY alias="JSUB000172_Study_0001" center_name="Individual" accession="JGAS000103">
    <IDENTIFIERS>
      <SECONDARY_ID>JGAS00000000103</SECONDARY_ID>
    </IDENTIFIERS>
    <DESCRIPTOR>
      <STUDY_TITLE>Global Architecture of anti-Tumor B-Cell Immunity against Gastric Cancer</STUDY_TITLE>
      <STUDY_TYPES>
        <STUDY_TYPE existing_study_type="Other" new_study_type="Transcriptome sequencing (Tumor only)"/>
        <STUDY_TYPE existing_study_type="Other" new_study_type="Repertoire sequencing (Tumor vs. Matched-Normal)"/>
      </STUDY_TYPES>
      <STUDY_ABSTRACT>Recent successes in tumor immunotherapies have warranted the importance of tumor immunity. Compared to the T-cell immunity, B-cell immune system in cancer is largely elusive. Here we immunogenetically profiled tumor-infiltrating B-cell and T-cell repertoires for exome- characterized diffuse-type gastric carcinoma (DGC), which is remarkable for its B-cell infiltrations, unraveling previously un-defined architectures of B-cell immunity and its interplays with T-cell immunity in cancer. We also performed transcriptome analysis to enumerate the proportions of tumor-infiltrating immune cells in the gastric cancer environment .</STUDY_ABSTRACT>
    </DESCRIPTOR>
    <GRANTS>
      <GRANT grant_id="26710009">
        <TITLE>KAKENHI Grant-in-Aid for Young Scientists (A)</TITLE>
        <AGENCY abbr="JSPS">Japan Society for the Promotion of Science</AGENCY>
      </GRANT>
      <GRANT grant_id="15655817">
        <TITLE>Practical Research for Innovative Cancer Control</TITLE>
        <AGENCY abbr="AMED">Japan Agency for Medical Research and Development</AGENCY>
      </GRANT>
      <GRANT grant_id="14014019">
        <TITLE>Basic Science and Platform Technology Program for Innovative Biological Medicine</TITLE>
        <AGENCY abbr="AMED">Japan Agency for Medical Research and Development</AGENCY>
      </GRANT>
    </GRANTS>
    <PUBLICATIONS>
      <PUBLICATION id="10.1016/j.celrep.2017.07.016" status="published">
        <DB_TYPE>DOI</DB_TYPE>
      </PUBLICATION>
    </PUBLICATIONS>
    <STUDY_ATTRIBUTES>
      <STUDY_ATTRIBUTE>
        <TAG>NBDC Number</TAG>
        <VALUE>hum0111</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Registration date</TAG>
        <VALUE>2017-05-19</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Submitting organization</TAG>
        <VALUE>Department of Genomic Pathology, Medical Research Institute, Tokyo Medical and Dental University</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Principal Investigator</TAG>
        <VALUE>Shumpei Ishikawa</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Molecular Data Type</TAG>
        <VALUE>Amplicon Sequencing of T/B cell antigen receptors</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Platform</TAG>
        <VALUE>MiSeq</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Vendor</TAG>
        <VALUE>Illumina</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>List</TAG>
        <VALUE/>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Molecular Data Type</TAG>
        <VALUE>Whole Transcriptome Sequencing</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Platform</TAG>
        <VALUE>HiSeq 2000</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Vendor</TAG>
        <VALUE>Illumina</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>List</TAG>
        <VALUE/>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Primary Phenotype</TAG>
        <VALUE>Stomach cancer</VALUE>
      </STUDY_ATTRIBUTE>
    </STUDY_ATTRIBUTES>
  </STUDY>
  <STUDY alias="JSUB000173_Study_0001" center_name="Individual" accession="JGAS000107">
    <IDENTIFIERS>
      <SECONDARY_ID>JGAS00000000107</SECONDARY_ID>
    </IDENTIFIERS>
    <DESCRIPTOR>
      <STUDY_TITLE>Epigenomic analysis of the human placenta and endometrium constituting the fetal-maternal interface</STUDY_TITLE>
      <STUDY_TYPES>
        <STUDY_TYPE existing_study_type="Transcriptome Sequencing"/>
        <STUDY_TYPE existing_study_type="Other" new_study_type="Bisulfite Sequencing, Chip-seq"/>
      </STUDY_TYPES>
      <STUDY_ABSTRACT>This study aims to determine the reference epigenomes of the human placenta and endometrium, which constitute the fetal-meternal interface, for future use in studies of human diseases associated with reproduction and development. In the placenta, we focus on cytotrophoblast and syncytiotrophoblast cells (both at first trimester and at term) and, in the endometrium, we focus on epitherial cells (at the follicular and secretory phases) and stroma cells. These reference epigenomic data will be of valuable resource in studying disease-associated differences in epigenomic modification in the reproductive system.</STUDY_ABSTRACT>
    </DESCRIPTOR>
    <GRANTS>
      <GRANT grant_id="">
        <TITLE>Core Research for Evolutional Science and Technology (CREST)</TITLE>
        <AGENCY abbr="AMED">Japan Agency for Medical Research and Development</AGENCY>
      </GRANT>
    </GRANTS>
    <PUBLICATIONS>
      <PUBLICATION id="29249463" status="published">
        <DB_TYPE>PUBMED</DB_TYPE>
      </PUBLICATION>
    </PUBLICATIONS>
    <STUDY_LINKS>
      <STUDY_LINK>
        <URL_LINK>
          <LABEL>http://ihec-epigenomes.net/</LABEL>
          <URL>http://ihec-epigenomes.net/</URL>
        </URL_LINK>
      </STUDY_LINK>
      <STUDY_LINK>
        <URL_LINK>
          <LABEL>http://crest-ihec.jp/english/index.html</LABEL>
          <URL>http://crest-ihec.jp/english/index.html</URL>
        </URL_LINK>
      </STUDY_LINK>
    </STUDY_LINKS>
    <STUDY_ATTRIBUTES>
      <STUDY_ATTRIBUTE>
        <TAG>NBDC Number</TAG>
        <VALUE>hum0086</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Registration date</TAG>
        <VALUE>2017-05-30</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Submitting organization</TAG>
        <VALUE>Department of Informative Genetics, Environment and Genome Research Center, Tohoku University Graduate School of Medicine</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Principal Investigator</TAG>
        <VALUE>Takahiro Arima</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Molecular Data Type</TAG>
        <VALUE>Transcriptome Sequencing</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Platform</TAG>
        <VALUE>HiSeq 2500</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Vendor</TAG>
        <VALUE>Illumina</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>List</TAG>
        <VALUE/>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Molecular Data Type</TAG>
        <VALUE>Bisulfite Sequencing</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Platform</TAG>
        <VALUE>HiSeq 1500</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Vendor</TAG>
        <VALUE>Illumina</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>List</TAG>
        <VALUE/>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Molecular Data Type</TAG>
        <VALUE>ChIP-seq</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Platform</TAG>
        <VALUE>HiSeq 2500</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Vendor</TAG>
        <VALUE>Illumina</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>List</TAG>
        <VALUE/>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Primary Phenotype</TAG>
        <VALUE>Normal/none</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Project</TAG>
        <VALUE>International Human Epigenome Consortium (IHEC)</VALUE>
      </STUDY_ATTRIBUTE>
    </STUDY_ATTRIBUTES>
  </STUDY>
  <STUDY alias="JSUB000177_Study_0001" center_name="Individual" accession="JGAS000112">
    <IDENTIFIERS>
      <SECONDARY_ID>JGAS00000000112</SECONDARY_ID>
    </IDENTIFIERS>
    <DESCRIPTOR>
      <STUDY_TITLE>Epigenome analysis of human trophoblast stem cells</STUDY_TITLE>
      <STUDY_TYPES>
        <STUDY_TYPE existing_study_type="Transcriptome Sequencing"/>
        <STUDY_TYPE existing_study_type="Other" new_study_type="Bisulfite Sequencing"/>
        <STUDY_TYPE existing_study_type="Other" new_study_type="ChIP Sequencing"/>
      </STUDY_TYPES>
      <STUDY_ABSTRACT>Trophoblast cells play an essential role in the interactions between the fetus and mother. Mouse trophoblast stem (TS) cells have been derived and used as the best in vitro model for molecular and functional analysis of mouse trophoblast lineages. However, attempts to derive human TS cells have so far been unsuccessful. In this study, we derived human TS cells from human blastocysts. Epigenome analysis revealed that the human TS cells maintained epigenome profiles similar to those of primary trophoblast cells.</STUDY_ABSTRACT>
    </DESCRIPTOR>
    <STUDY_ATTRIBUTES>
      <STUDY_ATTRIBUTE>
        <TAG>NBDC Number</TAG>
        <VALUE>hum0112</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Registration date</TAG>
        <VALUE>2017-05-30</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Submitting organization</TAG>
        <VALUE>Department of Informative Genetics, Environment and Genome Research Center, Tohoku University Graduate School of Medicine</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Principal Investigator</TAG>
        <VALUE>Takahiro Arima</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Molecular Data Type</TAG>
        <VALUE>Transcriptome Sequencing</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Platform</TAG>
        <VALUE>HiSeq 2500</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Vendor</TAG>
        <VALUE>Illumina</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>List</TAG>
        <VALUE/>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Molecular Data Type</TAG>
        <VALUE>Bisulfite Sequencing</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Platform</TAG>
        <VALUE>HiSeq 1500</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Vendor</TAG>
        <VALUE>Illumina</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>List</TAG>
        <VALUE/>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Molecular Data Type</TAG>
        <VALUE>ChIP Sequencing</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Platform</TAG>
        <VALUE>HiSeq 1500</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Vendor</TAG>
        <VALUE>Illumina</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>List</TAG>
        <VALUE/>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Primary Phenotype</TAG>
        <VALUE>Normal/none</VALUE>
      </STUDY_ATTRIBUTE>
    </STUDY_ATTRIBUTES>
  </STUDY>
  <STUDY alias="JSUB000178_Study_0001" center_name="Individual" accession="JGAS000207">
    <IDENTIFIERS>
      <SECONDARY_ID>JGAS00000000207</SECONDARY_ID>
    </IDENTIFIERS>
    <DESCRIPTOR>
      <STUDY_TITLE>Epigenomic analysis of human androgenetic trophoblast stem cells derived from complete hydatidiform mole</STUDY_TITLE>
      <STUDY_TYPES>
        <STUDY_TYPE existing_study_type="Transcriptome Sequencing"/>
        <STUDY_TYPE existing_study_type="Other" new_study_type="Bisulfite Sequencing"/>
      </STUDY_TYPES>
      <STUDY_ABSTRACT>A complete hydatidiform mole (CHM) is an abnormal pregnancy caused by genetic fertilization disorders. The aim of this study is to establish human trophoblast stem (TS) cell lines from CHMs and elucidate their pathogenesis. </STUDY_ABSTRACT>
    </DESCRIPTOR>
    <GRANTS>
      <GRANT grant_id="JP19gm1310001">
        <TITLE>Elucidation of the mechanisms underlying human placental development and design of a placenta-on-a-chip platform (AMED-CREST)</TITLE>
        <AGENCY abbr="AMED">Japan Agency for Medical Research and Development</AGENCY>
      </GRANT>
    </GRANTS>
    <PUBLICATIONS>
      <PUBLICATION id="31792181" status="published">
        <DB_TYPE>PUBMED</DB_TYPE>
      </PUBLICATION>
    </PUBLICATIONS>
    <STUDY_ATTRIBUTES>
      <STUDY_ATTRIBUTE>
        <TAG>NBDC Number</TAG>
        <VALUE>hum0206</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Registration date</TAG>
        <VALUE>2019-10-14</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Submitting organization</TAG>
        <VALUE>Tohoku University Graduate School of Medicine</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Principal Investigator</TAG>
        <VALUE>Takahiro Arima</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Molecular Data Type</TAG>
        <VALUE>Transcriptome Sequencing</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Platform</TAG>
        <VALUE>Hiseq 2500</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Vendor</TAG>
        <VALUE>Illumina</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>List</TAG>
        <VALUE/>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Molecular Data Type</TAG>
        <VALUE>Bisulfite Sequencing</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Platform</TAG>
        <VALUE>Hiseq 2500</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Vendor</TAG>
        <VALUE>Illumina</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>List</TAG>
        <VALUE/>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Primary Phenotype</TAG>
        <VALUE>Complete hydatidiform mole</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>IDC-10 Disease Classification</TAG>
        <VALUE>Classical hydatidiform mole (O01)</VALUE>
      </STUDY_ATTRIBUTE>
    </STUDY_ATTRIBUTES>
  </STUDY>
  <STUDY alias="JSUB000182_Study_0001" center_name="Individual" accession="JGAS000119">
    <IDENTIFIERS>
      <SECONDARY_ID>JGAS00000000119</SECONDARY_ID>
    </IDENTIFIERS>
    <DESCRIPTOR>
      <STUDY_TITLE>Identification of RNA biomarkers in Parkinson's disease patients</STUDY_TITLE>
      <STUDY_TYPES>
        <STUDY_TYPE existing_study_type="Case-Control"/>
        <STUDY_TYPE existing_study_type="Transcriptome Sequencing"/>
      </STUDY_TYPES>
      <STUDY_ABSTRACT>Parkinson?s disease (PD) is an age-related, chronic and progressive neurodegenerative disorder characterized by a loss of dopaminergic neurons and subsequent motor symptoms. These overt motor symptoms are often preceded by prodromal non-motor symptoms. Though a number of genetic and environmental factors have been identified to play a role in PD, more exact methods for both diagnosing and assessing prognosis are yet to be discovered. By analyzing the transcriptome of early-stage PD patients, this study aims to identify genes (including important non-coding RNAs) and pathways altered at disease onset that may be used as novel biomarkers for PD diagnosis as well as potential new drug targets. The study consists of three main sources of data: first year blood transcriptomes, second year blood transcriptome and matched neural stem cell (NSC)/neuron transcriptomes. All transcriptome libraries were synthesized and sequenced using no-amplification non-tagging cap analysis of gene expression (nAnT-iCAGE) on the Illumina HiSeq 2500 platform. Resulting data was mapped to the human genome annotation (hg38), processed CAGE tags were clustered ready for differential expression analyses. First year blood sequencing consisted of 22 PD patients and 10 healthy controls across four lanes. In the second year, a further four lanes were sequenced containing 17 PD patients (12 patients from the first year and 5 new patients) along with 10 healthy controls and 5 first year blood samples matching the new second year patients.</STUDY_ABSTRACT>
    </DESCRIPTOR>
    <GRANTS>
      <GRANT grant_id="">
        <TITLE>Development of metabolite biomarkers of Parkinson's disease and identification of drug seeds from chemical screening based on the biomarkers</TITLE>
        <AGENCY abbr="AMED">Japan Agency for Medical Research and Development</AGENCY>
      </GRANT>
    </GRANTS>
    <STUDY_LINKS>
      <STUDY_LINK>
        <URL_LINK>
          <LABEL>https://www.jst.go.jp/kisoken/crest/project/42/14531740.html</LABEL>
          <URL>https://www.jst.go.jp/kisoken/crest/project/42/14531740.html</URL>
        </URL_LINK>
      </STUDY_LINK>
    </STUDY_LINKS>
    <STUDY_ATTRIBUTES>
      <STUDY_ATTRIBUTE>
        <TAG>NBDC Number</TAG>
        <VALUE>hum0113</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Registration date</TAG>
        <VALUE>2017-09-19</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Submitting organization</TAG>
        <VALUE>RIKEN</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Principal Investigator</TAG>
        <VALUE>Piero Carninci</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Molecular Data Type</TAG>
        <VALUE>Transcription Start Site Sequencing (CAGE)</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Platform</TAG>
        <VALUE>HiSeq2500</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Vendor</TAG>
        <VALUE>Illumina</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>List</TAG>
        <VALUE/>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Primary Phenotype</TAG>
        <VALUE>Parkinson's disease</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Study Inclusion/Exclusion Criteria</TAG>
        <VALUE>Early stage of PD</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>CAGE</TAG>
        <VALUE>Transcription Start Site Sequencing</VALUE>
      </STUDY_ATTRIBUTE>
    </STUDY_ATTRIBUTES>
  </STUDY>
  <STUDY alias="JSUB000183_Study_0001" center_name="Individual" accession="JGAS000121">
    <IDENTIFIERS>
      <SECONDARY_ID>JGAS00000000121</SECONDARY_ID>
    </IDENTIFIERS>
    <DESCRIPTOR>
      <STUDY_TITLE>Controlling cell differentiation with precision through understanding the structure and dynamics of gene regulatory networks</STUDY_TITLE>
      <STUDY_TYPES>
        <STUDY_TYPE existing_study_type="Other" new_study_type="transcriptome, microarray"/>
      </STUDY_TYPES>
      <STUDY_ABSTRACT>We established a set of transgenic human ES cell lines that carry inducible expression gene cassette for singe transcriptional factor induction with Tet-ON system. Transcriptome data was obtained 48h after transgene induction by Microarray. We established inducible human ES lines about more than 700 genes, and achieved microarray analysis on 115 genes. Our data set has multiple characteristic properties; 1) the same platform across data set, 2) analyzed with dynamic cell status, 3) pre-determined initiation point on gene perturbation, 4)inducible in different cell status. In parallele, we also performed RNA sequenncig analysis on 435 transgene induced ES lines as well. 32 transgene induced transcriptome data were obtained from both Microarray and RNA sequencing, normalizing technical gaps between them. We hope those systematic data set to reveal transcriptional network structure and molecular mechanisms of cell differentiation.</STUDY_ABSTRACT>
    </DESCRIPTOR>
    <GRANTS>
      <GRANT grant_id="0">
        <TITLE>CREST</TITLE>
        <AGENCY abbr="JST">Japan Science and Technology Agency</AGENCY>
      </GRANT>
      <GRANT grant_id="17">
        <TITLE>Research Center Network for Realization of Regenerative Medicine</TITLE>
        <AGENCY abbr="AMED">Japan Agency for Medical Research and Development</AGENCY>
      </GRANT>
    </GRANTS>
    <STUDY_LINKS>
      <STUDY_LINK>
        <URL_LINK>
          <LABEL>http://www.jst.go.jp/kisoken/crest/en/project/35/e35_04.html</LABEL>
          <URL>http://www.jst.go.jp/kisoken/crest/en/project/35/e35_04.html</URL>
        </URL_LINK>
      </STUDY_LINK>
      <STUDY_LINK>
        <URL_LINK>
          <LABEL>http://systemsmedicine.jp/crest/</LABEL>
          <URL>http://systemsmedicine.jp/crest/</URL>
        </URL_LINK>
      </STUDY_LINK>
    </STUDY_LINKS>
    <STUDY_ATTRIBUTES>
      <STUDY_ATTRIBUTE>
        <TAG>NBDC Number</TAG>
        <VALUE>hum0115</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Registration date</TAG>
        <VALUE>2017-09-27</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Submitting organization</TAG>
        <VALUE>Department of Systems Medicine, Mitsunada SakaguchiLaboratory, Keio University School of Medicine
  </VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Principal Investigator</TAG>
        <VALUE>Minoru Ko</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Molecular Data Type</TAG>
        <VALUE>Expression profile, Microarray</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Platform</TAG>
        <VALUE>Agilent SurePrint G3 Human GE v2 8x60K Microarray (Design ID: 039494)</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Vendor</TAG>
        <VALUE>Agilent</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>List</TAG>
        <VALUE/>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Primary Phenotype</TAG>
        <VALUE>Normal, Embryonic stem cells</VALUE>
      </STUDY_ATTRIBUTE>
    </STUDY_ATTRIBUTES>
  </STUDY>
  <STUDY alias="JSUB000185_Study_0001" center_name="Individual" accession="JGAS000125">
    <IDENTIFIERS>
      <SECONDARY_ID>JGAS00000000125</SECONDARY_ID>
    </IDENTIFIERS>
    <DESCRIPTOR>
      <STUDY_TITLE>Neuron-specifc methylome analysis of Alzheimer's disease brain</STUDY_TITLE>
      <STUDY_TYPES>
        <STUDY_TYPE existing_study_type="Other" new_study_type="Methylome analysis"/>
      </STUDY_TYPES>
      <STUDY_ABSTRACT>Neuron-specific methylome analysis of Alzheimer's disease brain to detect epigenetic changes related to the pathomechanism.</STUDY_ABSTRACT>
    </DESCRIPTOR>
    <GRANTS>
      <GRANT grant_id="16">
        <TITLE>A novel neuro-epigenetic approach to the pathogenic mechanism of the neurodegenerative dementia diseases</TITLE>
        <AGENCY abbr="">KAKENHI Grant-in-Aid for Scientific Research (B)</AGENCY>
      </GRANT>
      <GRANT grant_id="17">
        <TITLE>Analysis of DNA damage mechanism in the novel cellular and mouse model of Alzheimer?s disease</TITLE>
        <AGENCY abbr="">KAKENHI Grant-in-Aid for Young Scientists (B)</AGENCY>
      </GRANT>
      <GRANT grant_id="16">
        <TITLE>Development of a new disease-modifying therapy and early diagnostic method of Alzheimer?s disease based on a cause of amyloid deposition observed in sporadic type</TITLE>
        <AGENCY abbr="">Japan Agency for Medical Research and Development</AGENCY>
      </GRANT>
    </GRANTS>
    <PUBLICATIONS>
      <PUBLICATION id="29042514" status="published">
        <DB_TYPE>PUBMED</DB_TYPE>
      </PUBLICATION>
    </PUBLICATIONS>
    <STUDY_LINKS>
      <STUDY_LINK>
        <URL_LINK>
          <LABEL>doi: 10.1073/pnas.1707151114</LABEL>
          <URL>doi: 10.1073/pnas.1707151114</URL>
        </URL_LINK>
      </STUDY_LINK>
    </STUDY_LINKS>
    <STUDY_ATTRIBUTES>
      <STUDY_ATTRIBUTE>
        <TAG>NBDC Number</TAG>
        <VALUE>hum0117</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Registration date</TAG>
        <VALUE>2017-12-04</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Submitting organization</TAG>
        <VALUE>The University of Tokyo</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Principal Investigator</TAG>
        <VALUE>Atsushi Iwata</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Molecular Data Type</TAG>
        <VALUE>Methylome analysis</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Platform</TAG>
        <VALUE>Infinium 450k</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Vendor</TAG>
        <VALUE>Illumina</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>List</TAG>
        <VALUE/>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Primary Phenotype</TAG>
        <VALUE>Alzheimer's disease</VALUE>
      </STUDY_ATTRIBUTE>
    </STUDY_ATTRIBUTES>
  </STUDY>
  <STUDY alias="JSUB000186_Study_0001" center_name="Individual" accession="JGAS000124">
    <IDENTIFIERS>
      <SECONDARY_ID>JGAS00000000124</SECONDARY_ID>
    </IDENTIFIERS>
    <DESCRIPTOR>
      <STUDY_TITLE>CAGE analysis for endometrial carcinoma</STUDY_TITLE>
      <STUDY_TYPES>
        <STUDY_TYPE existing_study_type="Transcriptome Sequencing"/>
      </STUDY_TYPES>
      <STUDY_ABSTRACT>For endometrial cancer patients, lymphadenectomy is recommended to exclude rarely metastasized cancer cells. This procedure is performed even in patients with low risk of recurrence despite the risk of complications such as lymphedema. A method to accurately identify cases with no lymph node metastases (LN-) before lymphadenectomy is therefore highly required. We approached this clinical problem by examining primary lesions of endometrial cancers with CAGE (Cap Analysis Gene Expression), which quantifies promoter-level expression across the genome. Fourteen profiles delineated distinct transcriptional networks between LN?+?and LN- cases, within those classified as having the low or intermediate risk of recurrence.</STUDY_ABSTRACT>
    </DESCRIPTOR>
    <GRANTS>
      <GRANT grant_id="15K10732">
        <TITLE>Grant-in-Aid for Scientific Research (C)</TITLE>
        <AGENCY abbr="MEXT">The Ministry of Education, Culture, Sports, Science and Technology, Japan</AGENCY>
      </GRANT>
      <GRANT grant_id="">
        <TITLE>Research grant to the RIKEN Preventive Medicine and Diagnosis Innovation Program</TITLE>
        <AGENCY abbr="MEXT">The Ministry of Education, Culture, Sports, Science and Technology, Japan</AGENCY>
      </GRANT>
      <GRANT grant_id="">
        <TITLE>Research grant to RIKEN Center for Life Science Technologies </TITLE>
        <AGENCY abbr="MEXT">The Ministry of Education, Culture, Sports, Science and Technology, Japan</AGENCY>
      </GRANT>
      <GRANT grant_id="">
        <TITLE>Research grant to RIKEN Omics Science Center</TITLE>
        <AGENCY abbr="MEXT">The Ministry of Education, Culture, Sports, Science and Technology, Japan</AGENCY>
      </GRANT>
    </GRANTS>
    <PUBLICATIONS>
      <PUBLICATION id="29074988" status="published">
        <DB_TYPE>PUBMED</DB_TYPE>
      </PUBLICATION>
    </PUBLICATIONS>
    <STUDY_ATTRIBUTES>
      <STUDY_ATTRIBUTE>
        <TAG>NBDC Number</TAG>
        <VALUE>hum0118</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Registration date</TAG>
        <VALUE>2017-11-30</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Submitting organization</TAG>
        <VALUE>RIKEN Preventive Medicine and Diagnosis Innovation Program</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Principal Investigator</TAG>
        <VALUE>Yoshihide Hayashizaki</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Molecular Data Type</TAG>
        <VALUE>Transcriptome (Cap Analysis Of Gene Expression)</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Platform</TAG>
        <VALUE>HiSeq2500</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Vendor</TAG>
        <VALUE>Illumina</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>List</TAG>
        <VALUE/>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Molecular Data Type</TAG>
        <VALUE>TACC2 cDNA amplicon cloning and sequencing</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Platform</TAG>
        <VALUE>sanger sequencing</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Vendor</TAG>
        <VALUE>Thermo Fisher</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>List</TAG>
        <VALUE/>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Primary Phenotype</TAG>
        <VALUE>Endometrial carcinoma</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Disease Type</TAG>
        <VALUE>Neoplasms</VALUE>
      </STUDY_ATTRIBUTE>
    </STUDY_ATTRIBUTES>
  </STUDY>
  <STUDY alias="JSUB000187_Study_0001" center_name="Individual" accession="JGAS000123">
    <IDENTIFIERS>
      <SECONDARY_ID>JGAS00000000123</SECONDARY_ID>
    </IDENTIFIERS>
    <DESCRIPTOR>
      <STUDY_TITLE>WFS1 mutation screening in a large series of Japanese hearing loss patients: Massively parallel DNA sequencing-based analysis</STUDY_TITLE>
      <STUDY_TYPES>
        <STUDY_TYPE existing_study_type="Case Set"/>
      </STUDY_TYPES>
      <STUDY_ABSTRACT>A heterozygous mutation in the Wolfram syndrome type 1 gene (WFS1) causes autosomal dominant nonsyndromic hereditary hearing loss, DFNA6/14/38, or Wolfram-like syndrome. To date, more than 40 different mutations have been reported to be responsible for DFNA6/14/38. In the present study, WFS1 variants were screened in a large series of Japanese hearing loss (HL) patients to clarify the prevalence and clinical characteristics of DFNA6/14/38 and Wolfram-like syndrome. Massively parallel DNA sequencing of 68 target genes was performed in 2,549 unrelated Japanese HL patients to identify genomic variations responsible for HL. The detailed clinical features in patients with WFS1 variants were collected from medical charts and analyzed. We successfully identified 13 WFS1 variants in 19 probands: eight of the 13 variants were previously reported mutations, including three mutations (p.A684V, p.K836N, and p.E864K) known to cause Wolfram-like syndrome, and five were novel mutations.</STUDY_ABSTRACT>
    </DESCRIPTOR>
    <STUDY_ATTRIBUTES>
      <STUDY_ATTRIBUTE>
        <TAG>NBDC Number</TAG>
        <VALUE>hum0005</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Registration date</TAG>
        <VALUE>2017-12-02</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Submitting organization</TAG>
        <VALUE>Shinshu University School of Medicine</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Principal Investigator</TAG>
        <VALUE>Shin-ichi Usami</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Molecular Data Type</TAG>
        <VALUE>Target resequencing</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Platform</TAG>
        <VALUE>Ion PGM, Ion Proton</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Vendor</TAG>
        <VALUE>Thermo Fisher Scientific</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>List</TAG>
        <VALUE/>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Molecular Data Type</TAG>
        <VALUE>Target resequencing</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Platform</TAG>
        <VALUE>HiSeq2000</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Vendor</TAG>
        <VALUE>Illumina</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>List</TAG>
        <VALUE/>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Primary Phenotype</TAG>
        <VALUE>Nonsyndromic hearing loss</VALUE>
      </STUDY_ATTRIBUTE>
    </STUDY_ATTRIBUTES>
  </STUDY>
  <STUDY alias="JSUB000188_Study_0001" center_name="Individual" accession="JGAS000126">
    <IDENTIFIERS>
      <SECONDARY_ID>JGAS00000000126</SECONDARY_ID>
    </IDENTIFIERS>
    <DESCRIPTOR>
      <STUDY_TITLE>Genome-wide analysis for non alcoholic fatty liver disease</STUDY_TITLE>
      <STUDY_TYPES>
        <STUDY_TYPE existing_study_type="Case-Control"/>
      </STUDY_TYPES>
      <STUDY_ABSTRACT>Genome-wide association study for the 902 patients of non alcoholic fatty liver disease (NAFLD) including non alcoholic steato hepatitis (NASH) and hepatocellurar carcinoma and 7672 controls.</STUDY_ABSTRACT>
    </DESCRIPTOR>
    <STUDY_ATTRIBUTES>
      <STUDY_ATTRIBUTE>
        <TAG>NBDC Number</TAG>
        <VALUE>hum0119</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Registration date</TAG>
        <VALUE>2018-01-11</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Submitting organization</TAG>
        <VALUE>Kyoto University</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Principal Investigator</TAG>
        <VALUE>Fumihiko Matsuda</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Molecular Data Type</TAG>
        <VALUE> Whole Genome Genotyping</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Platform</TAG>
        <VALUE>610k, 2.5M-8 and CoreExome Beadchip</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Vendor</TAG>
        <VALUE>Illumina</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>List</TAG>
        <VALUE/>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Primary Phenotype</TAG>
        <VALUE>Fatty liver</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Phenotype</TAG>
        <VALUE>Hepatitis</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Phenotype</TAG>
        <VALUE>Hepatocellular carcinoma</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Disease Type</TAG>
        <VALUE>Nutritional and Metabolic Diseases</VALUE>
      </STUDY_ATTRIBUTE>
    </STUDY_ATTRIBUTES>
  </STUDY>
  <STUDY alias="JSUB000189_Study_0001" center_name="Individual" accession="JGAS000221">
    <IDENTIFIERS>
      <SECONDARY_ID>JGAS00000000221</SECONDARY_ID>
    </IDENTIFIERS>
    <DESCRIPTOR>
      <STUDY_TITLE>The genetic analysis of circulating tumor DNA in blood of the digestive cancer patients to investigate the  prognostic factors of metastasis and reccurence.</STUDY_TITLE>
      <STUDY_TYPES>
        <STUDY_TYPE existing_study_type="Tumor vs. Matched-Normal"/>
      </STUDY_TYPES>
      <STUDY_ABSTRACT>A Darwinian evolutionary shift occurred early in the neutral evolution of advanced colorectal carcinoma (CRC) and copy number aberrations (CNA) were essential in the transition from adenoma to carcinoma. Subsequent to the primary evolution, we now focus on the evolutionary principle of the genome to foster postoperative recurrence of CRC. SO, We compared CNA, single nucleotide variance (SNV), RNA sequences between 8 primary and 11 metastatic sites from 10 CRCR cases.</STUDY_ABSTRACT>
    </DESCRIPTOR>
    <STUDY_ATTRIBUTES>
      <STUDY_ATTRIBUTE>
        <TAG>NBDC Number</TAG>
        <VALUE>hum0120</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Registration date</TAG>
        <VALUE>2020-03-13</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Submitting organization</TAG>
        <VALUE>Department of Surgery, Kyushu University Beppu Hospital</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Principal Investigator</TAG>
        <VALUE>Shotaro Sakimura</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Molecular Data Type</TAG>
        <VALUE>Whole Exome Sequencing</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Platform</TAG>
        <VALUE>Hiseq2500</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Vendor</TAG>
        <VALUE>Illumina</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>List</TAG>
        <VALUE/>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Molecular Data Type</TAG>
        <VALUE>Whole Transcriptome Sequencing</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Platform</TAG>
        <VALUE>Hiseq2500</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Vendor</TAG>
        <VALUE>Illumina</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Molecular Data Type</TAG>
        <VALUE>T cell receptor Sequencing</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Platform</TAG>
        <VALUE>MiSeq</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Vendor</TAG>
        <VALUE>Illumina</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>List</TAG>
        <VALUE/>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Primary Phenotype</TAG>
        <VALUE>Colon cancer</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>ICD-10 Disease Classification</TAG>
        <VALUE>Colon, unspecified (C18.9)</VALUE>
      </STUDY_ATTRIBUTE>
    </STUDY_ATTRIBUTES>
  </STUDY>
  <STUDY alias="JSUB000192_Study_0001" center_name="Individual" accession="JGAS000129">
    <IDENTIFIERS>
      <SECONDARY_ID>JGAS00000000129</SECONDARY_ID>
    </IDENTIFIERS>
    <DESCRIPTOR>
      <STUDY_TITLE>Identification of the genes associated with EGFR-mutant lung cancer</STUDY_TITLE>
      <STUDY_TYPES>
        <STUDY_TYPE existing_study_type="Case Set"/>
        <STUDY_TYPE existing_study_type="Exome Sequencing"/>
      </STUDY_TYPES>
      <STUDY_ABSTRACT>To gain an insight into the genetic factors underlying the carcinogenesis of EGFR-mutant lung adenocarcinoma, we sequenced the exomes in peripheral-blood DNA from the patients.</STUDY_ABSTRACT>
    </DESCRIPTOR>
    <GRANTS>
      <GRANT grant_id="11127011">
        <TITLE>Project for Development of Innovative Research on Cancer Therapeutics</TITLE>
        <AGENCY abbr="AMED">Japan Agency for Medical Research and Development</AGENCY>
      </GRANT>
    </GRANTS>
    <PUBLICATIONS>
      <PUBLICATION id="28294470" status="published">
        <DB_TYPE>PUBMED</DB_TYPE>
      </PUBLICATION>
    </PUBLICATIONS>
    <STUDY_LINKS>
      <STUDY_LINK>
        <URL_LINK>
          <LABEL>http://www.med.niigata-u.ac.jp/resp/welcome.html</LABEL>
          <URL>http://www.med.niigata-u.ac.jp/resp/welcome.html</URL>
        </URL_LINK>
      </STUDY_LINK>
    </STUDY_LINKS>
    <STUDY_ATTRIBUTES>
      <STUDY_ATTRIBUTE>
        <TAG>NBDC Number</TAG>
        <VALUE>hum0124</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Registration date</TAG>
        <VALUE>2018-03-19</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Submitting organization</TAG>
        <VALUE>Niigata University Graduate School of Medical and Dental Sciences</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Principal Investigator</TAG>
        <VALUE>Toshiaki Kikuchi</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Molecular Data Type</TAG>
        <VALUE>Exome Sequencing</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Platform</TAG>
        <VALUE>AB SOLiD 4 System</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Vendor</TAG>
        <VALUE>Applied Biosystems</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>List</TAG>
        <VALUE/>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Primary Phenotype</TAG>
        <VALUE>Non-small cell lung carcinoma</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Study Inclusion/Exclusion Criteria</TAG>
        <VALUE>EGFR-mutant lung adenocarcinoma</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Disease Type</TAG>
        <VALUE>Neoplasms</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>mutation</TAG>
        <VALUE>epidermal growth factor receptor (EGFR) </VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>disease</TAG>
        <VALUE>lung adenocarcinoma</VALUE>
      </STUDY_ATTRIBUTE>
    </STUDY_ATTRIBUTES>
  </STUDY>
  <STUDY alias="JSUB000193_Study_0001" center_name="Individual" accession="JGAS000127">
    <IDENTIFIERS>
      <SECONDARY_ID>JGAS00000000127</SECONDARY_ID>
    </IDENTIFIERS>
    <DESCRIPTOR>
      <STUDY_TITLE>Innate myeloid cell sbuset-specific gene expression patterns in the human colon are altered in Crohn's disease patients</STUDY_TITLE>
      <STUDY_TYPES>
        <STUDY_TYPE existing_study_type="Transcriptome Sequencing"/>
      </STUDY_TYPES>
      <STUDY_ABSTRACT>Background: There is a heterogeneous subset innate myeloid cells, such as macrophages and dendritic cells, in the human intestinal lamina propria. Several studies have demonstrated that these cells contribute to the maintenance of gut homeostasis through induction of inflammatory responses and tolerance via cell type-specific mechanisms; whereas, disrupted innate immune responses are implicated in the pathogenesis of Crohn?s disease. However, the detailed mechanisms by which each innate myeloid subset regulates gut homeostasis and inflammation largely remains unknown.
  Aim: We aimed to clarify the comprehensive gene expression profiles of innate myeloid cell subsets in the lamina propria from normal human colons (NC) and the inflamed colon sites from patients with Crohn?s disease (CDi).
  Methods: We performed RNA-sequencing analysis and precise bioinformatics analysis on three innate myeloid cell subsets, CD14-CD11c-, CD14-CD11c+, and CD14+CD11c+CD163low cells from NC and CDi.
  Results: Transcriptional analysis of the three subsets from the NC showed distinct gene expression patterns and gene ontology (GO) enrichment analysis revealed the associated innate myeloid subset-specific biological process (BP) terms. In addition, changes in gene expression patterns were observed in innate myeloid subsets from CDi. Furthermore, the core GO-BP terms for the genes upregulated in the innate myeloid cells from CDi were distinct from those found in NC.
  Conclusion: Our data identified the innate myeloid cell subset-specific transcriptomes and the associated enriched GO-BP terms in the NC and found these patterns were altered in CDi.
  </STUDY_ABSTRACT>
    </DESCRIPTOR>
    <PUBLICATIONS>
      <PUBLICATION id="30343293" status="published">
        <DB_TYPE>PUBMED</DB_TYPE>
      </PUBLICATION>
    </PUBLICATIONS>
    <STUDY_ATTRIBUTES>
      <STUDY_ATTRIBUTE>
        <TAG>NBDC Number</TAG>
        <VALUE>hum0125</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Registration date</TAG>
        <VALUE>2018-03-01</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Submitting organization</TAG>
        <VALUE>Experimental Immunology, iFReC, Osaka University</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Principal Investigator</TAG>
        <VALUE>Shimon Sakaguchi</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Molecular Data Type</TAG>
        <VALUE>Transcriptome Sequencing</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Platform</TAG>
        <VALUE>Ion S5</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Vendor</TAG>
        <VALUE>Thermo Fisher Scienfitic</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>List</TAG>
        <VALUE/>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Primary Phenotype</TAG>
        <VALUE>Crohn's disease</VALUE>
      </STUDY_ATTRIBUTE>
    </STUDY_ATTRIBUTES>
  </STUDY>
  <STUDY alias="JSUB000195_Study_0001" center_name="Individual" accession="JGAS000130">
    <IDENTIFIERS>
      <SECONDARY_ID>JGAS00000000130</SECONDARY_ID>
    </IDENTIFIERS>
    <DESCRIPTOR>
      <STUDY_TITLE>Molecular Profiling and Sequential Somatic Mutation Shift in Hypermutator Tumors Harboring POLE Mutations</STUDY_TITLE>
      <STUDY_TYPES>
        <STUDY_TYPE existing_study_type="Tumor vs. Matched-Normal"/>
      </STUDY_TYPES>
      <STUDY_ABSTRACT>Defective DNA polymerase ? (POLE) proofreading leads to extensive somatic mutations that exhibits biased mutational properties; however, the characteristics of POLE-mutated tumors remain unclear. In present study, we described a molecular profile using whole exome sequencing based on the  transition of somatic mutations in 10 POLE-mutated solid tumors that obtained from 2,42 Japanese patients. The bias of accumulated variations in this mutant was quantified to follow a pattern of somatic mutations, thereby classifying the sequential mutation shift into three periods. During the period prior to occurrence of the aberrant POLE, no accumulation of mutations in cancer-related genes was observed, whereas PTEN was highly mutated in conjunction with or subsequent to the event, suggesting that POLE and PTEN mutations were responsible for the development of POLE-mutated tumors. Furthermore, homologous recombination was restored after occurring PTEN mutations. Our strategy for estimation of the footprint of somatic mutations may provide new insight toward the understanding of mutation-driven tumorigenesis.</STUDY_ABSTRACT>
    </DESCRIPTOR>
    <PUBLICATIONS>
      <PUBLICATION id="25743347" status="published">
        <DB_TYPE>PUBMED</DB_TYPE>
      </PUBLICATION>
      <PUBLICATION id="28003583" status="published">
        <DB_TYPE>PUBMED</DB_TYPE>
      </PUBLICATION>
      <PUBLICATION id="28003584" status="published">
        <DB_TYPE>PUBMED</DB_TYPE>
      </PUBLICATION>
    </PUBLICATIONS>
    <STUDY_LINKS>
      <STUDY_LINK>
        <URL_LINK>
          <LABEL>https://www.scchr.jp/project-hope.html</LABEL>
          <URL>https://www.scchr.jp/project-hope.html</URL>
        </URL_LINK>
      </STUDY_LINK>
    </STUDY_LINKS>
    <STUDY_ATTRIBUTES>
      <STUDY_ATTRIBUTE>
        <TAG>NBDC Number</TAG>
        <VALUE>hum0127</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Registration date</TAG>
        <VALUE>2018-03-16</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Submitting organization</TAG>
        <VALUE>Shizuoka Cancer Center</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Principal Investigator</TAG>
        <VALUE>Ken Yamaguchi</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Molecular Data Type</TAG>
        <VALUE>Whole Exome Sequencing</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Platform</TAG>
        <VALUE>Ion Torrent Proton</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Vendor</TAG>
        <VALUE>Thermo Fisher Scientific</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>List</TAG>
        <VALUE/>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Primary Phenotype</TAG>
        <VALUE>Neoplasm [HP:0002664]</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Disease Type</TAG>
        <VALUE>Neoplasms</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>hypermutator</TAG>
        <VALUE>DNA polymerase e (POLE)</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>tumor suppressor gene</TAG>
        <VALUE>PTEN</VALUE>
      </STUDY_ATTRIBUTE>
    </STUDY_ATTRIBUTES>
  </STUDY>
  <STUDY alias="JSUB000196_Study_0001" center_name="Individual" accession="JGAS000153">
    <IDENTIFIERS>
      <SECONDARY_ID>JGAS00000000153</SECONDARY_ID>
    </IDENTIFIERS>
    <DESCRIPTOR>
      <STUDY_TITLE>Gene expression analysis for nasal polyps</STUDY_TITLE>
      <STUDY_TYPES>
        <STUDY_TYPE existing_study_type="Transcriptome Sequencing"/>
      </STUDY_TYPES>
      <STUDY_ABSTRACT>The aim of the study is to identify the gene expression profile and biomarkers related with chronic rhinosinusitis with nasal polyps (CRSwNP). RNA-sequencing was performed to identify differentially expressed genes between nasal polyps (NP) and inferior turbinate mucosa from 6 patients with CRSwNP. We validated the RNA-seq results by quantitative real-time PCR.</STUDY_ABSTRACT>
    </DESCRIPTOR>
    <GRANTS>
      <GRANT grant_id="0">
        <TITLE>Novel strategy of the treatment for severe eosinophilic chronic rhinosinusitis.</TITLE>
        <AGENCY abbr="AMED">Japan Agency for Medical Research and Development</AGENCY>
      </GRANT>
    </GRANTS>
    <PUBLICATIONS>
      <PUBLICATION id="30061580" status="published">
        <DB_TYPE>PUBMED</DB_TYPE>
      </PUBLICATION>
    </PUBLICATIONS>
    <STUDY_ATTRIBUTES>
      <STUDY_ATTRIBUTE>
        <TAG>NBDC Number</TAG>
        <VALUE>hum0128</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Registration date</TAG>
        <VALUE>2018-07-30</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Submitting organization</TAG>
        <VALUE>University of Fukui</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Principal Investigator</TAG>
        <VALUE>Shigeharu Fujieda</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Molecular Data Type</TAG>
        <VALUE>RNA-seq</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Platform</TAG>
        <VALUE>HiSeq2000</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Vendor</TAG>
        <VALUE>Illumina</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>List</TAG>
        <VALUE/>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Primary Phenotype</TAG>
        <VALUE>chronic rhinosinusitis</VALUE>
      </STUDY_ATTRIBUTE>
    </STUDY_ATTRIBUTES>
  </STUDY>
  <STUDY alias="JSUB000197_Study_0001" center_name="Individual" accession="JGAS000151">
    <IDENTIFIERS>
      <SECONDARY_ID>JGAS00000000151</SECONDARY_ID>
    </IDENTIFIERS>
    <DESCRIPTOR>
      <STUDY_TITLE>WGS analysis of Japanese liver cancer</STUDY_TITLE>
      <STUDY_TYPES>
        <STUDY_TYPE existing_study_type="Tumor vs. Matched-Normal"/>
      </STUDY_TYPES>
      <STUDY_ABSTRACT>Liver cancer is prevalent worldwide, mainly associated with virus infection, and its underlying etiology and genomic structure are heterogeneous. Here we provide a whole-genome landscape of somatic alterations in 300 Japanese liver cancers. Our comprehensive analysis elucidated point mutations in non-coding regions, structural variants (SVs), and virus integrations, in addition to coding mutations, and demonstrated new mutational signatures related with liver carcinogenesis, novel recurrently mutated coding and non-coding regions such as lincRNA NEAT1/MALAT1, promoters, CTCF binding sites, and regulatory regions. SV analysis found a significant association with replication timing, and revealed that known cancer genes (CDKN2A, CCND1, APC, and TERT) and new cancer genes (ASH1L, NCOR1, MACROD2) were recurrently affected by SVs, leading to altered expression of nearby genes. These results emphasize the value of whole genome sequencing analysis to discover cancer driver mutations and to understand comprehensive molecular profiles of liver cancer, especially for SVs and non-coding mutations.</STUDY_ABSTRACT>
    </DESCRIPTOR>
    <PUBLICATIONS>
      <PUBLICATION id="27064257" status="published">
        <DB_TYPE>PUBMED</DB_TYPE>
      </PUBLICATION>
      <PUBLICATION id="31130341" status="published">
        <DB_TYPE>PUBMED</DB_TYPE>
      </PUBLICATION>
    </PUBLICATIONS>
    <STUDY_ATTRIBUTES>
      <STUDY_ATTRIBUTE>
        <TAG>NBDC Number</TAG>
        <VALUE>hum0158</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Registration date</TAG>
        <VALUE>2018-03-26</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Submitting organization</TAG>
        <VALUE>RIKEN Center for Integrative Medical Sciences</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Principal Investigator</TAG>
        <VALUE>Hidewaki Nakagawa</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Molecular Data Type</TAG>
        <VALUE>Whole Genome Sequencing</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Platform</TAG>
        <VALUE>Genome Analyzer IIx</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Vendor</TAG>
        <VALUE>Illumina</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>List</TAG>
        <VALUE/>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Molecular Data Type</TAG>
        <VALUE>Whole Genome Sequencing</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Platform</TAG>
        <VALUE>HiSeq 2000</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Vendor</TAG>
        <VALUE>Illumina</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>List</TAG>
        <VALUE/>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Primary Phenotype</TAG>
        <VALUE>Liver cancer</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Disease Type</TAG>
        <VALUE>Neoplasms</VALUE>
      </STUDY_ATTRIBUTE>
    </STUDY_ATTRIBUTES>
  </STUDY>
  <STUDY alias="JSUB000198_Study_0001" center_name="Individual" accession="JGAS000131">
    <IDENTIFIERS>
      <SECONDARY_ID>JGAS00000000131</SECONDARY_ID>
    </IDENTIFIERS>
    <DESCRIPTOR>
      <STUDY_TITLE>Chromatin remodeler CHD7 regulates the stem cell identity of human neural progenitors</STUDY_TITLE>
      <STUDY_TYPES>
        <STUDY_TYPE existing_study_type="Other" new_study_type="ChIP Sequencing"/>
      </STUDY_TYPES>
      <STUDY_ABSTRACT>Multiple congenital disorders often present complex phenotypes, but how the mutation of individual genetic factors can lead to multiple defects remains poorly understood. In the present study, we used human neuroepithelial (NE) cells and CHARGE patient-derived cells as an in vitro model system to identify the function of chromodomain helicase DNA-binding 7 (CHD7) in NE?neural crest bifurcation, thus revealing an etiological link between the central nervous system (CNS) and craniofacial anomalies observed in CHARGE syndrome. We found that CHD7 is required for epigenetic activation of superenhancers and CNS-specific enhancers, which support the maintenance of the NE and CNS lineage identities. Furthermore, we found that BRN2 and SOX21 are downstream effectors of CHD7, which shapes cellular identities by enhancing a CNS-specific cellular program and indirectly repressing non- CNS-specific cellular programs. Based on our results, CHD7, through its interactions with superenhancer elements, acts as a regulatory hub in the orchestration of the spatiotemporal dynamics of transcription factors to regulate NE and CNS lineage identities.</STUDY_ABSTRACT>
    </DESCRIPTOR>
    <PUBLICATIONS>
      <PUBLICATION id="29440260" status="published">
        <DB_TYPE>PUBMED</DB_TYPE>
      </PUBLICATION>
    </PUBLICATIONS>
    <STUDY_ATTRIBUTES>
      <STUDY_ATTRIBUTE>
        <TAG>NBDC Number</TAG>
        <VALUE>hum0129</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Registration date</TAG>
        <VALUE>2018-03-30</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Submitting organization</TAG>
        <VALUE>Department of Physiology, Keio University Schools of Medicine</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Principal Investigator</TAG>
        <VALUE>Hideyuki Okano</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Molecular Data Type</TAG>
        <VALUE>ChIP Sequencing</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Platform</TAG>
        <VALUE>HiSeq 2500</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Vendor</TAG>
        <VALUE>Illumina</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>List</TAG>
        <VALUE/>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Primary Phenotype</TAG>
        <VALUE>CHARGE syndrome</VALUE>
      </STUDY_ATTRIBUTE>
    </STUDY_ATTRIBUTES>
  </STUDY>
  <STUDY alias="JSUB000199_Study_0001" center_name="Individual" accession="JGAS000150">
    <IDENTIFIERS>
      <SECONDARY_ID>JGAS00000000150</SECONDARY_ID>
    </IDENTIFIERS>
    <DESCRIPTOR>
      <STUDY_TITLE>Genetic and transcriptional landscape of plasma cells in POEMS syndrome</STUDY_TITLE>
      <STUDY_TYPES>
        <STUDY_TYPE existing_study_type="Transcriptome Sequencing"/>
        <STUDY_TYPE existing_study_type="Exome Sequencing"/>
        <STUDY_TYPE existing_study_type="Other" new_study_type="Targeted-seq"/>
      </STUDY_TYPES>
      <STUDY_ABSTRACT>POEMS syndrome is a rare paraneoplastic disease, associated with monoclonal plasma cells whose pathogenic importance remains unclear. We performed comprehensive genetic analyses of plasma cells in 20 patients with POEMS syndrome. Whole exome sequencing and targeted sequencing identified 7 recurrently mutated genes: KLHL6, LTB, EHD1, EML4, HEPHL1, HIPK1, and PCDH10. None of the driver gene mutations frequently found in multiple myeloma (MM) such as NRAS, KRAS, BRAF, and TP53 was detected. Copy number analysis showed chromosomal abnormalities shared with monoclonal gammopathy of undetermined significance (MGUS). RNA sequencing revealed a transcription profile specific to POEMS syndrome, especially in terms of tumorigenesis. Unexpectedly, disease-specific VEGFA expression was not increased in POEMS syndrome. Our study illustrates that the genetic and transcriptional profiles of plasma cells in POEMS syndrome are distinct from MM and MGUS, indicating its unique pathogenesis.</STUDY_ABSTRACT>
    </DESCRIPTOR>
    <GRANTS>
      <GRANT grant_id="26461397">
        <TITLE>Genetic and transcriptional landscape of plasma cells in POEMS syndrome</TITLE>
        <AGENCY abbr="">the Japan Society for the Promotion of Science KAKENHI</AGENCY>
      </GRANT>
      <GRANT grant_id="15">
        <TITLE>Clonal immunoglobulin lamda light-chain gene rearrangements detected by NGS in POEMS syndrome</TITLE>
        <AGENCY abbr="">the Japan Society for the Promotion of Science KAKENHI</AGENCY>
      </GRANT>
    </GRANTS>
    <PUBLICATIONS>
      <PUBLICATION id="30635632" status="published">
        <DB_TYPE>PUBMED</DB_TYPE>
      </PUBLICATION>
    </PUBLICATIONS>
    <STUDY_ATTRIBUTES>
      <STUDY_ATTRIBUTE>
        <TAG>NBDC Number</TAG>
        <VALUE>hum0130</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Registration date</TAG>
        <VALUE>2018-08-29</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Submitting organization</TAG>
        <VALUE>Department of Hematology, Chiba University Hospital, Chiba, Japan</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Principal Investigator</TAG>
        <VALUE>Emiko Sakaida</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Molecular Data Type</TAG>
        <VALUE>Transcriptome Sequencing</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Platform</TAG>
        <VALUE>Illumina HiSeq 1500</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Vendor</TAG>
        <VALUE>Illumina</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>List</TAG>
        <VALUE/>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Molecular Data Type</TAG>
        <VALUE>Exome Sequencing</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Platform</TAG>
        <VALUE>Illumina HiSeq 2500</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Vendor</TAG>
        <VALUE>Illumina</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>List</TAG>
        <VALUE/>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Molecular Data Type</TAG>
        <VALUE>Targeted-seq</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Platform</TAG>
        <VALUE>MiSeq</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Vendor</TAG>
        <VALUE>Illumina</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>List</TAG>
        <VALUE/>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Primary Phenotype</TAG>
        <VALUE>Abnormality of blood and blood-forming tissues</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Phenotype</TAG>
        <VALUE>Hematological neoplasm</VALUE>
      </STUDY_ATTRIBUTE>
    </STUDY_ATTRIBUTES>
  </STUDY>
  <STUDY alias="JSUB000201_Study_0001" center_name="Individual" accession="JGAS000218">
    <IDENTIFIERS>
      <SECONDARY_ID>JGAS00000000218</SECONDARY_ID>
    </IDENTIFIERS>
    <DESCRIPTOR>
      <STUDY_TITLE>Expression profiling of Gorlin iPSCs in the osteoblast induction culture </STUDY_TITLE>
      <STUDY_TYPES>
        <STUDY_TYPE existing_study_type="Case-Control"/>
        <STUDY_TYPE existing_study_type="Transcriptome Sequencing"/>
      </STUDY_TYPES>
      <STUDY_ABSTRACT>In this study, we utilized human induced pluripotent stem cell (iPSC)-based models of the two diseases, named Gorlin syndrome and McCune Albright synfrome, to understand the roles of Hh signaling in osteogenesis, especially in mineralization. To examine which signaling pathways and genetic networks were affected by Gorlin syndrome-associated PTCH1 mutation in human osteoblastogenesis, we performed RNA sequencing (RNA-seq) analysis in the osteoblast induction culture of WT and Gorlin iPSCs. </STUDY_ABSTRACT>
    </DESCRIPTOR>
    <GRANTS>
      <GRANT grant_id="16K20427">
        <TITLE>Elucidation of the pathological mechanism of Gorlin syndrome using disease-specific iPS cells</TITLE>
        <AGENCY abbr="jsps">Japan society for the promotion of science</AGENCY>
      </GRANT>
      <GRANT grant_id="16K20428">
        <TITLE>Elucidation of the pathological mechanism of Gorlin syndrome using disease-specific iPS cells</TITLE>
        <AGENCY abbr="jsps">Tokyo Dental College Research Branding Project</AGENCY>
      </GRANT>
      <GRANT grant_id="0">
        <TITLE/>
        <AGENCY>Tokyo Dental College Research Branding Project</AGENCY>
      </GRANT>
    </GRANTS>
    <PUBLICATIONS>
      <PUBLICATION id="28915250" status="published">
        <DB_TYPE>PUBMED</DB_TYPE>
      </PUBLICATION>
    </PUBLICATIONS>
    <STUDY_ATTRIBUTES>
      <STUDY_ATTRIBUTE>
        <TAG>NBDC Number</TAG>
        <VALUE>hum0107</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Registration date</TAG>
        <VALUE>2020-02-10</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Submitting organization</TAG>
        <VALUE>Tokyo Dental College</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Principal Investigator</TAG>
        <VALUE>Toshifumi Azuma</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Molecular Data Type</TAG>
        <VALUE>RNA seq</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Platform</TAG>
        <VALUE>HiSeq2500</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Vendor</TAG>
        <VALUE>Illumina</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>List</TAG>
        <VALUE/>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Primary Phenotype</TAG>
        <VALUE>Basal Cell Nevus Syndrome OMIM:109400</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Phenotype</TAG>
        <VALUE>Gorlin Syndrome ORPHA:377</VALUE>
      </STUDY_ATTRIBUTE>
    </STUDY_ATTRIBUTES>
  </STUDY>
  <STUDY alias="JSUB000202_Study_0001" center_name="Individual" accession="JGAS000132">
    <IDENTIFIERS>
      <SECONDARY_ID>JGAS00000000132</SECONDARY_ID>
    </IDENTIFIERS>
    <DESCRIPTOR>
      <STUDY_TITLE>Transcriptome analysis of Williams syndrome</STUDY_TITLE>
      <STUDY_TYPES>
        <STUDY_TYPE existing_study_type="Case-Control"/>
      </STUDY_TYPES>
      <STUDY_ABSTRACT>Williams syndrome (WS) is a neurodevelopmental disorder caused by microdeletion on chromosome 7q11.23, and has attracted much attention for its distinctive features, such as hypersociability. However, it remains unclear which genes are involved in the complex phenotypes of their condition. Here, we performed transcriptome analysis of peripheral blood to identify genes associated with WS.</STUDY_ABSTRACT>
    </DESCRIPTOR>
    <GRANTS>
      <GRANT grant_id="0">
        <TITLE>AMED-CREST</TITLE>
        <AGENCY abbr="AMED">Japan Agency for Medical Research and Development</AGENCY>
      </GRANT>
      <GRANT grant_id="16">
        <TITLE>KAKENHI</TITLE>
        <AGENCY abbr="JSPS">Japan Society for the Promotion of Science</AGENCY>
      </GRANT>
    </GRANTS>
    <PUBLICATIONS>
      <PUBLICATION id="30362171" status="published">
        <DB_TYPE>PUBMED</DB_TYPE>
      </PUBLICATION>
    </PUBLICATIONS>
    <STUDY_LINKS>
      <STUDY_LINK>
        <URL_LINK>
          <LABEL>http://www.anat1dadb.med.kyoto-u.ac.jp/</LABEL>
          <URL>http://www.anat1dadb.med.kyoto-u.ac.jp/</URL>
        </URL_LINK>
      </STUDY_LINK>
    </STUDY_LINKS>
    <STUDY_ATTRIBUTES>
      <STUDY_ATTRIBUTE>
        <TAG>NBDC Number</TAG>
        <VALUE>hum0131</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Registration date</TAG>
        <VALUE>2018-03-30</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Submitting organization</TAG>
        <VALUE>Kyoto University</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Principal Investigator</TAG>
        <VALUE>Masatoshi Hagiwara</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Molecular Data Type</TAG>
        <VALUE>Whole Transcriptome Sequeicing</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Platform</TAG>
        <VALUE>Ion Proton</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Vendor</TAG>
        <VALUE>Thermo Fisher Scientific</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>List</TAG>
        <VALUE/>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Primary Phenotype</TAG>
        <VALUE>Williams syndrome</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Study Inclusion/Exclusion Criteria</TAG>
        <VALUE>We profiled the transcriptomes from 6 WS patients and 8 controls from peripheral blood.</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Disease Type</TAG>
        <VALUE>Congenital, Hereditary, and Neonatal Diseases and Abnormalities</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>disease</TAG>
        <VALUE>Williams syndrome</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>data type</TAG>
        <VALUE>Transcriptome</VALUE>
      </STUDY_ATTRIBUTE>
    </STUDY_ATTRIBUTES>
  </STUDY>
  <STUDY alias="JSUB000203_Study_0001" center_name="Individual" accession="JGAS000137">
    <IDENTIFIERS>
      <SECONDARY_ID>JGAS00000000137</SECONDARY_ID>
    </IDENTIFIERS>
    <DESCRIPTOR>
      <STUDY_TITLE>Whole genome sequencing and mutation rate analysis of Vietnamese trios with paternal dioxin exposure</STUDY_TITLE>
      <STUDY_TYPES>
        <STUDY_TYPE existing_study_type="Whole Genome Sequencing"/>
        <STUDY_TYPE existing_study_type="Parent-Offspring Trios"/>
      </STUDY_TYPES>
      <STUDY_ABSTRACT>2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) or dioxin, is commonly considered the most toxic man-made substance, and from 1962 to 1971, more than 19 million gallons of Agent Orange (AO) and other toxic chemicals contaminated with dioxin were sprayed in South of Vietnam. Dioxin exposure impacts human health and diseases, and birth defects and teratogenesis were frequently observed in children of persons who have been exposed to dioxin in Vietnam. However, the impact of dioxin on human mutation rate has not yet been analyzed. To identify and characterize the genetic alterations in the individuals exposed to dioxin, we perfomed whole genome sequencing of nine Vietnamese trios whose fathers were exposed to dioxin. </STUDY_ABSTRACT>
    </DESCRIPTOR>
    <PUBLICATIONS>
      <PUBLICATION id="29969170" status="published">
        <DB_TYPE>PUBMED</DB_TYPE>
      </PUBLICATION>
    </PUBLICATIONS>
    <STUDY_ATTRIBUTES>
      <STUDY_ATTRIBUTE>
        <TAG>NBDC Number</TAG>
        <VALUE>hum0132</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Registration date</TAG>
        <VALUE>2018-05-07</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Submitting organization</TAG>
        <VALUE>RIKEN Center for Integrative Medical Sciences</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Principal Investigator</TAG>
        <VALUE>Hidewaki Nakagawa</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Molecular Data Type</TAG>
        <VALUE>Whole Genome Sequencing</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Platform</TAG>
        <VALUE>HiSeq 2000</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Vendor</TAG>
        <VALUE>Illumina</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>List</TAG>
        <VALUE/>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Molecular Data Type</TAG>
        <VALUE>Whole Genome Sequencing</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Platform</TAG>
        <VALUE>HiSeq 2500</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Vendor</TAG>
        <VALUE>Illumina</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>List</TAG>
        <VALUE/>
      </STUDY_ATTRIBUTE>
    </STUDY_ATTRIBUTES>
  </STUDY>
  <STUDY alias="JSUB000208_Study_0001" center_name="Individual" accession="JGAS000144">
    <IDENTIFIERS>
      <SECONDARY_ID>JGAS00000000144</SECONDARY_ID>
    </IDENTIFIERS>
    <DESCRIPTOR>
      <STUDY_TITLE>A multicenter study of susceptibility genes to type 1 diabetes</STUDY_TITLE>
      <STUDY_TYPES>
        <STUDY_TYPE existing_study_type="Case-Control"/>
      </STUDY_TYPES>
      <STUDY_ABSTRACT>The first genome-wide association study of fulminant type 1 diabetes mellitus was performed in Japanese individuals. As previously reported using a candidate gene approach, a strong association was observed with multiple SNPs in the HLA region, and the strongest association was seen for rs9268853 in the class II DR region (P=1.56 x 10-23, odds ratio [OR] 3.18). In addition, rs11170445 in CSAD/lnc-ITGB7-1 on chromosome 12q13.13 showed an association at a genome-wide significance level (P=7.58 x 10-9, OR 1.96). Fine mapping of the region revealed that rs3782151 in CSAD/lnc-ITGB7-1 showed the lowest P value (P=4.60 x 10-9, OR 1.97 [95% CI 1.57-2.48]). The risk allele of rs3782151 is a cis-expression quantitative trait locus (eQTL) for ITGB7 that significantly increases the expression of this gene. CSAD/lnc-ITGB7-1 was strongly associated with the susceptibility to fulminant, but not classical autoimmune, type 1 diabetes, implicating this locus in the distinct phenotype of fulminant type 1 diabetes.</STUDY_ABSTRACT>
    </DESCRIPTOR>
    <PUBLICATIONS>
      <PUBLICATION id="30552108" status="published">
        <DB_TYPE>PUBMED</DB_TYPE>
      </PUBLICATION>
    </PUBLICATIONS>
    <STUDY_ATTRIBUTES>
      <STUDY_ATTRIBUTE>
        <TAG>NBDC Number</TAG>
        <VALUE>hum0137</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Registration date</TAG>
        <VALUE>2018-07-17</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Submitting organization</TAG>
        <VALUE>Department of Endocrinology, Metabolism and Diabetes
  Kinkdai University Faculty of Medicine</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Principal Investigator</TAG>
        <VALUE>Hiroshi Ikegami</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Molecular Data Type</TAG>
        <VALUE>Amplicon Sequencing</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Platform</TAG>
        <VALUE>Ion Proton</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Vendor</TAG>
        <VALUE>Thermo Fisher Scientific</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>List</TAG>
        <VALUE/>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Primary Phenotype</TAG>
        <VALUE>fulminant type 1 diabetes mellitus</VALUE>
      </STUDY_ATTRIBUTE>
    </STUDY_ATTRIBUTES>
  </STUDY>
  <STUDY alias="JSUB000210_Study_0001" center_name="Individual" accession="JGAS000146">
    <IDENTIFIERS>
      <SECONDARY_ID>JGAS00000000146</SECONDARY_ID>
    </IDENTIFIERS>
    <DESCRIPTOR>
      <STUDY_TITLE>DNA demethylation is associated with malignant progression of low-grade gliomas</STUDY_TITLE>
      <STUDY_TYPES>
        <STUDY_TYPE existing_study_type="Tumor vs. Matched-Normal"/>
        <STUDY_TYPE existing_study_type="Exome Sequencing"/>
        <STUDY_TYPE existing_study_type="Transcriptome Sequencing"/>
        <STUDY_TYPE existing_study_type="Other" new_study_type="DNA methylation array"/>
      </STUDY_TYPES>
      <STUDY_ABSTRACT>To elucidate the mechanisms of tumor progression is key to discovering strategies for treating patients with lower-grade glioma. Thus to characterize the changes in the molecular profile during malignant progression, we performed methylation array analysis (122 tumors), whole-exome sequencing (36 tumors and matched normal samples), and RNA sequencing (31 tumors). This cohort included 24 matched pairs of initial lower-grade gliomas and recurrent tumors, most of which showed malignant progression when they recurred. Nearly half of IDH-mutant glioblastomas that had progressed from lower-grade gliomas exhibited characteristic partial DNA demethylation in previously methylated genomic regions of their corresponding initial tumors, which had the glioma CpG island methylator phenotype (G-CIMP). In these glioblastomas, cell cycle-related genes were upregulated, RB and PI3K-AKT pathway genes were frequently altered. Notably, bioinformatics analysis revealed that late-replicating domain was significantly enriched in the demethylated regions that were mostly located in non-regulatory regions, suggesting that the loss of DNA methylation during malignant transformation may involve mainly passive demethylation due to a delay in maintenance of methylation during accelerated cell division. Nonetheless, a limited number of genes including IGF2BP3, which potentially drives cell proliferation, were presumed to be upregulated due to demethylation of their promoter. Thus, cell proliferation was further promoted by passive demethylation in the promoter region of these oncogenic genes. Our data indicated that demethylation of the G-CIMP profile found in a subset of recurrent gliomas reflects accelerated cell divisions accompanied by malignant transformation. Oncogenic genes activated by such epigenetic change represent potential therapeutic targets.</STUDY_ABSTRACT>
    </DESCRIPTOR>
    <GRANTS>
      <GRANT grant_id="">
        <TITLE>Identification of new molecular targets with profiling of malignant mesothelioma / Development of therapeutic modalities against intractable cancers via identification of new therapeutic targets with molecular profiling / P-DIRECT: Project for Development of Innovative Research on Cancer Therapeutics</TITLE>
        <AGENCY abbr="MEXT">Ministry of Education, Culture, Sports, Science and Technology</AGENCY>
      </GRANT>
      <GRANT grant_id="">
        <TITLE>Identification of new molecular targets with profiling of malignant mesothelioma / Development of therapeutic modalities against intractable cancers via identification of new therapeutic targets with molecular profiling / P-DIRECT: Project for Development of Innovative Research on Cancer Therapeutics</TITLE>
        <AGENCY abbr="AMED">Japan Agency for Medical Research and Development</AGENCY>
      </GRANT>
    </GRANTS>
    <STUDY_ATTRIBUTES>
      <STUDY_ATTRIBUTE>
        <TAG>NBDC Number</TAG>
        <VALUE>hum0006</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Registration date</TAG>
        <VALUE>2018-07-25</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Submitting organization</TAG>
        <VALUE>Department of Neurosurgery, The University of Tokyo</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Principal Investigator</TAG>
        <VALUE>Nobuhito Saito</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Molecular Data Type</TAG>
        <VALUE>Exome sequencing</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Platform</TAG>
        <VALUE>HiSeq 2000</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Vendor</TAG>
        <VALUE>Illumina</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>List</TAG>
        <VALUE/>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Molecular Data Type</TAG>
        <VALUE>Transcriptome profiling by high-throughput sequencing</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Platform</TAG>
        <VALUE>HiSeq 2000</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Vendor</TAG>
        <VALUE>Illumina</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>List</TAG>
        <VALUE/>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Molecular Data Type</TAG>
        <VALUE>Methylation profiling by array</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Platform</TAG>
        <VALUE>Infinium HumanMethylation450 BeadChip</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Vendor</TAG>
        <VALUE>Illumina</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>List</TAG>
        <VALUE/>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Primary Phenotype</TAG>
        <VALUE>Glioma</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Cancer Type</TAG>
        <VALUE>Glioma</VALUE>
      </STUDY_ATTRIBUTE>
    </STUDY_ATTRIBUTES>
  </STUDY>
  <STUDY alias="JSUB000211_Study_0001" center_name="Individual" accession="JGAS000136">
    <IDENTIFIERS>
      <SECONDARY_ID>JGAS00000000136</SECONDARY_ID>
    </IDENTIFIERS>
    <DESCRIPTOR>
      <STUDY_TITLE>Research for drug discovery and elucidation of pathophysiology using disease-specific iPS cells</STUDY_TITLE>
      <STUDY_TYPES>
        <STUDY_TYPE existing_study_type="Exome Sequencing"/>
      </STUDY_TYPES>
      <STUDY_ABSTRACT>We investigated roles of KRAS on stemness maintenance and differentiation propensity in the context of induced pluripotent stem cells (iPSCs) using isogenic KRAS mutant (G13C/WT) and wild-type (WT/WT) iPSCs from the same RAS-associated autoimmune lymphoproliferative syndrome-like disease (RALD) patients. Exome-seq analysis was conducted to compare gene profiles of WT/WT and G13C/WT iPS cells. We have not found any differences of gene mutation in the two genotypes.   </STUDY_ABSTRACT>
    </DESCRIPTOR>
    <STUDY_ATTRIBUTES>
      <STUDY_ATTRIBUTE>
        <TAG>NBDC Number</TAG>
        <VALUE>hum0139</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Registration date</TAG>
        <VALUE>2018-05-29</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Submitting organization</TAG>
        <VALUE>The University of Tokyo</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Principal Investigator</TAG>
        <VALUE>Makoto Otsu</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Molecular Data Type</TAG>
        <VALUE>Exome Sequencing</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Platform</TAG>
        <VALUE>HiSeq 1500</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Vendor</TAG>
        <VALUE>Illumina</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>List</TAG>
        <VALUE/>
      </STUDY_ATTRIBUTE>
    </STUDY_ATTRIBUTES>
  </STUDY>
  <STUDY alias="JSUB000212_Study_0001" center_name="Individual" accession="JGAS000138">
    <IDENTIFIERS>
      <SECONDARY_ID>JGAS00000000138</SECONDARY_ID>
    </IDENTIFIERS>
    <DESCRIPTOR>
      <STUDY_TITLE>DNA methylation array analysis of pediatric T-cell acute lymphoblastic leukemia</STUDY_TITLE>
      <STUDY_TYPES>
        <STUDY_TYPE existing_study_type="Other" new_study_type="DNA methylation array"/>
      </STUDY_TYPES>
      <STUDY_ABSTRACT>Pediatric T-cell acute lymphoblastic leukemia (T-ALL) is rare and its pathogenesis is poorly understood. To investigate epigenetic profiles of pediatric T-ALL, we performed DNA methylation array analysis in 79 cases of pediatric T-ALL.</STUDY_ABSTRACT>
    </DESCRIPTOR>
    <STUDY_ATTRIBUTES>
      <STUDY_ATTRIBUTE>
        <TAG>NBDC Number</TAG>
        <VALUE>hum0096</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Registration date</TAG>
        <VALUE>2018-06-01</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Submitting organization</TAG>
        <VALUE>Department of Pediatrics, The University of Tokyo</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Principal Investigator</TAG>
        <VALUE>Junko Takita</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Molecular Data Type</TAG>
        <VALUE>DNA methylation array</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Platform</TAG>
        <VALUE>HumanMethylationEPIC</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Vendor</TAG>
        <VALUE>Illumina</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>List</TAG>
        <VALUE>EPICb1, EPICb4</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Primary Phenotype</TAG>
        <VALUE>T-ALL</VALUE>
      </STUDY_ATTRIBUTE>
    </STUDY_ATTRIBUTES>
  </STUDY>
  <STUDY alias="JSUB000213_Study_0001" center_name="Individual" accession="JGAS000135">
    <IDENTIFIERS>
      <SECONDARY_ID>JGAS00000000135</SECONDARY_ID>
    </IDENTIFIERS>
    <DESCRIPTOR>
      <STUDY_TITLE>Treg cell subset-specific gene expression patterns in human head and neck cancer</STUDY_TITLE>
      <STUDY_TYPES>
        <STUDY_TYPE existing_study_type="Transcriptome Sequencing"/>
      </STUDY_TYPES>
      <STUDY_ABSTRACT>Backgrand: The occurrence of head and neck cancer has been increased all over the world. Although the prognosis has been improved by using several treatment modalities including immunotherapy, it is still unsatisfying. It is still unclear why the immunotherapy is effective only for partial amount of patients. To resolve this problem and to make a new treatment strategy based on human immune system, further investigation of antitumor immunity is required. Regulatory T (Treg) cells play critical roles in human immune responses including antitumor immunity. Therefore, the research to elucidate Treg function is strongly urged to clarify the mechanisms of antitumor immunity.
  Methods: We performed RNA-seuencing analysis of regulatory T cells infiltrating head and neck cancer. We devided into four populations, DP, CD25+, CTLA4+, DN and analyzed gene expressions.
  Results: The gene expression patterns of Treg-related genes were different between CD25+ cells and CD25- cells. Furthermore, DP cells had unique gene expression pattern compared to other populations.
  Conclusions: We found Treg cells infiltrating head and neck cancer had high expression levels of Treg-related genes and DP cells had unique gene expression pattern that may become a target of new treatment strategy.
  Regulatory T (Treg) cells play critical roles in human immune responses including antitumor immunity. Therefore, the research to elucidate Treg function is strongly urged to clarify the mechanisms of antitumor immunity.</STUDY_ABSTRACT>
    </DESCRIPTOR>
    <PUBLICATIONS>
      <PUBLICATION id="30485427" status="published">
        <DB_TYPE>PUBMED</DB_TYPE>
      </PUBLICATION>
    </PUBLICATIONS>
    <STUDY_ATTRIBUTES>
      <STUDY_ATTRIBUTE>
        <TAG>NBDC Number</TAG>
        <VALUE>hum0141</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Registration date</TAG>
        <VALUE>2018-05-16</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Submitting organization</TAG>
        <VALUE>Department of Immunology, Nagoya City University Graduate School of Medical Sciences</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Principal Investigator</TAG>
        <VALUE>Sayuri Yamazaki</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Molecular Data Type</TAG>
        <VALUE>Transcriptome Sequencing</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Platform</TAG>
        <VALUE>Ion S5</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Vendor</TAG>
        <VALUE>Thermo Fisher Scientific</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>List</TAG>
        <VALUE/>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Primary Phenotype</TAG>
        <VALUE>Neoplasm of head and neck</VALUE>
      </STUDY_ATTRIBUTE>
    </STUDY_ATTRIBUTES>
  </STUDY>
  <STUDY alias="JSUB000214_Study_0001" center_name="Individual" accession="JGAS000158">
    <IDENTIFIERS>
      <SECONDARY_ID>JGAS00000000158</SECONDARY_ID>
    </IDENTIFIERS>
    <DESCRIPTOR>
      <STUDY_TITLE>Prediction of response to preoperative chemoradiotherapy in rectal cancer based on whole-exome sequencing and transcriptomic analysis</STUDY_TITLE>
      <STUDY_TYPES>
        <STUDY_TYPE existing_study_type="Tumor vs. Matched-Normal"/>
        <STUDY_TYPE existing_study_type="Exome Sequencing"/>
      </STUDY_TYPES>
      <STUDY_ABSTRACT>Accumulating evidence suggests that radiotherapeutic success has an immune-associated component.  We aimed to investigate the immunogenomic profiles associated with response to preoperative chemoradiotherapy (CRT) in patients with locally advanced rectal cancer.</STUDY_ABSTRACT>
    </DESCRIPTOR>
    <STUDY_ATTRIBUTES>
      <STUDY_ATTRIBUTE>
        <TAG>NBDC Number</TAG>
        <VALUE>hum0140</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Registration date</TAG>
        <VALUE>2018-10-19</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Submitting organization</TAG>
        <VALUE>The Cancer Institute Hospital of JFCR</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Principal Investigator</TAG>
        <VALUE>takashi akiyoshi</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Molecular Data Type</TAG>
        <VALUE>Exome Sequencing</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Platform</TAG>
        <VALUE>Hiseq 2000</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Vendor</TAG>
        <VALUE>Illumina</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>List</TAG>
        <VALUE/>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Primary Phenotype</TAG>
        <VALUE>Colorectal Cancer</VALUE>
      </STUDY_ATTRIBUTE>
    </STUDY_ATTRIBUTES>
  </STUDY>
  <STUDY alias="JSUB000215_Study_0001" center_name="Individual" accession="JGAS000141">
    <IDENTIFIERS>
      <SECONDARY_ID>JGAS00000000141</SECONDARY_ID>
    </IDENTIFIERS>
    <DESCRIPTOR>
      <STUDY_TITLE>Global Architecture of anti-Tumor B-Cell Immunity against Gastric Cancer</STUDY_TITLE>
      <STUDY_TYPES>
        <STUDY_TYPE existing_study_type="Other" new_study_type="Transcriptome sequencing (Tumor only)"/>
        <STUDY_TYPE existing_study_type="Other" new_study_type="Repertoire sequencing (Tumor vs. Matched-Normal)"/>
      </STUDY_TYPES>
      <STUDY_ABSTRACT>Recent successes in tumor immunotherapies have warranted the importance of tumor immunity. Compared to the T-cell immunity, B-cell immune system in cancer is largely elusive. Here we immunogenetically profiled tumor-infiltrating B-cell and T-cell repertoires for exome- characterized diffuse-type gastric carcinoma (DGC), which is remarkable for its B-cell infiltrations, unraveling previously un-defined architectures of B-cell immunity and its interplays with T-cell immunity in cancer. We also performed transcriptome analysis to enumerate the proportions of tumor-infiltrating immune cells in the gastric cancer environment .</STUDY_ABSTRACT>
    </DESCRIPTOR>
    <GRANTS>
      <GRANT grant_id="26710009">
        <TITLE>KAKENHI Grant-in-Aid for Young Scientists (A)</TITLE>
        <AGENCY abbr="JSPS">Japan Society for the Promotion of Science</AGENCY>
      </GRANT>
      <GRANT grant_id="15655817">
        <TITLE>Practical Research for Innovative Cancer Control</TITLE>
        <AGENCY abbr="AMED">Japan Agency for Medical Research and Development</AGENCY>
      </GRANT>
      <GRANT grant_id="14014019">
        <TITLE>Basic Science and Platform Technology Program for Innovative Biological Medicine</TITLE>
        <AGENCY abbr="AMED">Japan Agency for Medical Research and Development</AGENCY>
      </GRANT>
    </GRANTS>
    <STUDY_ATTRIBUTES>
      <STUDY_ATTRIBUTE>
        <TAG>NBDC Number</TAG>
        <VALUE>hum0111</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Registration date</TAG>
        <VALUE>2018-06-15</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Submitting organization</TAG>
        <VALUE>Department of Genomic Pathology, Medical Research Institute, Tokyo Medical and Dental University</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Principal Investigator</TAG>
        <VALUE>Shumpei Ishikawa</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Molecular Data Type</TAG>
        <VALUE>Amplicon Sequencing of T/B cell antigen receptors</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Platform</TAG>
        <VALUE>MiSeq</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Vendor</TAG>
        <VALUE>Illumina</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>List</TAG>
        <VALUE/>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Primary Phenotype</TAG>
        <VALUE>Stomach cancer</VALUE>
      </STUDY_ATTRIBUTE>
    </STUDY_ATTRIBUTES>
  </STUDY>
  <STUDY alias="JSUB000218_Study_0001" center_name="Individual" accession="JGAS000147">
    <IDENTIFIERS>
      <SECONDARY_ID>JGAS00000000147</SECONDARY_ID>
    </IDENTIFIERS>
    <DESCRIPTOR>
      <STUDY_TITLE>Transcriptome sequencing, DNA methylation analysis, and SNP array analysis of acute lymphoblastic leukemia in Down syndrome</STUDY_TITLE>
      <STUDY_TYPES>
        <STUDY_TYPE existing_study_type="Transcriptome Sequencing"/>
        <STUDY_TYPE existing_study_type="Other" new_study_type="DNA metylation analysis"/>
        <STUDY_TYPE existing_study_type="Other" new_study_type="SNP array analysis"/>
      </STUDY_TYPES>
      <STUDY_ABSTRACT>Pathogenesis of acute lymphoblastic leukemia in Down syndrome (DS-ALL) is poorly understood. To investigate molecular basis of DS-ALL, we performed whole transcriptome sequencing, DNA methylation array, and SNP array analysis in 43 cases of DS-ALL.</STUDY_ABSTRACT>
    </DESCRIPTOR>
    <PUBLICATIONS>
      <PUBLICATION id="31385395" status="published">
        <DB_TYPE>PUBMED</DB_TYPE>
      </PUBLICATION>
    </PUBLICATIONS>
    <STUDY_ATTRIBUTES>
      <STUDY_ATTRIBUTE>
        <TAG>NBDC Number</TAG>
        <VALUE>hum0144</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Registration date</TAG>
        <VALUE>2018-07-20</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Submitting organization</TAG>
        <VALUE>Department of Pediatrics, The University of Tokyo</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Principal Investigator</TAG>
        <VALUE>Junko Takita</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Molecular Data Type</TAG>
        <VALUE>Transcriptome Sequencing</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Platform</TAG>
        <VALUE>Hiseq 2500</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Vendor</TAG>
        <VALUE>Illumina</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>List</TAG>
        <VALUE/>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Molecular Data Type</TAG>
        <VALUE>DNA metylation analysis</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Platform</TAG>
        <VALUE>Methylation450K BeadChip</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Vendor</TAG>
        <VALUE>Illumina</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>List</TAG>
        <VALUE/>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Molecular Data Type</TAG>
        <VALUE>DNA metylation analysis</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Platform</TAG>
        <VALUE>MethylationEPIC BeadChip</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Vendor</TAG>
        <VALUE>Illumina</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>List</TAG>
        <VALUE/>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Molecular Data Type</TAG>
        <VALUE>SNP array analysis</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Platform</TAG>
        <VALUE>Affymetrix Genome-Wide Human SNP Nsp/Sty 6.0</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Vendor</TAG>
        <VALUE>Affymetrix</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>List</TAG>
        <VALUE/>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Molecular Data Type</TAG>
        <VALUE>SNP array analysis</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Platform</TAG>
        <VALUE>Affymetrix CytoScan HD Array</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Vendor</TAG>
        <VALUE>Affymetrix</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>List</TAG>
        <VALUE/>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Primary Phenotype</TAG>
        <VALUE>B-cell precursor acute lymphoblastic leukemia</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Phenotype</TAG>
        <VALUE>Down syndrome</VALUE>
      </STUDY_ATTRIBUTE>
    </STUDY_ATTRIBUTES>
  </STUDY>
  <STUDY alias="JSUB000219_Study_0001" center_name="Individual" accession="JGAS000222">
    <IDENTIFIERS>
      <SECONDARY_ID>JGAS00000000222</SECONDARY_ID>
    </IDENTIFIERS>
    <DESCRIPTOR>
      <STUDY_TITLE>Ten colorectal cancer patients with locally advanced primary tumors who underwent primary tumor resection following neoadjuvant chemotherapy (NAC).</STUDY_TITLE>
      <STUDY_TYPES>
        <STUDY_TYPE existing_study_type="Tumor vs. Matched-Normal"/>
      </STUDY_TYPES>
      <STUDY_ABSTRACT>Background
  We aim to investigate the utility of serial gene mutation tracking for locally advanced CRC in those who underwent curative resection following neoadjuvant chemotherapy.
  Methods
  We prospectively collected 10 locally advanced CRC cases for which curative resection was performed following preoperative neoadjuvant chemotherapy. Tissues from the primary tumour, distant metastatic tumours, and blood plasma were obtained during serial treatment. Comprehensive mutation analysis of 47 cancer-associated genes was performed using a pre-designed gene panel and next-generation sequencing.
  Results
  All cases showed a partial response to neoadjuvant chemotherapy, and pathological R0 resection was accomplished. In primary tumours, non-synonymous mutations were detected at between 1 and 14 sites before chemotherapy and at between 1 and 2 sites after. Founder mutations were precisely detected in blood plasma and metastatic tumours during longitudinal treatment.
  Conclusions
  Serial mutational analysis indicated that subclonal selection occurs during chemotherapy and that plasma can substitute for tumourous tissue in mutational analysis for drug selection and treatment decisions.</STUDY_ABSTRACT>
    </DESCRIPTOR>
    <PUBLICATIONS>
      <PUBLICATION id="30072744" status="published">
        <DB_TYPE>PUBMED</DB_TYPE>
      </PUBLICATION>
    </PUBLICATIONS>
    <STUDY_ATTRIBUTES>
      <STUDY_ATTRIBUTE>
        <TAG>NBDC Number</TAG>
        <VALUE>hum0145</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Registration date</TAG>
        <VALUE>2020-03-13</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Submitting organization</TAG>
        <VALUE>Department of Surgery, Kyushu University Beppu Hospital</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Principal Investigator</TAG>
        <VALUE>Shotaro Sakimura</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Molecular Data Type</TAG>
        <VALUE>Target Sequencing</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Platform</TAG>
        <VALUE>HiSeq 2500</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Vendor</TAG>
        <VALUE>Illumina</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>List</TAG>
        <VALUE/>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Primary Phenotype</TAG>
        <VALUE>Colon cancer</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>ICD-10 Disease Classification</TAG>
        <VALUE>Colon, unspecified  (C18.9)</VALUE>
      </STUDY_ATTRIBUTE>
    </STUDY_ATTRIBUTES>
  </STUDY>
  <STUDY alias="JSUB000221_Study_0001" center_name="Individual" accession="JGAS000145">
    <IDENTIFIERS>
      <SECONDARY_ID>JGAS00000000145</SECONDARY_ID>
    </IDENTIFIERS>
    <DESCRIPTOR>
      <STUDY_TITLE>Na?ve Treg-specific genomic DNA hypomethylation for autoimmune disease susceptibility</STUDY_TITLE>
      <STUDY_TYPES>
        <STUDY_TYPE existing_study_type="Whole Genome Sequencing"/>
      </STUDY_TYPES>
      <STUDY_ABSTRACT>Naturally occurring regulatory T (Treg) cells, which are specifically expressing the transcription factor FOXP3, CD25 and CTLA-4, are indispensable for the maintenance of immunological self-tolerance and homeostasis. Mutations of the FOXP3, CD25 and CTLA4 genes compromise the function of natural FOXP3+CD25+CD4+ Treg cells and cause severe autoimmune diseases showing Mendelian inheritance. Also, altered Treg-specific epigenetic changes, such as DNA hypomethylation and enhancer activation, impair the expression of these molecules in developing Treg cells, causing autoimmune diseases. It is obscure, however, whether Treg cells significantly contribute to the development of polygenic common autoimmune diseases (such as type 1 diabetes and rheumatoid arthritis), which afflict ~10% of the population. Recent genome-wide association study (GWAS) of common autoimmune diseases has revealed many autoimmune disease-associated single nucleotide polymorphisms (SNPs) in enhancer regions of immune cells, for example, in non-coding regions of T cell activation-associated genes such as CD25 and CTLA4. These findings, especially the involvement of common T-cell genes in the functions of both Treg cells and effector T cells, prompt one to ask whether autoimmune disease-associated causative SNPs impact on the functions of either disease-causing effector T cells or disease-suppressing Treg cells. Here, we have explored epigenetic profiles of human Treg and conventional T (Tconv) cells in na?ve or activated states, and found that autoimmune disease-associated SNPs are predominantly enriched in Treg-specific CpG demethylated regions (Treg-DRs), which were mostly included in Treg-specific super-enhancers. Treg-DRs are developmentally established in na?ve Treg cells before antigenic stimulation, distinct from activation-induced CpG hypomethylation in Treg or Tconv cells, and highly associated with Treg cell-specific transcriptional and epigenetic changes. Taken together, genetic variants affecting endogenous development of natural Treg cells and their Treg-intrinsic functions are causative of common autoimmune diseases, indicating natural Treg cells as a key target for their treatment and prevention. </STUDY_ABSTRACT>
    </DESCRIPTOR>
    <GRANTS>
      <GRANT grant_id="17gm0410016h0006">
        <TITLE>Devising novel methods to control chronic inflammation via regulatory T cells</TITLE>
        <AGENCY abbr="AMED">Japan Agency for MedicalResearch and Development</AGENCY>
      </GRANT>
      <GRANT grant_id="18gm0010005h0001">
        <TITLE>Study of Immunoregulatory technology targeting regulatory T cells</TITLE>
        <AGENCY abbr="AMED">Japan Agency for MedicalResearch and Development</AGENCY>
      </GRANT>
      <GRANT grant_id="15H04744">
        <TITLE>Clarification of regulatory T cell-specific epigenome</TITLE>
        <AGENCY abbr="JSPS">Japan Society for the Promotion of Science</AGENCY>
      </GRANT>
      <GRANT grant_id="16H06295">
        <TITLE>Study of the function and development of regulatory T cells</TITLE>
        <AGENCY abbr="JSPS">Japan Society for the Promotion of Science</AGENCY>
      </GRANT>
    </GRANTS>
    <PUBLICATIONS>
      <PUBLICATION id="32362325" status="published">
        <DB_TYPE>PUBMED</DB_TYPE>
      </PUBLICATION>
    </PUBLICATIONS>
    <STUDY_ATTRIBUTES>
      <STUDY_ATTRIBUTE>
        <TAG>NBDC Number</TAG>
        <VALUE>hum0147</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Registration date</TAG>
        <VALUE>2018-08-01</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Submitting organization</TAG>
        <VALUE>IFReC, Osaka University</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Principal Investigator</TAG>
        <VALUE>Shimon Sakaguchi</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Molecular Data Type</TAG>
        <VALUE>Whole genome bisulfite sequencing</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Platform</TAG>
        <VALUE>HiSeq 2500, NovaSeq 6000</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Vendor</TAG>
        <VALUE>Illumina</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>List</TAG>
        <VALUE/>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Molecular Data Type</TAG>
        <VALUE>Whole genome sequencing</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Platform</TAG>
        <VALUE>Ion S5</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Vendor</TAG>
        <VALUE>Thermo Fisher Scientific</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>List</TAG>
        <VALUE/>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Primary Phenotype</TAG>
        <VALUE>Healthy donors</VALUE>
      </STUDY_ATTRIBUTE>
    </STUDY_ATTRIBUTES>
  </STUDY>
  <STUDY alias="JSUB000222_Study_0001" center_name="Individual" accession="JGAS000149">
    <IDENTIFIERS>
      <SECONDARY_ID>JGAS00000000149</SECONDARY_ID>
    </IDENTIFIERS>
    <DESCRIPTOR>
      <STUDY_TITLE>The exploratory research of diagnositic biomarker and therapeutic targets of renal cell carcinoma.</STUDY_TITLE>
      <STUDY_TYPES>
        <STUDY_TYPE existing_study_type="Transcriptome Sequencing"/>
      </STUDY_TYPES>
      <STUDY_ABSTRACT>We search more effective markers, which predict worse prognosis in patients with RCC and become targets for therapy of RCC, using tissues of patients with RCC by global transcriptional analysis.</STUDY_ABSTRACT>
    </DESCRIPTOR>
    <PUBLICATIONS>
      <PUBLICATION id="30906638" status="published">
        <DB_TYPE>PUBMED</DB_TYPE>
      </PUBLICATION>
    </PUBLICATIONS>
    <STUDY_ATTRIBUTES>
      <STUDY_ATTRIBUTE>
        <TAG>NBDC Number</TAG>
        <VALUE>hum0148</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Registration date</TAG>
        <VALUE>2018-09-03</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Submitting organization</TAG>
        <VALUE>The Cancer Institute Hospital Of JFCR</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Principal Investigator</TAG>
        <VALUE>Takeshi Yuasa</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Molecular Data Type</TAG>
        <VALUE>RNA-seq</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Platform</TAG>
        <VALUE>Genome Analyzer IIx</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Vendor</TAG>
        <VALUE>Illumina</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>List</TAG>
        <VALUE/>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Primary Phenotype</TAG>
        <VALUE>Renal cell carcinoma</VALUE>
      </STUDY_ATTRIBUTE>
    </STUDY_ATTRIBUTES>
  </STUDY>
  <STUDY alias="JSUB000228_Study_0001" center_name="Individual" accession="JGAS000182">
    <IDENTIFIERS>
      <SECONDARY_ID>JGAS00000000182</SECONDARY_ID>
    </IDENTIFIERS>
    <DESCRIPTOR>
      <STUDY_TITLE>Analysis of genomic alterations in dedifferentiated liposarcoma</STUDY_TITLE>
      <STUDY_TYPES>
        <STUDY_TYPE existing_study_type="Tumor vs. Matched-Normal"/>
        <STUDY_TYPE existing_study_type="Exome Sequencing"/>
        <STUDY_TYPE existing_study_type="Transcriptome Sequencing"/>
      </STUDY_TYPES>
      <STUDY_ABSTRACT>Multiomics analysis of rare cancers to identify genetic alterations related with pathogenesis and prognosis. To identification of genetics alterations of Dedifferentiated liposarcoma, DNAs and RNAs were extracted from  dedifferentiated liposarcoma and paired non-cancer (normal) tissues. NGS libaraies were prepared by using Agilent SureSelect XT Human All Exon V5 + IncRNA kit for whole exome sequencing (WES) and TruSeq Stranded mRNA Prep kit or TruSeq RNA Access Library Prep kit (RNA seq). Sequencing was perfomred by Illumina HiSeq 2500.</STUDY_ABSTRACT>
    </DESCRIPTOR>
    <PUBLICATIONS>
      <PUBLICATION id="28099935" status="published">
        <DB_TYPE>PUBMED</DB_TYPE>
      </PUBLICATION>
    </PUBLICATIONS>
    <STUDY_ATTRIBUTES>
      <STUDY_ATTRIBUTE>
        <TAG>NBDC Number</TAG>
        <VALUE>hum0152</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Registration date</TAG>
        <VALUE>2019-05-14</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Submitting organization</TAG>
        <VALUE>Department of Clinical Genomics, National Cancer Center Research Institute</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Principal Investigator</TAG>
        <VALUE>Hitoshi Ichikawa</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Molecular Data Type</TAG>
        <VALUE>Whole Exome Sequencing</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Platform</TAG>
        <VALUE>HiSeq 2500</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Vendor</TAG>
        <VALUE>Illumina</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>List</TAG>
        <VALUE/>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Molecular Data Type</TAG>
        <VALUE>RNA Sequencing</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Platform</TAG>
        <VALUE>HiSeq 2500</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Vendor</TAG>
        <VALUE>Illumina</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>List</TAG>
        <VALUE/>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Primary Phenotype</TAG>
        <VALUE>Cancer</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Phenotype</TAG>
        <VALUE>Liposarcoma</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Phenotype</TAG>
        <VALUE>Sarcoma</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>IDC-10 Disease Classification</TAG>
        <VALUE>Malignant neoplasm of other connective and soft tissue (C49)</VALUE>
      </STUDY_ATTRIBUTE>
    </STUDY_ATTRIBUTES>
  </STUDY>
  <STUDY alias="JSUB000231_Study_0001" center_name="Individual" accession="JGAS000177">
    <IDENTIFIERS>
      <SECONDARY_ID>JGAS00000000177</SECONDARY_ID>
    </IDENTIFIERS>
    <DESCRIPTOR>
      <STUDY_TITLE>Integrated Exome and RNA Sequencing of Dedifferentiated Liposarcoma</STUDY_TITLE>
      <STUDY_TYPES>
        <STUDY_TYPE existing_study_type="Tumor vs. Matched-Normal"/>
        <STUDY_TYPE existing_study_type="Exome Sequencing"/>
        <STUDY_TYPE existing_study_type="Transcriptome Sequencing"/>
      </STUDY_TYPES>
      <STUDY_ABSTRACT>Multiomics analysis of rare cancers to identify genetic alterations related with pathogenesis and prognosis. To identification of genetics alterations of Dedifferentiated liposarcoma, DNAs and RNAs were extracted from  dedifferentiated liposarcoma and paired non-cancer (normal) tissues. NGS libaraies were prepared by using Agilent SureSelect XT Human All Exon V5 + IncRNA kit for whole exome sequencing (WES) and TruSeq Stranded mRNA Prep kit or TruSeq RNA Access Library Prep kit (RNA seq). Sequencing was perfomred by Illumina HiSeq 2500.</STUDY_ABSTRACT>
    </DESCRIPTOR>
    <PUBLICATIONS>
      <PUBLICATION id="31107544" status="published">
        <DB_TYPE>PUBMED</DB_TYPE>
      </PUBLICATION>
    </PUBLICATIONS>
    <STUDY_ATTRIBUTES>
      <STUDY_ATTRIBUTE>
        <TAG>NBDC Number</TAG>
        <VALUE>hum0153</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Registration date</TAG>
        <VALUE>2019-03-26</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Submitting organization</TAG>
        <VALUE>Graduate School of Frontier Sciences, The University of Tokyo</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Principal Investigator</TAG>
        <VALUE>Koichi Matsuda</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Molecular Data Type</TAG>
        <VALUE>Whole Exome Sequencing</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Platform</TAG>
        <VALUE>HiSeq 2500</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Vendor</TAG>
        <VALUE>Illumina</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>List</TAG>
        <VALUE/>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Molecular Data Type</TAG>
        <VALUE>RNA Sequencing</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Platform</TAG>
        <VALUE>HiSeq 2500</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Vendor</TAG>
        <VALUE>Illumina</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>List</TAG>
        <VALUE/>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Primary Phenotype</TAG>
        <VALUE>Cancer</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Phenotype</TAG>
        <VALUE>Liposarcoma</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Phenotype</TAG>
        <VALUE>Sarcoma</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>IDC-10 Disease Classification</TAG>
        <VALUE>Malignant neoplasm of other connective and soft tissue (C49)</VALUE>
      </STUDY_ATTRIBUTE>
    </STUDY_ATTRIBUTES>
  </STUDY>
  <STUDY alias="JSUB000232_Study_0001" center_name="Individual" accession="JGAS000155">
    <IDENTIFIERS>
      <SECONDARY_ID>JGAS00000000155</SECONDARY_ID>
    </IDENTIFIERS>
    <DESCRIPTOR>
      <STUDY_TITLE>Whole genome sequencing analysis of esophageal squamous cell carcinoma</STUDY_TITLE>
      <STUDY_TYPES>
        <STUDY_TYPE existing_study_type="Tumor vs. Matched-Normal"/>
      </STUDY_TYPES>
      <STUDY_ABSTRACT>Whole genome sequencing analysis of esophageal squamous cell carcinoma and the association of their genomic features with the response of neo-aduvant chemotherapy</STUDY_ABSTRACT>
    </DESCRIPTOR>
    <STUDY_ATTRIBUTES>
      <STUDY_ATTRIBUTE>
        <TAG>NBDC Number</TAG>
        <VALUE>hum0160</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Registration date</TAG>
        <VALUE>2018-10-16</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Submitting organization</TAG>
        <VALUE>RIKEN Center for Integrative Medical Sciences</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Principal Investigator</TAG>
        <VALUE>Hidewaki Nakagawa</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Molecular Data Type</TAG>
        <VALUE>Whole Genome Sequencing</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Platform</TAG>
        <VALUE>HiSeq 2000</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Vendor</TAG>
        <VALUE>Illumina</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>List</TAG>
        <VALUE/>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Molecular Data Type</TAG>
        <VALUE>Whole Genome Sequencing</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Platform</TAG>
        <VALUE>HiSeq 2500</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Vendor</TAG>
        <VALUE>Illumina</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>List</TAG>
        <VALUE/>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Molecular Data Type</TAG>
        <VALUE>Whole Genome Sequencing</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Platform</TAG>
        <VALUE>HiSeq X Five</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Vendor</TAG>
        <VALUE>Illumina</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>List</TAG>
        <VALUE/>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Primary Phenotype</TAG>
        <VALUE>Cancer</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>IDC-10 Disease Classification</TAG>
        <VALUE>Malignant neoplasm of oesophagus (C15)</VALUE>
      </STUDY_ATTRIBUTE>
    </STUDY_ATTRIBUTES>
  </STUDY>
  <STUDY alias="JSUB000238_Study_0001" center_name="Individual" accession="JGAS000164">
    <IDENTIFIERS>
      <SECONDARY_ID>JGAS00000000164</SECONDARY_ID>
    </IDENTIFIERS>
    <DESCRIPTOR>
      <STUDY_TITLE>Comprehensive assay for the molecular profiling of cancer by target enrichment from formalin-fixed paraffin-embedded specimens</STUDY_TITLE>
      <STUDY_TYPES>
        <STUDY_TYPE existing_study_type="Other" new_study_type="Target sequencing"/>
      </STUDY_TYPES>
      <STUDY_ABSTRACT>Tumor molecular profiling is becoming a standard of care for patients with cancer, but the optimal platform for cancer sequencing remains undetermined. We established a comprehensive assay, the Todai OncoPanel (TOP), which consists of DNA and RNA hybridization capture-based next-generation sequencing panels. A novel method for target enrichment, named the junction capture method, was developed for the RNA panel to accurately and cost-effectively detect 365 fusion genes as well as aberrantly spliced transcripts. The TOP RNA panel can also measure the expression profiles of an additional 109 genes. The TOP DNA panel was developed to detect single nucleotide variants and insertions/deletions for 464 genes, to calculate tumor mutation burden and microsatellite instability status, and to infer chromosomal copy number. Clinically relevant somatic mutations were identified in 32.2% (59/183) of patients by prospective TOP testing, signifying the clinical utility of TOP for providing personalized medicine to cancer patients.</STUDY_ABSTRACT>
    </DESCRIPTOR>
    <PUBLICATIONS>
      <PUBLICATION id="30737998" status="published">
        <DB_TYPE>PUBMED</DB_TYPE>
      </PUBLICATION>
    </PUBLICATIONS>
    <STUDY_ATTRIBUTES>
      <STUDY_ATTRIBUTE>
        <TAG>NBDC Number</TAG>
        <VALUE>hum0157</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Registration date</TAG>
        <VALUE>2019-01-28</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Submitting organization</TAG>
        <VALUE>The University of Tokyo</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Principal Investigator</TAG>
        <VALUE>Kohei Miyazono</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Molecular Data Type</TAG>
        <VALUE>Target Sequencing</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Platform</TAG>
        <VALUE>NextSeq 500</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Vendor</TAG>
        <VALUE>Illumina</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>List</TAG>
        <VALUE/>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Primary Phenotype</TAG>
        <VALUE>Cancer</VALUE>
      </STUDY_ATTRIBUTE>
    </STUDY_ATTRIBUTES>
  </STUDY>
  <STUDY alias="JSUB000239_Study_0001" center_name="Individual" accession="JGAS000159">
    <IDENTIFIERS>
      <SECONDARY_ID>JGAS00000000159</SECONDARY_ID>
    </IDENTIFIERS>
    <DESCRIPTOR>
      <STUDY_TITLE>3.5KJPNv2, an allele frequency panel of 3,552 Japanese individuals</STUDY_TITLE>
      <STUDY_TYPES>
        <STUDY_TYPE existing_study_type="Cohort"/>
        <STUDY_TYPE existing_study_type="Population"/>
      </STUDY_TYPES>
      <STUDY_ABSTRACT>In the Tohoku Medical Megabank Project, we have conducted whole-genome sequencing of nearly 4,000 individuals from a Japanese population, and constructed an allele frequency panel of 3,552 individuals (3.5KJPNv2) after removing genetically related individuals. The 3.5KJPNv2 was constructed by using a standard pipeline including the 1KGP and gnomAD algorithms to reduce technical biases and to allow comparisons to other populations. The 3.5KJPNv2 includes variants in chromosome X and mitochondrial genome as well as autosome.
      The submitter has changed the access level of this study from controlled-access [Type I] to un-restricted access since 11th, January, 2019. The un-restricted access data ?hum0015.v3.3.5kjpnv2.v1? are available at  the NBDC site: https://humandbs.biosciencedbc.jp/en/hum0015-v3. This study does not contain any controlled-access dataset.</STUDY_ABSTRACT>
    </DESCRIPTOR>
    <GRANTS>
      <GRANT grant_id="0">
        <TITLE>Tohoku Medical Megabank Project (Tohoku University) Special Account of the Great East Japan Earthquake Disaster Recovery</TITLE>
        <AGENCY abbr="AMED">the Japan Agency for Medical Research and Development</AGENCY>
      </GRANT>
      <GRANT grant_id="0">
        <TITLE>Tohoku Medical Megabank Project (Tohoku University) General Accounting</TITLE>
        <AGENCY abbr="AMED">the Japan Agency for Medical Research and Development</AGENCY>
      </GRANT>
      <GRANT grant_id="0">
        <TITLE>Tohoku Medical Megabank Project (Iwate Medical University) Special Account of the Great East Japan Earthquake Disaster Recovery</TITLE>
        <AGENCY abbr="AMED">the Japan Agency for Medical Research and Development</AGENCY>
      </GRANT>
      <GRANT grant_id="0">
        <TITLE>Tohoku Medical Megabank Project (Iwate Medical University) General Accounting</TITLE>
        <AGENCY abbr="AMED">the Japan Agency for Medical Research and Development</AGENCY>
      </GRANT>
    </GRANTS>
    <STUDY_LINKS>
      <STUDY_LINK>
        <URL_LINK>
          <LABEL>https://www.amed.go.jp/program/list/04/01/001.html</LABEL>
          <URL>https://www.amed.go.jp/program/list/04/01/001.html</URL>
        </URL_LINK>
      </STUDY_LINK>
      <STUDY_LINK>
        <URL_LINK>
          <LABEL>http://iwate-megabank.org/</LABEL>
          <URL>http://iwate-megabank.org/</URL>
        </URL_LINK>
      </STUDY_LINK>
      <STUDY_LINK>
        <URL_LINK>
          <LABEL>https://www.megabank.tohoku.ac.jp/tommo</LABEL>
          <URL>https://www.megabank.tohoku.ac.jp/tommo</URL>
        </URL_LINK>
      </STUDY_LINK>
      <STUDY_LINK>
        <URL_LINK>
          <LABEL>The un-restricted access data of this study ?hum0015.v3.3.5kjpnv2.v1? are available at the NBDC site</LABEL>
          <URL>https://humandbs.biosciencedbc.jp/en/hum0015-v3</URL>
        </URL_LINK>
      </STUDY_LINK>
    </STUDY_LINKS>
    <STUDY_ATTRIBUTES>
      <STUDY_ATTRIBUTE>
        <TAG>NBDC Number</TAG>
        <VALUE>hum0015</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Registration date</TAG>
        <VALUE>2018-11-29</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Submitting organization</TAG>
        <VALUE>Tohoku Medical Megabank Organization, Tohoku University</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Principal Investigator</TAG>
        <VALUE>Masayuki Yamamoto</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Molecular Data Type</TAG>
        <VALUE>Whole Genome Sequencing</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Platform</TAG>
        <VALUE>HiSeq 2500</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Vendor</TAG>
        <VALUE>Illumina</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>List</TAG>
        <VALUE/>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Primary Phenotype</TAG>
        <VALUE>General individuals</VALUE>
      </STUDY_ATTRIBUTE>
    </STUDY_ATTRIBUTES>
  </STUDY>
  <STUDY alias="JSUB000240_Study_0001" center_name="Individual" accession="JGAS000160">
    <IDENTIFIERS>
      <SECONDARY_ID>JGAS00000000160</SECONDARY_ID>
    </IDENTIFIERS>
    <DESCRIPTOR>
      <STUDY_TITLE>Susceptibility loci for tanning ability in Japanese population identified by genome-wide association study</STUDY_TITLE>
      <STUDY_TYPES>
        <STUDY_TYPE existing_study_type="GWAS"/>
        <STUDY_TYPE existing_study_type="Cohort"/>
      </STUDY_TYPES>
      <STUDY_ABSTRACT>We performed genome-wide association studies of Japanese Skin Type for
  Japanese individuals from a cohort study by the Tohoku Medical
  Megabank Project in order to identify variants related to tanning
  ability and skin pigmentation. We used imputed genotype data of 9,187
  Japanese individuals, of which 4,475 individuals are from Miyagi
  prefecture and 4,712 individuals are from Iwate prefecture. Skin Type
  information was obtained from the questionnaire for cohort
  participants.</STUDY_ABSTRACT>
    </DESCRIPTOR>
    <STUDY_ATTRIBUTES>
      <STUDY_ATTRIBUTE>
        <TAG>NBDC Number</TAG>
        <VALUE>hum0164</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Registration date</TAG>
        <VALUE>2018-12-03</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Submitting organization</TAG>
        <VALUE>Tohoku University Graduate School of Medicine, Dermatology</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Principal Investigator</TAG>
        <VALUE>Setsuya Aiba</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Molecular Data Type</TAG>
        <VALUE>Whole Genome Genotyping</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Platform</TAG>
        <VALUE>Infinium OmniExpressExome-8 Kit</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Vendor</TAG>
        <VALUE>Illumina</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>List</TAG>
        <VALUE/>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Primary Phenotype</TAG>
        <VALUE>Japanese Skin Type</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Phenotype</TAG>
        <VALUE>Melanoma</VALUE>
      </STUDY_ATTRIBUTE>
    </STUDY_ATTRIBUTES>
  </STUDY>
  <STUDY alias="JSUB000241_Study_0001" center_name="Individual" accession="JGAS000162">
    <IDENTIFIERS>
      <SECONDARY_ID>JGAS00000000162</SECONDARY_ID>
    </IDENTIFIERS>
    <DESCRIPTOR>
      <STUDY_TITLE>Whole exome sequencing of familial MDS, Two patients</STUDY_TITLE>
      <STUDY_TYPES>
        <STUDY_TYPE existing_study_type="Exome Sequencing"/>
      </STUDY_TYPES>
      <STUDY_ABSTRACT>Although several causal genes of familial myelodysplastic syndromes (MDS) have been identified, the genetic landscape and the molecular pathogenesis are not totally understood. To explore novel driver genes and their pathogenetic significance, we performed whole exome sequence analysis of two individuals from a familial MDS pedigree and several candidate single-nucleotide variants were identified. Knockdown screening revealed that downregulation of a candidate gene enhanced colony forming capacity of primary murine bone marrow (BM) stem/progenitor cells. Our results indicate that a familial MDS-associated germline mutation in the candidate gene induces accumulation of DNA double-strand breaks, possibly through impaired PCNA polyubiquitination.</STUDY_ABSTRACT>
    </DESCRIPTOR>
    <PUBLICATIONS>
      <PUBLICATION id="30696947" status="published">
        <DB_TYPE>PUBMED</DB_TYPE>
      </PUBLICATION>
    </PUBLICATIONS>
    <STUDY_ATTRIBUTES>
      <STUDY_ATTRIBUTE>
        <TAG>NBDC Number</TAG>
        <VALUE>hum0165</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Registration date</TAG>
        <VALUE>2018-12-13</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Submitting organization</TAG>
        <VALUE>The University of Tokyo</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Principal Investigator</TAG>
        <VALUE>Mineo Kurokawa</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Molecular Data Type</TAG>
        <VALUE>Whole exome sequencing</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Platform</TAG>
        <VALUE>HiSeq 2500</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Vendor</TAG>
        <VALUE>Illumina</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>List</TAG>
        <VALUE/>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Primary Phenotype</TAG>
        <VALUE>Myelodysplasia (HP:0002863)</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>IDC-10 Disease Classification</TAG>
        <VALUE>Meylodysplastic syndrome (D46)</VALUE>
      </STUDY_ATTRIBUTE>
    </STUDY_ATTRIBUTES>
  </STUDY>
  <STUDY alias="JSUB000245_Study_0001" center_name="Individual" accession="JGAS000169">
    <IDENTIFIERS>
      <SECONDARY_ID>JGAS00000000169</SECONDARY_ID>
    </IDENTIFIERS>
    <DESCRIPTOR>
      <STUDY_TITLE>Whole exome sequencing of uterine adenomyosis</STUDY_TITLE>
      <STUDY_TYPES>
        <STUDY_TYPE existing_study_type="Exome Sequencing"/>
      </STUDY_TYPES>
      <STUDY_ABSTRACT>Uterine adenomyosis, defined by proliferation of the ectopic endometrial glands in myometrium, is a common benign uterine disorder that significantly impairs the quality of life of the women it affects. Adenomyosis lesions have chronic inflammatory reactions as well as cancer-like features such as invasive capacity into the normal myometrium. In contrast to endometriosis and leiomyoma, the genomic characterization of adenomyosis has yet to be reported. We conducted high-coverage whole exome sequencing analyses of freshly frozen adenomyosis samples, as well as co-occurring leiomyoma. Our WES analyses showed that adenomyosis is a clonal disorder with somatic mutations.</STUDY_ABSTRACT>
    </DESCRIPTOR>
    <STUDY_ATTRIBUTES>
      <STUDY_ATTRIBUTE>
        <TAG>NBDC Number</TAG>
        <VALUE>hum0168</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Registration date</TAG>
        <VALUE>2019-03-11</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Submitting organization</TAG>
        <VALUE>National Cancer Center Research Institute</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Principal Investigator</TAG>
        <VALUE>Hiroyuki Mano</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Molecular Data Type</TAG>
        <VALUE>Whole Exome Sequencing</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Platform</TAG>
        <VALUE>HiSeq 2500</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Vendor</TAG>
        <VALUE>Illumina</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>List</TAG>
        <VALUE/>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Primary Phenotype</TAG>
        <VALUE>a common benign uterine disorder</VALUE>
      </STUDY_ATTRIBUTE>
    </STUDY_ATTRIBUTES>
  </STUDY>
  <STUDY alias="JSUB000247_Study_0001" center_name="Individual" accession="JGAS000178">
    <IDENTIFIERS>
      <SECONDARY_ID>JGAS00000000178</SECONDARY_ID>
    </IDENTIFIERS>
    <DESCRIPTOR>
      <STUDY_TITLE>Comprehensive genomic analysis of patient derived orthotopic xenograft model in primary central nervous system lymphoma</STUDY_TITLE>
      <STUDY_TYPES>
        <STUDY_TYPE existing_study_type="Exome Sequencing"/>
      </STUDY_TYPES>
      <STUDY_ABSTRACT>The purpose of this study is to investigate genetic background of orthotopic xenograft cells and aseess consistency with parent tumor cells. For exome sequencing, we used two distinct PCNSL cells (YML9 and YML11). We also performed RNA sequencing for 7 PCNSL patient tumor cells to compare NF-kB pathway activation. </STUDY_ABSTRACT>
    </DESCRIPTOR>
    <STUDY_ATTRIBUTES>
      <STUDY_ATTRIBUTE>
        <TAG>NBDC Number</TAG>
        <VALUE>hum0169</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Registration date</TAG>
        <VALUE>2019-04-25</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Submitting organization</TAG>
        <VALUE>Department of Neurosurgery, Yokohama City Uiversity</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Principal Investigator</TAG>
        <VALUE>Tetsuya Yamamoto</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Molecular Data Type</TAG>
        <VALUE>Whole Exome Sequencing</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Platform</TAG>
        <VALUE>HiSeq 2500</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Vendor</TAG>
        <VALUE>Illumina</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>List</TAG>
        <VALUE/>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Primary Phenotype</TAG>
        <VALUE>Primary Central Nervous System Lymphoma</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Phenotype</TAG>
        <VALUE>Neoplasm of the brain</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>IDC-10 Disease Classification</TAG>
        <VALUE>Primary Central Nervous System Lymphoma (C859)</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Disease</TAG>
        <VALUE>Primary Central Nervous System Lymphoma</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Study sample</TAG>
        <VALUE>Orthotopic xenograft model</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Library Strategy</TAG>
        <VALUE>Whole exome sequencing </VALUE>
      </STUDY_ATTRIBUTE>
    </STUDY_ATTRIBUTES>
  </STUDY>
  <STUDY alias="JSUB000250_Study_0001" center_name="Individual" accession="JGAS000171">
    <IDENTIFIERS>
      <SECONDARY_ID>JGAS00000000171</SECONDARY_ID>
    </IDENTIFIERS>
    <DESCRIPTOR>
      <STUDY_TITLE>C-MACH reduced-representation bisulfite sequencing (RRBS)</STUDY_TITLE>
      <STUDY_TYPES>
        <STUDY_TYPE existing_study_type="Other" new_study_type="RRBS"/>
      </STUDY_TYPES>
      <STUDY_ABSTRACT>Umbilical cord blood (CB) has been commonly used as an epigenetic surrogate of fetuses. Here, we propose umbilical cord tissue (UC) as an alternative surrogate for epigenetic studies on fetuses. To explore the feasibility to examine UC epigenome by deep sequencing, we determined CpG methylation profiles of human postnatal UC by reduced representation bisulfite sequencing. We compared DNA methylomes between UC and CB. To investigate the effect of folate during pregnancy on fetal DNA methylation, we compared fetal UC DNA methylation between low and high levels of maternal plasma folate. Our study suggests that UC is useful as an alternative surrogate for studying environmental effects on DNA methylation in human fetuses, compensating CB by providing additional information about epigenetic regulation of genes.</STUDY_ABSTRACT>
    </DESCRIPTOR>
    <STUDY_ATTRIBUTES>
      <STUDY_ATTRIBUTE>
        <TAG>NBDC Number</TAG>
        <VALUE>hum0173</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Registration date</TAG>
        <VALUE>2019-03-15</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Submitting organization</TAG>
        <VALUE>Chiba University</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Principal Investigator</TAG>
        <VALUE>Chisato Mori</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Molecular Data Type</TAG>
        <VALUE>Whole Genome (NGS)</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Platform</TAG>
        <VALUE>NextSeq</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Vendor</TAG>
        <VALUE>Illumina </VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>List</TAG>
        <VALUE/>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Primary Phenotype</TAG>
        <VALUE>healthy infant</VALUE>
      </STUDY_ATTRIBUTE>
    </STUDY_ATTRIBUTES>
  </STUDY>
  <STUDY alias="JSUB000252_Study_0001" center_name="Individual" accession="JGAS000174">
    <IDENTIFIERS>
      <SECONDARY_ID>JGAS00000000174</SECONDARY_ID>
    </IDENTIFIERS>
    <DESCRIPTOR>
      <STUDY_TITLE>Development of actionable molecular targets and/or biomarkers for prognostication and patient stratification in gynecological cancer based on whole-exome sequencing and epigenomic analysis</STUDY_TITLE>
      <STUDY_TYPES>
        <STUDY_TYPE existing_study_type="Tumor vs. Matched-Normal"/>
        <STUDY_TYPE existing_study_type="Exome Sequencing"/>
      </STUDY_TYPES>
      <STUDY_ABSTRACT>We collected 187 samples of normal and primary tumor tissues in 69 cases of endometrial carcinoma. The purpose of this study is to develop actionable molecular targets and/or biomarkers for prognostication and patient stratification.</STUDY_ABSTRACT>
    </DESCRIPTOR>
    <STUDY_ATTRIBUTES>
      <STUDY_ATTRIBUTE>
        <TAG>NBDC Number</TAG>
        <VALUE>hum0175</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Registration date</TAG>
        <VALUE>2019-04-08</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Submitting organization</TAG>
        <VALUE>Japanese Foundation for Cancer Research</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Principal Investigator</TAG>
        <VALUE>Nobuhiro Takeshima</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Molecular Data Type</TAG>
        <VALUE>Exome Sequencing</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Platform</TAG>
        <VALUE>Hiseq 2000</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Vendor</TAG>
        <VALUE>Illumina</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>List</TAG>
        <VALUE/>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Primary Phenotype</TAG>
        <VALUE>Endometrial Carcinoma</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>IDC-10 Disease Classification</TAG>
        <VALUE>Endometrium (C541)</VALUE>
      </STUDY_ATTRIBUTE>
    </STUDY_ATTRIBUTES>
  </STUDY>
  <STUDY alias="JSUB000253_Study_0001" center_name="Individual" accession="JGAS000172">
    <IDENTIFIERS>
      <SECONDARY_ID>JGAS00000000172</SECONDARY_ID>
    </IDENTIFIERS>
    <DESCRIPTOR>
      <STUDY_TITLE>Comprehensive sequencing analyses of uterine and ovarian carcinosarcoma</STUDY_TITLE>
      <STUDY_TYPES>
        <STUDY_TYPE existing_study_type="Tumor vs. Matched-Normal"/>
      </STUDY_TYPES>
      <STUDY_ABSTRACT>We collected 109 primary tumor and mached normal samples of uterine and ovarian carcinosarcoma. The purpose of this study is to find novel therapeutic options for carcinosarcoma as well as a clue to understand the molecular histogenic mechanism.</STUDY_ABSTRACT>
    </DESCRIPTOR>
    <STUDY_ATTRIBUTES>
      <STUDY_ATTRIBUTE>
        <TAG>NBDC Number</TAG>
        <VALUE>hum0176</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Registration date</TAG>
        <VALUE>2019-03-18</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Submitting organization</TAG>
        <VALUE>Japanese Foundation for Cancer Research</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Principal Investigator</TAG>
        <VALUE>Seiichi Mori</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Molecular Data Type</TAG>
        <VALUE>Exome Sequencing</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Platform</TAG>
        <VALUE>Hiseq 2000</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Vendor</TAG>
        <VALUE>Illumina</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>List</TAG>
        <VALUE/>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Molecular Data Type</TAG>
        <VALUE>Target Capture Sequencing</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Platform</TAG>
        <VALUE>Hiseq 2000</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Vendor</TAG>
        <VALUE>Illumina</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>List</TAG>
        <VALUE/>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Primary Phenotype</TAG>
        <VALUE>Uterine and Ovarian Carcinosarcoma</VALUE>
      </STUDY_ATTRIBUTE>
    </STUDY_ATTRIBUTES>
  </STUDY>
  <STUDY alias="JSUB000258_Study_0001" center_name="Individual" accession="JGAS000197">
    <IDENTIFIERS>
      <SECONDARY_ID>JGAS00000000197</SECONDARY_ID>
    </IDENTIFIERS>
    <DESCRIPTOR>
      <STUDY_TITLE>Whole-genome bisulfite sequencing for high-grade glioma</STUDY_TITLE>
      <STUDY_TYPES>
        <STUDY_TYPE existing_study_type="Other" new_study_type="Whole-genome bisulfite sequencing"/>
        <STUDY_TYPE existing_study_type="Transcriptome Sequencing"/>
        <STUDY_TYPE existing_study_type="Other" new_study_type="ChIP sequencing"/>
      </STUDY_TYPES>
      <STUDY_ABSTRACT>We conducted whole-genome bisulfite sequencing to delineate base-resolution methylomes of gliomas harboring G34R mutation as well as those harboring K27M and no mutations in H3F3A. Comparative analysis of these three glioma subgroups revealed that G34 subgroup exhibited lower global methylation levels, comparable CpG island (CGI) methylation levels, and compromised hypermethylation of telomere-proximal CGIs, compared to the other two subgroups. Genomic regions specifically hypermethylated in G34 subgroup were enriched for CGIs. CGIs with G34V-mutated histone H3.3 in the glioma cell line KNS-42 were hypermethylated compared to those without it, suggesting a correlation between G34-mutated histone H3.3 in CGI hypermethylation.</STUDY_ABSTRACT>
      <RELATED_STUDIES>
        <RELATED_STUDY>
          <RELATED_LINK>
            <DB>sra</DB>
            <ID>DRA010212</ID>
            <LABEL>DRA010212</LABEL>
          </RELATED_LINK>
          <IS_PRIMARY>false</IS_PRIMARY>
        </RELATED_STUDY>
      </RELATED_STUDIES>
    </DESCRIPTOR>
    <GRANTS>
      <GRANT grant_id="JP16am0101059">
        <TITLE>Improvements and Support in Methylome Analysis</TITLE>
        <AGENCY abbr="AMED">Japan Agency for MedicalResearch and Development</AGENCY>
      </GRANT>
      <GRANT grant_id="JP19am0101103">
        <TITLE>Support and Improvements in Advanced Methylomics</TITLE>
        <AGENCY abbr="AMED">Japan Agency for MedicalResearch and Development</AGENCY>
      </GRANT>
      <GRANT grant_id="17H06305">
        <TITLE>Development and Applications of Next-Generation Epigenome Analysis Techniques</TITLE>
        <AGENCY abbr="JSPS">Japan Society for the Promotion of Science</AGENCY>
      </GRANT>
    </GRANTS>
    <STUDY_ATTRIBUTES>
      <STUDY_ATTRIBUTE>
        <TAG>NBDC Number</TAG>
        <VALUE>hum0177</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Registration date</TAG>
        <VALUE>2019-06-13</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Submitting organization</TAG>
        <VALUE>Department of Medical Biochemistry, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Principal Investigator</TAG>
        <VALUE>Takashi Ito</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Molecular Data Type</TAG>
        <VALUE>Whole-genome bisulfite sequencing</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Platform</TAG>
        <VALUE>Hiseq X Ten</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Vendor</TAG>
        <VALUE>Illumina</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>List</TAG>
        <VALUE/>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Molecular Data Type</TAG>
        <VALUE>RNA sequencing</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Platform</TAG>
        <VALUE>NovaSeq 6000</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Vendor</TAG>
        <VALUE>Illumina</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>List</TAG>
        <VALUE/>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Molecular Data Type</TAG>
        <VALUE>ChIP sequencing</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Platform</TAG>
        <VALUE>NovaSeq 6000</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Vendor</TAG>
        <VALUE>Illumina</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>List</TAG>
        <VALUE/>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Primary Phenotype</TAG>
        <VALUE>Glioma (HP:0009733)</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>IDC-10 Disease Classification</TAG>
        <VALUE>Glioma (C71.9)</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>application</TAG>
        <VALUE>Whole-genome bisulfite sequencing</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>disease</TAG>
        <VALUE>glioma</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>gene</TAG>
        <VALUE>H3F3A</VALUE>
      </STUDY_ATTRIBUTE>
    </STUDY_ATTRIBUTES>
  </STUDY>
  <STUDY alias="JSUB000259_Study_0001" center_name="Individual" accession="JGAS000166">
    <IDENTIFIERS>
      <SECONDARY_ID>JGAS00000000166</SECONDARY_ID>
    </IDENTIFIERS>
    <DESCRIPTOR>
      <STUDY_TITLE>OTOF mutation analysis with massively parallel DNA sequencing in 2,265 Japanese sensorineural hearing loss patients.</STUDY_TITLE>
      <STUDY_TYPES>
        <STUDY_TYPE existing_study_type="Case Set"/>
      </STUDY_TYPES>
      <STUDY_ABSTRACT>The OTOF gene, encoding otoferlin, is reported to be one of the major causes of non-syndromic recessive sensorineural hearing loss, and is also reported to be the most common cause of non-syndromic recessive auditory neuropathy spectrum disorder (ANSD). In the present study, we performed OTOF mutation analysis using massively parallel DNA sequencing (MPS) to reveal the frequency and clinical characteristics of OTOF-related hearing loss in a large hearing loss population. </STUDY_ABSTRACT>
    </DESCRIPTOR>
    <GRANTS>
      <GRANT grant_id="16">
        <TITLE>Development of the unified data storage of clinical and genomic information for sensory disorders.</TITLE>
        <AGENCY abbr="AMED">Japan Agency for Medical Research and Development</AGENCY>
      </GRANT>
      <GRANT grant_id="19">
        <TITLE>Development of evidence based clinical management for hereditary hearing loss.</TITLE>
        <AGENCY abbr="AMED">Japan Agency for Medical Research and Development</AGENCY>
      </GRANT>
    </GRANTS>
    <STUDY_ATTRIBUTES>
      <STUDY_ATTRIBUTE>
        <TAG>NBDC Number</TAG>
        <VALUE>hum0005</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Registration date</TAG>
        <VALUE>2019-03-25</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Submitting organization</TAG>
        <VALUE>Shinshu University School of Medicine</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Principal Investigator</TAG>
        <VALUE>Shin-ichi Usami</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Molecular Data Type</TAG>
        <VALUE>Target resequencing</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Platform</TAG>
        <VALUE>Ion PGM, Ion Proton</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Vendor</TAG>
        <VALUE>Thermo Fisher Scientific</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>List</TAG>
        <VALUE/>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Molecular Data Type</TAG>
        <VALUE>Target resequencing</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Platform</TAG>
        <VALUE>HiSeq2000</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Vendor</TAG>
        <VALUE>Illumina</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>List</TAG>
        <VALUE/>
      </STUDY_ATTRIBUTE>
    </STUDY_ATTRIBUTES>
  </STUDY>
  <STUDY alias="JSUB000261_Study_0001" center_name="Individual" accession="JGAS000186">
    <IDENTIFIERS>
      <SECONDARY_ID>JGAS00000000186</SECONDARY_ID>
    </IDENTIFIERS>
    <DESCRIPTOR>
      <STUDY_TITLE>Shotgun metagenome sequencing of saliva samples using PromethION</STUDY_TITLE>
      <STUDY_TYPES>
        <STUDY_TYPE existing_study_type="Control Set"/>
      </STUDY_TYPES>
      <STUDY_ABSTRACT>Using PromethION, we conduct shotgun metagenome sequencing of human saliva, where both bacteria and bacteriophages are densely living, to study both microbiome and virome.  We aim to explore, for example, relative abundance of bacteira and bacteriophages, distribution of contig lengh. types of phages and prophages, frequency of novel phages revealed by the long-reads and their taxonomic classification, and characteristics of genes encoded by the phages.</STUDY_ABSTRACT>
    </DESCRIPTOR>
    <GRANTS>
      <GRANT grant_id="19H04846">
        <TITLE>JSPS KAKENHI</TITLE>
        <AGENCY abbr="jsps">Japan society for the promotion of science</AGENCY>
      </GRANT>
    </GRANTS>
    <STUDY_ATTRIBUTES>
      <STUDY_ATTRIBUTE>
        <TAG>NBDC Number</TAG>
        <VALUE>hum0179</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Registration date</TAG>
        <VALUE>2019-05-18</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Submitting organization</TAG>
        <VALUE>National Institute of Infectious Diseases, Antimicrobial Resistance Research Center</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Principal Investigator</TAG>
        <VALUE>Koji Yahara</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Molecular Data Type</TAG>
        <VALUE>Whole Genome Sequencing</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Platform</TAG>
        <VALUE>PromethION</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Vendor</TAG>
        <VALUE>Oxford Nanopore</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>List</TAG>
        <VALUE/>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Primary Phenotype</TAG>
        <VALUE>Healthy control</VALUE>
      </STUDY_ATTRIBUTE>
    </STUDY_ATTRIBUTES>
  </STUDY>
  <STUDY alias="JSUB000263_Study_0001" center_name="Individual" accession="JGAS000180">
    <IDENTIFIERS>
      <SECONDARY_ID>JGAS00000000180</SECONDARY_ID>
    </IDENTIFIERS>
    <DESCRIPTOR>
      <STUDY_TITLE>Nanopore whole-genome sequencing of sample RK067 and variant-call data (SNVs and intermediate-sized deletions) of 174 Japanese samples.</STUDY_TITLE>
      <STUDY_TYPES>
        <STUDY_TYPE existing_study_type="Whole Genome Sequencing"/>
      </STUDY_TYPES>
      <STUDY_ABSTRACT>We performed whole-genome sequencing of a human samples using Oxford Nanopore MinION sequencer, so as to be able to establish methods to detect and identify structural variations in Japanese individuals. Intermediate-sized deletions were identified from 174 Japanese samples? short-reads whole-genome sequencing data. Variant call information of these intermediate-sized deletions were joined with SNVs identified in a previous study (Fujimoto, A et al., Nat Genet, 2016) to create a reference panel for use in imputation.</STUDY_ABSTRACT>
      <RELATED_STUDIES>
        <RELATED_STUDY>
          <RELATED_LINK>
            <DB>sra</DB>
            <ID>DRA008482</ID>
            <LABEL>DRA008482</LABEL>
          </RELATED_LINK>
          <IS_PRIMARY>false</IS_PRIMARY>
        </RELATED_STUDY>
      </RELATED_STUDIES>
    </DESCRIPTOR>
    <GRANTS>
      <GRANT grant_id="18km0405207h0003">
        <TITLE>Development of advanced data analysis methods for genome sequencing</TITLE>
        <AGENCY abbr="AMED">Japan Agency for Medical Research and Development</AGENCY>
      </GRANT>
    </GRANTS>
    <PUBLICATIONS>
      <PUBLICATION id="31340865" status="published">
        <DB_TYPE>PUBMED</DB_TYPE>
      </PUBLICATION>
    </PUBLICATIONS>
    <STUDY_ATTRIBUTES>
      <STUDY_ATTRIBUTE>
        <TAG>NBDC Number</TAG>
        <VALUE>hum0182</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Registration date</TAG>
        <VALUE>2019-05-17</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Submitting organization</TAG>
        <VALUE>Kyoto University, Graduate School of Medicine</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Principal Investigator</TAG>
        <VALUE>Akihiro Fujimoto</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Molecular Data Type</TAG>
        <VALUE>Whole Genome Sequencing</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Platform</TAG>
        <VALUE>MinION</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Vendor</TAG>
        <VALUE>Oxford Nanopore</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>List</TAG>
        <VALUE/>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Primary Phenotype</TAG>
        <VALUE>Healthy control sample</VALUE>
      </STUDY_ATTRIBUTE>
    </STUDY_ATTRIBUTES>
  </STUDY>
  <STUDY alias="JSUB000267_Study_0001" center_name="Individual" accession="JGAS000176">
    <IDENTIFIERS>
      <SECONDARY_ID>JGAS00000000176</SECONDARY_ID>
    </IDENTIFIERS>
    <DESCRIPTOR>
      <STUDY_TITLE>Genomic Structural Variants in Japanese Malignant mesothelioma patients</STUDY_TITLE>
      <STUDY_TYPES>
        <STUDY_TYPE existing_study_type="Case Set"/>
      </STUDY_TYPES>
      <STUDY_ABSTRACT>We extracted genomic DNAs from established mesothelioma cell lines from Japanese malignant mesothelioma patients. We sequenced those genomic DNAs using 10X Genomics sequencing technologies, and analyzed genomic structural variations.</STUDY_ABSTRACT>
    </DESCRIPTOR>
    <GRANTS>
      <GRANT grant_id="">
        <TITLE>Identification of new molecular targets with profiling of malignant mesothelioma / Development of therapeutic modalities against intractable cancers via identification of new therapeutic targets with molecular profiling / P-DIRECT: Project for Development of Innovative Research on Cancer Therapeutics</TITLE>
        <AGENCY abbr="MEXT">Ministry of Education, Culture, Sports, Science and Technology</AGENCY>
      </GRANT>
      <GRANT grant_id="">
        <TITLE>Identification of new molecular targets with profiling of malignant mesothelioma / Development of therapeutic modalities against intractable cancers via identification of new therapeutic targets with molecular profiling / P-DIRECT: Project for Development of Innovative Research on Cancer Therapeutics</TITLE>
        <AGENCY abbr="AMED">Japan Agency for Medical Research and Development</AGENCY>
      </GRANT>
      <GRANT grant_id="GRIFIN">
        <TITLE>Informatics for analyzing de novo human genome assemblies</TITLE>
        <AGENCY abbr="AMED">Japan Agency for Medical Research and Development</AGENCY>
      </GRANT>
    </GRANTS>
    <STUDY_ATTRIBUTES>
      <STUDY_ATTRIBUTE>
        <TAG>NBDC Number</TAG>
        <VALUE>hum0053</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Registration date</TAG>
        <VALUE>2019-04-25</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Submitting organization</TAG>
        <VALUE>Aichi Cancer Center Research Institute, Division of Immunology</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Principal Investigator</TAG>
        <VALUE>Yoshitaka Sekido</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Molecular Data Type</TAG>
        <VALUE>Whole Genome Sequencing, Structural Variants</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Platform</TAG>
        <VALUE>Chromium</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Vendor</TAG>
        <VALUE>10X Chromium</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>List</TAG>
        <VALUE/>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Primary Phenotype</TAG>
        <VALUE>Malignant mesothelioma</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>IDC-10 Disease Classification</TAG>
        <VALUE>Malignant Mesothelioma of Pleura (C45.0)</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Disease Type</TAG>
        <VALUE>Neoplasms</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Cancer Type</TAG>
        <VALUE>Mesothelioma</VALUE>
      </STUDY_ATTRIBUTE>
    </STUDY_ATTRIBUTES>
  </STUDY>
  <STUDY alias="JSUB000269_Study_0001" center_name="Individual" accession="JGAS000194">
    <IDENTIFIERS>
      <SECONDARY_ID>JGAS00000000194</SECONDARY_ID>
    </IDENTIFIERS>
    <DESCRIPTOR>
      <STUDY_TITLE>Viral integration analysis of hepatocellular carcinoma using virus capture sequence.</STUDY_TITLE>
      <STUDY_TYPES>
        <STUDY_TYPE existing_study_type="Other" new_study_type="Virus Capture Sequencing"/>
        <STUDY_TYPE existing_study_type="Transcriptome Sequencing"/>
      </STUDY_TYPES>
      <STUDY_ABSTRACT>Hepatitis B viral (HBV) DNA is frequently integrated into the genome of hepatocellular carcinoma (HCC) in patients with chronic HBV infection (chronic HBV, hereafter), whereas it is yet to be clarified in patients after HBV disappearance (prior HBV, hereafter). This study aimed to identify viral integration such as HBV and adeno-associated virus type 2 (AAV2) into the HCC genome as oncogenic event. </STUDY_ABSTRACT>
    </DESCRIPTOR>
    <GRANTS>
      <GRANT grant_id="JP18hk0102049">
        <TITLE>Research on Development of New Medical Devices</TITLE>
        <AGENCY abbr="AMED">Japan Agency for Medical Research and Development??</AGENCY>
      </GRANT>
      <GRANT grant_id="JP18ck0106265">
        <TITLE>Practical Research for Innovative Cancer Control</TITLE>
        <AGENCY abbr="AMED">Japan Agency for Medical Research and Development??</AGENCY>
      </GRANT>
      <GRANT grant_id="JP18fk0210040">
        <TITLE>Program for Basic and Clinical Research on Hepatitis</TITLE>
        <AGENCY abbr="AMED">Japan Agency for Medical Research and Development??</AGENCY>
      </GRANT>
      <GRANT grant_id="JP17K07195">
        <TITLE>Grant-in-Aid for Scientific Research (C)</TITLE>
        <AGENCY abbr="MEXT">Ministry of Education, Culture, Sports, Science, and Technology </AGENCY>
      </GRANT>
    </GRANTS>
    <PUBLICATIONS>
      <PUBLICATION id="31320595" status="published">
        <DB_TYPE>PUBMED</DB_TYPE>
      </PUBLICATION>
    </PUBLICATIONS>
    <STUDY_ATTRIBUTES>
      <STUDY_ATTRIBUTE>
        <TAG>NBDC Number</TAG>
        <VALUE>hum0187</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Registration date</TAG>
        <VALUE>2019-05-28</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Submitting organization</TAG>
        <VALUE>Genome Science laboratory, RCAST, the University of Tokyo</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Principal Investigator</TAG>
        <VALUE>Hiroyuki Aburatani</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Molecular Data Type</TAG>
        <VALUE>Target Capture Sequencing</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Platform</TAG>
        <VALUE>MiSeq</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Vendor</TAG>
        <VALUE>Illumina</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>List</TAG>
        <VALUE/>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Molecular Data Type</TAG>
        <VALUE>RNAsequencing</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Platform</TAG>
        <VALUE>Hiseq 2000</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Vendor</TAG>
        <VALUE>Illumina</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>List</TAG>
        <VALUE/>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Primary Phenotype</TAG>
        <VALUE>Hepatocellular carcinoma</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>IDC-10 Disease Classification</TAG>
        <VALUE>Hepatocellular carcinoma (C22.0)</VALUE>
      </STUDY_ATTRIBUTE>
    </STUDY_ATTRIBUTES>
  </STUDY>
  <STUDY alias="JSUB000270_Study_0001" center_name="Individual" accession="JGAS000179">
    <IDENTIFIERS>
      <SECONDARY_ID>JGAS00000000179</SECONDARY_ID>
    </IDENTIFIERS>
    <DESCRIPTOR>
      <STUDY_TITLE>Identification of driver oncogenes in scirrhous-type gastric cancer cell lines</STUDY_TITLE>
      <STUDY_TYPES>
        <STUDY_TYPE existing_study_type="Exome Sequencing"/>
        <STUDY_TYPE existing_study_type="Transcriptome Sequencing"/>
      </STUDY_TYPES>
      <STUDY_ABSTRACT>Scirrhous type gastric cancer (SGC) is one of the most intractable cancer subtypes in human, and its therapeutic targets have been rarely identified to date. Exploration of somatic mutations in the SGC genome with the next generation sequencers has been hampered by low tumor contents by the markedly increased fibrous tissues. Thus, SGC cell lines may be useful resources to search for novel oncogenes in. Here we have conducted whole exome sequencing and RNA sequencing on two SGC cell lines, OCUM-8 and OCUM-9. Interestingly, most of the mutations thus identified have not been reported. In OCUM-8 cells, a novel CD44-IGF1R fusion gene is discovered, the protein product of which ligates the amino-terminus of CD44 to the transmembrane and the tyrosine-kinase domains of IGF1R. Further, both of CD44 and IGF1R are markedly amplified in the OCUM-8 genome and abundantly expressed. CD44-IGF1R has a transforming ability, and the suppression of its kinase activity leads to rapid cell death of OCUM-8. On the other hand, OCUM-9 seems to possess multiple oncogenic events in its genome. The MET gene is highly amplified, and the treatment of OCUM-9 with crizotinib, a MET inhibitor, results in cell death. Further, a novel BORCS5-ETV6 fusion gene is identified in the OCUM-9 genome. BORCS5-ETV6 possesses oncogenic activity, and suppression of its message partially inhibits cell growth. Prevalence of these novel fusion genes among SGC awaits further investigation, but we validate the significance of cell lines as appropriate reagents for detailed genomic analyses of SGC. </STUDY_ABSTRACT>
    </DESCRIPTOR>
    <STUDY_ATTRIBUTES>
      <STUDY_ATTRIBUTE>
        <TAG>NBDC Number</TAG>
        <VALUE>hum0188</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Registration date</TAG>
        <VALUE>2019-05-17</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Submitting organization</TAG>
        <VALUE>National Cancer Center Research Institute</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Principal Investigator</TAG>
        <VALUE>Hiroyuki Mano</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Molecular Data Type</TAG>
        <VALUE>Whole Exome Sequencing</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Platform</TAG>
        <VALUE>HiSeq 2500</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Vendor</TAG>
        <VALUE>Illumina</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>List</TAG>
        <VALUE/>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Molecular Data Type</TAG>
        <VALUE>RNA Sequencing</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Platform</TAG>
        <VALUE>HiSeq 2500</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Vendor</TAG>
        <VALUE>Illumina</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>List</TAG>
        <VALUE/>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Primary Phenotype</TAG>
        <VALUE>Gastric cancer</VALUE>
      </STUDY_ATTRIBUTE>
    </STUDY_ATTRIBUTES>
  </STUDY>
  <STUDY alias="JSUB000277_Study_0001" center_name="Individual" accession="JGAS000188">
    <IDENTIFIERS>
      <SECONDARY_ID>JGAS00000000188</SECONDARY_ID>
    </IDENTIFIERS>
    <DESCRIPTOR>
      <STUDY_TITLE>Integrated multi-omics analysis of pediatric hepatoblastoma</STUDY_TITLE>
      <STUDY_TYPES>
        <STUDY_TYPE existing_study_type="Transcriptome Sequencing"/>
        <STUDY_TYPE existing_study_type="Other" new_study_type="Target capture sequencing"/>
        <STUDY_TYPE existing_study_type="Other" new_study_type="SNP array"/>
        <STUDY_TYPE existing_study_type="Other" new_study_type="DNA methylation array"/>
      </STUDY_TYPES>
      <STUDY_ABSTRACT>Hepatoblastoma (HBL) is the most common malignant liver tumor in childhood and is clinically heterogeneous. In spite of its heterogeneity, the molecular basis responsible for the difference between low-risk and high-risk HBL has not been fully clarified. To address this issue, we carried out multi-omics analysis on 59 HBL samples to generate comprehensive profiles of gene mutation, copy-number alteration, DNA methylation and gene expression. By integrating these data, we aimed to unravel the heterogeneity of HBL and identify genetic determinants and therapy targets of high-risk HBL. </STUDY_ABSTRACT>
    </DESCRIPTOR>
    <GRANTS>
      <GRANT grant_id="157100000120">
        <TITLE>Investigation of novel molecular targets of intractable pediatric solid tumors using integrated genetic analysis</TITLE>
        <AGENCY abbr="">Project for Development of Innovative Research on Cancer Therapeutics</AGENCY>
      </GRANT>
      <GRANT grant_id="26293242">
        <TITLE>Studies on clonal evolutions which regulate metastasis and relapse in pediatric solid tumors using spatiotemporal and comprehensive genome-wide analysis</TITLE>
        <AGENCY abbr="jsps">Japan society for the promotion of science</AGENCY>
      </GRANT>
    </GRANTS>
    <PUBLICATIONS>
      <PUBLICATION id="26138366" status="published">
        <DB_TYPE>PUBMED</DB_TYPE>
      </PUBLICATION>
      <PUBLICATION id="24675358" status="published">
        <DB_TYPE>PUBMED</DB_TYPE>
      </PUBLICATION>
      <PUBLICATION id="29296183" status="published">
        <DB_TYPE>PUBMED</DB_TYPE>
      </PUBLICATION>
      <PUBLICATION id="29233928" status="published">
        <DB_TYPE>PUBMED</DB_TYPE>
      </PUBLICATION>
    </PUBLICATIONS>
    <STUDY_ATTRIBUTES>
      <STUDY_ATTRIBUTE>
        <TAG>NBDC Number</TAG>
        <VALUE>hum0035</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Registration date</TAG>
        <VALUE>2019-06-13</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Submitting organization</TAG>
        <VALUE>Department of Pediatrics, Graduate School of Medicine, Kyoto University</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Principal Investigator</TAG>
        <VALUE>Junko Takita</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Molecular Data Type</TAG>
        <VALUE>Transcriptome Sequencing</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Platform</TAG>
        <VALUE>Hiseq 2000/2500</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Vendor</TAG>
        <VALUE>Illumina</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>List</TAG>
        <VALUE/>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Molecular Data Type</TAG>
        <VALUE>Target capture sequencing</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Platform</TAG>
        <VALUE>Hiseq 2000/2500</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Vendor</TAG>
        <VALUE>Illumina</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>List</TAG>
        <VALUE/>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Molecular Data Type</TAG>
        <VALUE>SNP array</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Platform</TAG>
        <VALUE>Human Mapping 250K Nsp Array for Cytogenetics</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Vendor</TAG>
        <VALUE>Affymetrix</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>List</TAG>
        <VALUE/>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Molecular Data Type</TAG>
        <VALUE>DNA methylation array</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Platform</TAG>
        <VALUE>Infinium MethylationEPIC BeadChip</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Vendor</TAG>
        <VALUE>Illumina</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>List</TAG>
        <VALUE/>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Primary Phenotype</TAG>
        <VALUE>Hepatoblastoma</VALUE>
      </STUDY_ATTRIBUTE>
    </STUDY_ATTRIBUTES>
  </STUDY>
  <STUDY alias="JSUB000281_Study_0001" center_name="Individual" accession="JGAS000189">
    <IDENTIFIERS>
      <SECONDARY_ID>JGAS00000000189</SECONDARY_ID>
    </IDENTIFIERS>
    <DESCRIPTOR>
      <STUDY_TITLE>Target sequencing of ROS1-rearranged lung cancer patients</STUDY_TITLE>
      <STUDY_TYPES>
        <STUDY_TYPE existing_study_type="Other" new_study_type="Target capture sequencing"/>
      </STUDY_TYPES>
      <STUDY_ABSTRACT>We performed target capture sequencing of ROS1-rearranged non-small cell lung cancer patients to develop and examine the efficacy of new molecular targeted drug against ROS1 tyrosine kinase.</STUDY_ABSTRACT>
    </DESCRIPTOR>
    <GRANTS>
      <GRANT grant_id="JP16H04715">
        <TITLE>KAKENHI Grant-in Aid for Scientific Research</TITLE>
        <AGENCY abbr="JSPS">Japanese Society for the Promotion of Science</AGENCY>
      </GRANT>
      <GRANT grant_id="JP19H03524">
        <TITLE>KAKENHI Grant-in Aid for Scientific Research</TITLE>
        <AGENCY abbr="JSPS">Japanese Society for the Promotion of Science</AGENCY>
      </GRANT>
      <GRANT grant_id="JP15H02368">
        <TITLE>KAKENHI Grant-in Aid for Scientific Research</TITLE>
        <AGENCY abbr="JSPS">Japanese Society for the Promotion of Science</AGENCY>
      </GRANT>
      <GRANT grant_id="JP17H06327">
        <TITLE>KAKENHI Grant-in Aid for Scientific Research</TITLE>
        <AGENCY abbr="JSPS">Japanese Society for the Promotion of Science</AGENCY>
      </GRANT>
      <GRANT grant_id="JP19cm0106203h0004">
        <TITLE>AMED Grant</TITLE>
        <AGENCY abbr="AMED">Japan Agency for Medical Research and Development</AGENCY>
      </GRANT>
      <GRANT grant_id="JP19ck0106472h0001">
        <TITLE>AMED Grant</TITLE>
        <AGENCY abbr="AMED">Japan Agency for Medical Research and Development</AGENCY>
      </GRANT>
    </GRANTS>
    <STUDY_ATTRIBUTES>
      <STUDY_ATTRIBUTE>
        <TAG>NBDC Number</TAG>
        <VALUE>hum0194</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Registration date</TAG>
        <VALUE>2019-07-05</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Submitting organization</TAG>
        <VALUE>Japanese Foundation for Cancer Research</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Principal Investigator</TAG>
        <VALUE>Ryohei Katayama</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Molecular Data Type</TAG>
        <VALUE>Target capture Sequencing</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Platform</TAG>
        <VALUE>Miseq</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Vendor</TAG>
        <VALUE>Illumina</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>List</TAG>
        <VALUE/>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Primary Phenotype</TAG>
        <VALUE>Lung adenocarcinoma (HP:0030078)</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>IDC-10 Disease Classification</TAG>
        <VALUE>Malignant neoplasm of bronchus and lung (C34)</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>disease</TAG>
        <VALUE>ROS1-rearranged non-small cell lung cancer</VALUE>
      </STUDY_ATTRIBUTE>
    </STUDY_ATTRIBUTES>
  </STUDY>
  <STUDY alias="JSUB000284_Study_0001" center_name="Individual" accession="JGAS000191">
    <IDENTIFIERS>
      <SECONDARY_ID>JGAS00000000191</SECONDARY_ID>
    </IDENTIFIERS>
    <DESCRIPTOR>
      <STUDY_TITLE>CLDN14 mutation identifed from Japanese sensorineural hearing loss patient.</STUDY_TITLE>
      <STUDY_TYPES>
        <STUDY_TYPE existing_study_type="Case Set"/>
      </STUDY_TYPES>
      <STUDY_ABSTRACT>The CLDN14 gene, encoding claudin 14, is reported to be one of the rare causes of non-syndromic autosomal dominant sensorineural hearing loss. The detailed clinical characteristics of CLDN14 associated hearing loss is still remain unclear. In the present study, we performed CLDN14 mutation analysis using massively parallel DNA sequencing (MPS) to reveal the clinical characteristics of CLDN14-related hearing loss in a large hearing loss population. </STUDY_ABSTRACT>
    </DESCRIPTOR>
    <GRANTS>
      <GRANT grant_id="16kk0205010h0001">
        <TITLE>Development of the unified data storage of clinical and genomic information for sensory disorders.</TITLE>
        <AGENCY abbr="AMED">Japan Agency for Medical Research and Development</AGENCY>
      </GRANT>
      <GRANT grant_id="19ek0109363h0002">
        <TITLE>Development of evidence based clinical management for hereditary hearing loss.</TITLE>
        <AGENCY abbr="AMED">Japan Agency for Medical Research and Development</AGENCY>
      </GRANT>
    </GRANTS>
    <STUDY_ATTRIBUTES>
      <STUDY_ATTRIBUTE>
        <TAG>NBDC Number</TAG>
        <VALUE>hum0005</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Registration date</TAG>
        <VALUE>2019-07-19</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Submitting organization</TAG>
        <VALUE>Shinshu University School of Medicine</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Principal Investigator</TAG>
        <VALUE>Shin-ichi Usami</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Molecular Data Type</TAG>
        <VALUE>Target resequencing</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Platform</TAG>
        <VALUE>Ion Proton</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Vendor</TAG>
        <VALUE>Thermo Fisher Scientific</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>List</TAG>
        <VALUE/>
      </STUDY_ATTRIBUTE>
    </STUDY_ATTRIBUTES>
  </STUDY>
  <STUDY alias="JSUB000285_Study_0001" center_name="Individual" accession="JGAS000192">
    <IDENTIFIERS>
      <SECONDARY_ID>JGAS00000000192</SECONDARY_ID>
    </IDENTIFIERS>
    <DESCRIPTOR>
      <STUDY_TITLE>Mutational Spectrums and Clinical Features of Patients with LOXHD1 Variants Identified in a 8,074 Hearing Loss Patient Cohort.</STUDY_TITLE>
      <STUDY_TYPES>
        <STUDY_TYPE existing_study_type="Case Set"/>
      </STUDY_TYPES>
      <STUDY_ABSTRACT>Variants of LOXHD1 gene, which are expressed in hair cells of the cochlea and vestibule, have been reported to cause a progressive form of autosomal recessive non-syndromic hereditary hearing loss, DFNB77. In this study, genetic screening was conducted on 8,074 Japanese hearing loss patients utilizing the massively parallel DNA sequencing, to identify individuals with LOXHD1 variants and to assess their phenotypes. 28 affected individuals and 21 LOXHD1 variants were identified, among which 13 were novel variants.</STUDY_ABSTRACT>
    </DESCRIPTOR>
    <GRANTS>
      <GRANT grant_id="16kk0205010h0001">
        <TITLE>Development of the unified data storage of clinical and genomic information for sensory disorders.</TITLE>
        <AGENCY abbr="AMED">Japan Agency for Medical Research and Development</AGENCY>
      </GRANT>
      <GRANT grant_id="19ek0109363h0002">
        <TITLE>Development of evidence based clinical management for hereditary hearing loss.</TITLE>
        <AGENCY abbr="AMED">Japan Agency for Medical Research and Development</AGENCY>
      </GRANT>
    </GRANTS>
    <STUDY_ATTRIBUTES>
      <STUDY_ATTRIBUTE>
        <TAG>NBDC Number</TAG>
        <VALUE>hum0005</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Registration date</TAG>
        <VALUE>2019-07-19</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Submitting organization</TAG>
        <VALUE>Shinshu University School of Medicine</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Principal Investigator</TAG>
        <VALUE>Shin-ichi Usami</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Molecular Data Type</TAG>
        <VALUE>Target resequencing</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Platform</TAG>
        <VALUE>Ion Proton</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Vendor</TAG>
        <VALUE>Thermo Fisher Scientific</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>List</TAG>
        <VALUE/>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Molecular Data Type</TAG>
        <VALUE>Target resequencing</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Platform</TAG>
        <VALUE>HiSeq 2000</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Vendor</TAG>
        <VALUE>Illumina</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>List</TAG>
        <VALUE/>
      </STUDY_ATTRIBUTE>
    </STUDY_ATTRIBUTES>
  </STUDY>
  <STUDY alias="JSUB000287_Study_0001" center_name="Individual" accession="JGAS000205">
    <IDENTIFIERS>
      <SECONDARY_ID>JGAS00000000205</SECONDARY_ID>
    </IDENTIFIERS>
    <DESCRIPTOR>
      <STUDY_TITLE>Elucidation of disease state by multi-layered omics analysis</STUDY_TITLE>
      <STUDY_TYPES>
        <STUDY_TYPE existing_study_type="Population"/>
      </STUDY_TYPES>
      <STUDY_ABSTRACT>We performed  a comprehensive metagenome-wide association study by utilizing whole-genome shotgun sequencing.
  We elucidated a gut microbiome???s role in human biology of the Japanese population.</STUDY_ABSTRACT>
    </DESCRIPTOR>
    <PUBLICATIONS>
      <PUBLICATION id="31699813" status="published">
        <DB_TYPE>PUBMED</DB_TYPE>
      </PUBLICATION>
    </PUBLICATIONS>
    <STUDY_ATTRIBUTES>
      <STUDY_ATTRIBUTE>
        <TAG>NBDC Number</TAG>
        <VALUE>hum0197</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Registration date</TAG>
        <VALUE>2019-09-19</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Submitting organization</TAG>
        <VALUE>Osaka University Graduate School of Medicine</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Principal Investigator</TAG>
        <VALUE>Yukinori Okada</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Molecular Data Type</TAG>
        <VALUE>Whole Genome Sequencing</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Platform</TAG>
        <VALUE>Hiseq 3000</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Vendor</TAG>
        <VALUE>Illumina</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>List</TAG>
        <VALUE/>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Primary Phenotype</TAG>
        <VALUE>Japanese population</VALUE>
      </STUDY_ATTRIBUTE>
    </STUDY_ATTRIBUTES>
  </STUDY>
  <STUDY alias="JSUB000289_Study_0001" center_name="Individual" accession="JGAS000198">
    <IDENTIFIERS>
      <SECONDARY_ID>JGAS00000000198</SECONDARY_ID>
    </IDENTIFIERS>
    <DESCRIPTOR>
      <STUDY_TITLE>Identification of therapeutic target molecules for prostate cancer by using next generation sequencer</STUDY_TITLE>
      <STUDY_TYPES>
        <STUDY_TYPE existing_study_type="Transcriptome Sequencing"/>
      </STUDY_TYPES>
      <STUDY_ABSTRACT>Comprehensive transcriptional characterization of cancer tissues can reveal important molecular signatures associated with the disease progression. Long non-coding RNA (LncRNA) has a diversity of functions such as transcription, epigenetic and gene regulation in cancer cells including prostate cancer cells. Here, we performed directional RNA-sequence (RNA-seq) on clinical samples obtained from prostate cancer (PC) and lethal castration-resistant PC (CRPC) patients to identify novel molecular signatures including protein coding genes and non-coding RNAs induced in CRPC tissues.</STUDY_ABSTRACT>
    </DESCRIPTOR>
    <GRANTS>
      <GRANT grant_id="17H04334">
        <TITLE>Integrative analysis of the epigenetic regulatory mechanism for the progression of prostate cancer to treatment-resistance</TITLE>
        <AGENCY abbr="JSPS">Japan Society for the Promotion of Science</AGENCY>
      </GRANT>
      <GRANT grant_id="18K09128">
        <TITLE>Precision medicine for metastatic prostate cancer via estrogen and androgen blockade</TITLE>
        <AGENCY abbr="JSPS">Japan Society for the Promotion of Science</AGENCY>
      </GRANT>
      <GRANT grant_id="15K10576">
        <TITLE>Personalized medicine for advanced prostate cancer</TITLE>
        <AGENCY abbr="JSPS">Japan Society for the Promotion of Science</AGENCY>
      </GRANT>
    </GRANTS>
    <STUDY_ATTRIBUTES>
      <STUDY_ATTRIBUTE>
        <TAG>NBDC Number</TAG>
        <VALUE>hum0199</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Registration date</TAG>
        <VALUE>2019-08-21</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Submitting organization</TAG>
        <VALUE>Jichi Mecical University</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Principal Investigator</TAG>
        <VALUE>Tetsuya Fujimura</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Molecular Data Type</TAG>
        <VALUE>directional RNA sequencing</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Platform</TAG>
        <VALUE>Hiseq 2500</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Vendor</TAG>
        <VALUE>Illumina</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>List</TAG>
        <VALUE/>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Primary Phenotype</TAG>
        <VALUE>castration-resistant prostate cancer</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>IDC-10 Disease Classification</TAG>
        <VALUE>Malignant neoplasm of prostate (C61)</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>disease</TAG>
        <VALUE>prostate cancer</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Sequencing Library Strategy</TAG>
        <VALUE>RNA-seq</VALUE>
      </STUDY_ATTRIBUTE>
    </STUDY_ATTRIBUTES>
  </STUDY>
  <STUDY alias="JSUB000292_Study_0001" center_name="Individual" accession="JGAS000199">
    <IDENTIFIERS>
      <SECONDARY_ID>JGAS00000000199</SECONDARY_ID>
    </IDENTIFIERS>
    <DESCRIPTOR>
      <STUDY_TITLE>Somatic inflammatory gene mutations accumulate in human ulcerative colitis epithelium</STUDY_TITLE>
      <STUDY_TYPES>
        <STUDY_TYPE existing_study_type="Exome Sequencing"/>
        <STUDY_TYPE existing_study_type="Case-Control"/>
        <STUDY_TYPE existing_study_type="Other" new_study_type="Target Capture Sequencing"/>
      </STUDY_TYPES>
      <STUDY_ABSTRACT>We performed whole exome sequencing and targeted sequencing of ulcerative colitis with/without colitis associated neoplasm and healthy indivisuals. The aim of this study was to calculate the influence of inflammation and age on a count of genetic mutations in colonic epithelium, and to identify the specific signal pathways on which the significant genetic mutations accumulating in ulcerative colitis patients' colonic epithelium.</STUDY_ABSTRACT>
    </DESCRIPTOR>
    <PUBLICATIONS>
      <PUBLICATION id="10.1038/s41586-019-1844-5" status="published">
        <DB_TYPE>DOI</DB_TYPE>
      </PUBLICATION>
    </PUBLICATIONS>
    <STUDY_ATTRIBUTES>
      <STUDY_ATTRIBUTE>
        <TAG>NBDC Number</TAG>
        <VALUE>hum0201</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Registration date</TAG>
        <VALUE>2019-08-27</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Submitting organization</TAG>
        <VALUE>Department of Organoid Medicine, Keio University School of Medicine</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Principal Investigator</TAG>
        <VALUE>Toshiro Sato</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Molecular Data Type</TAG>
        <VALUE>Whole Exome Sequencing</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Platform</TAG>
        <VALUE>HiSeq 2500, HiSeq 4000</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Vendor</TAG>
        <VALUE>Illumina</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>List</TAG>
        <VALUE/>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Primary Phenotype</TAG>
        <VALUE>Ulcerative colitis (HP:0100279)</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Phenotype</TAG>
        <VALUE>Colon cancer (HP:0003003)</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>IDC-10 Disease Classification</TAG>
        <VALUE>Ulcerative colitis (K51)</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>IDC-10 Disease Classification</TAG>
        <VALUE>Malignant neoplasm of colon???? (C18)</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>IDC-10 Disease Classification</TAG>
        <VALUE>Malignant neoplasm of rectosigmoid junction (C19)</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>IDC-10 Disease Classification</TAG>
        <VALUE>Malignant neoplasm of rectum (C20)</VALUE>
      </STUDY_ATTRIBUTE>
    </STUDY_ATTRIBUTES>
  </STUDY>
  <STUDY alias="JSUB000297_Study_0001" center_name="Individual" accession="JGAS000206">
    <IDENTIFIERS>
      <SECONDARY_ID>JGAS00000000206</SECONDARY_ID>
    </IDENTIFIERS>
    <DESCRIPTOR>
      <STUDY_TITLE>Establishment of an integrated database for clinical and genomic data in cancer</STUDY_TITLE>
      <STUDY_TYPES>
        <STUDY_TYPE existing_study_type="Other" new_study_type="Targeted capture sequence"/>
        <STUDY_TYPE existing_study_type="Cohort"/>
      </STUDY_TYPES>
      <STUDY_ABSTRACT>In this study, to clarify the genomic varieties of MM in Asian population, we planned to investigate the genomic features in Japanese population, represented as an Asian cohort, and preformed the comprehensive genomic analysis of MM cells with newly diagnosed multiple myeloma (NDMM) by means of targeted capture sequencing (TCS) method. In our TCS assay, MM cells are subjected to the detection of following genomic abnormalities; IG rearrangements, IG associated translocations, CNAs, and somatic mutations from 340 genes related to the pathogenesis and therapeutic agent of MM. </STUDY_ABSTRACT>
    </DESCRIPTOR>
    <GRANTS>
      <GRANT grant_id="16kk0205005h0001">
        <TITLE>Establishment of an integrated database for clinical and genomic data in cancer</TITLE>
        <AGENCY abbr="AMED">Japan Agency for Medical Research and development</AGENCY>
      </GRANT>
    </GRANTS>
    <PUBLICATIONS>
      <PUBLICATION id="32386081" status="published">
        <DB_TYPE>PUBMED</DB_TYPE>
      </PUBLICATION>
    </PUBLICATIONS>
    <STUDY_LINKS>
      <STUDY_LINK>
        <URL_LINK>
          <LABEL>https://www.amed.go.jp/content/files/jp/houkoku_h28/0401047/h28_008.pdf</LABEL>
          <URL>https://www.amed.go.jp/content/files/jp/houkoku_h28/0401047/h28_008.pdf</URL>
        </URL_LINK>
      </STUDY_LINK>
    </STUDY_LINKS>
    <STUDY_ATTRIBUTES>
      <STUDY_ATTRIBUTE>
        <TAG>NBDC Number</TAG>
        <VALUE>hum0203</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Registration date</TAG>
        <VALUE>2019-09-24</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Submitting organization</TAG>
        <VALUE>Clinical Research Center, Nagoya Medical Center</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Principal Investigator</TAG>
        <VALUE>Masashi Sanada</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Molecular Data Type</TAG>
        <VALUE>Targeted capture sequence</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Platform</TAG>
        <VALUE>HiSeq 2500</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Vendor</TAG>
        <VALUE>Illumina</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>List</TAG>
        <VALUE/>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Primary Phenotype</TAG>
        <VALUE>Multiple Myeloma(HP:0006775,ORPHA:29073)</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Phenotype</TAG>
        <VALUE>Hematological neoplasm(HP:0004377)</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>IDC-10 Disease Classification</TAG>
        <VALUE>Multiple Myeloma (C900)</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Disease</TAG>
        <VALUE>Multiple Myeloma</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Molecular Data Type</TAG>
        <VALUE>Targeted capture sequence</VALUE>
      </STUDY_ATTRIBUTE>
    </STUDY_ATTRIBUTES>
  </STUDY>
  <STUDY alias="JSUB000302_Study_0001" center_name="Individual" accession="JGAS000214">
    <IDENTIFIERS>
      <SECONDARY_ID>JGAS00000000214</SECONDARY_ID>
    </IDENTIFIERS>
    <DESCRIPTOR>
      <STUDY_TITLE>comprehensive genetic analysis and database construction for head and neck cancer</STUDY_TITLE>
      <STUDY_TYPES>
        <STUDY_TYPE existing_study_type="Exome Sequencing"/>
      </STUDY_TYPES>
      <STUDY_ABSTRACT>The main purpose is to conduct comprehensive genetic analysis of head and neck malignant tumor tissue and patient-derived blood, and to construct a database for it. By analyzing these databases, we aim to clinically identify recurrence and metastasis prediction markers and establish new molecular target therapies.</STUDY_ABSTRACT>
    </DESCRIPTOR>
    <PUBLICATIONS>
      <PUBLICATION id="16436996" status="published">
        <DB_TYPE>PUBMED</DB_TYPE>
      </PUBLICATION>
    </PUBLICATIONS>
    <STUDY_ATTRIBUTES>
      <STUDY_ATTRIBUTE>
        <TAG>NBDC Number</TAG>
        <VALUE>hum0208</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Registration date</TAG>
        <VALUE>2019-12-25</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Submitting organization</TAG>
        <VALUE>Department of Otorhinolaryngology, Kyushu University</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Principal Investigator</TAG>
        <VALUE>KENSUKE KOIKE</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Molecular Data Type</TAG>
        <VALUE>Whole Exome Sequencing</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Platform</TAG>
        <VALUE>HiSeq X Ten</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Vendor</TAG>
        <VALUE>Illumina </VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>List</TAG>
        <VALUE/>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Primary Phenotype</TAG>
        <VALUE>cancer of the external auditory canal</VALUE>
      </STUDY_ATTRIBUTE>
    </STUDY_ATTRIBUTES>
  </STUDY>
  <STUDY alias="JSUB000303_Study_0001" center_name="Individual" accession="JGAS000211">
    <IDENTIFIERS>
      <SECONDARY_ID>JGAS00000000211</SECONDARY_ID>
    </IDENTIFIERS>
    <DESCRIPTOR>
      <STUDY_TITLE>Elucidation of genomic pathology of a patient with concurrent acute myeloid leukemia and mediastinal germ cell tumor</STUDY_TITLE>
      <STUDY_TYPES>
        <STUDY_TYPE existing_study_type="Exome Sequencing"/>
      </STUDY_TYPES>
      <STUDY_ABSTRACT>The occurrence of a mediastinal germ cell tumor (GCT) and hematological malignancy in the same patient is very rare. Whole exome sequencing was performed for concurrent acute myeloid leukemia (acute megakaryoblastic leukemia) and mediastinal germ cell tumor. Somatic mutations, such as TP53 or PTEN, were commonly identified in both acute myeloid leukemia and mediastinal germ cell tumor, suggesting the common founder clone. Normal buccal cells were used as a control. Illumina NextSeq 500 platform were used.
  </STUDY_ABSTRACT>
    </DESCRIPTOR>
    <GRANTS>
      <GRANT grant_id="30-A-1">
        <TITLE>Development of a comprehensive genomic profiling assay for hematological malignancies.</TITLE>
        <AGENCY>National Cancer Center Research and Development Funds</AGENCY>
      </GRANT>
      <GRANT grant_id="30-GH-3">
        <TITLE>Establishment of a method to identify high-risk groups for the development of hematological tumors.</TITLE>
        <AGENCY>Grant-in-Aid for Clinical Research from University of Miyazaki Hospital</AGENCY>
      </GRANT>
    </GRANTS>
    <PUBLICATIONS>
      <PUBLICATION id="31898539" status="published">
        <DB_TYPE>PUBMED</DB_TYPE>
      </PUBLICATION>
    </PUBLICATIONS>
    <STUDY_ATTRIBUTES>
      <STUDY_ATTRIBUTE>
        <TAG>NBDC Number</TAG>
        <VALUE>hum0210</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Registration date</TAG>
        <VALUE>2019-11-26</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Submitting organization</TAG>
        <VALUE>Division of Gastroenterology and Hematology, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Principal Investigator</TAG>
        <VALUE>Kazuya Shimoda</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Molecular Data Type</TAG>
        <VALUE>whole-exome sequencing</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Platform</TAG>
        <VALUE>NextSeq 500</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Vendor</TAG>
        <VALUE>Illumina</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>List</TAG>
        <VALUE/>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Primary Phenotype</TAG>
        <VALUE>Acute myeloid leukemia, Germ cell tumor, hematological malignancy, acute megakaryoblastic leukemia, concurrent, commonly, TP53, PTEN</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Study Inclusion/Exclusion Criteria</TAG>
        <VALUE>not set</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>IDC-10 Disease Classification</TAG>
        <VALUE>Acute megakaryoblastic leukemia (C94.2)</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>IDC-10 Disease Classification</TAG>
        <VALUE>Acute myeloblastic leukemia (C92.0)</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>IDC-10 Disease Classification</TAG>
        <VALUE>Malignant neoplasm: Anterior mediastinum (C38.1)</VALUE>
      </STUDY_ATTRIBUTE>
    </STUDY_ATTRIBUTES>
  </STUDY>
  <STUDY alias="JSUB000310_Study_0001" center_name="Individual" accession="JGAS000216">
    <IDENTIFIERS>
      <SECONDARY_ID>JGAS00000000216</SECONDARY_ID>
    </IDENTIFIERS>
    <DESCRIPTOR>
      <STUDY_TITLE>Whole exome sequencing of surgically resected lung adenocarcinomas and gastric adenocarcinomas.</STUDY_TITLE>
      <STUDY_TYPES>
        <STUDY_TYPE existing_study_type="Exome Sequencing"/>
      </STUDY_TYPES>
      <STUDY_ABSTRACT>We performed whole exome sequencing of surgically resected lung adenocarcinomas and gastric adenocarcinomas.</STUDY_ABSTRACT>
    </DESCRIPTOR>
    <PUBLICATIONS>
      <PUBLICATION id="32005679" status="published">
        <DB_TYPE>PUBMED</DB_TYPE>
      </PUBLICATION>
    </PUBLICATIONS>
    <STUDY_ATTRIBUTES>
      <STUDY_ATTRIBUTE>
        <TAG>NBDC Number</TAG>
        <VALUE>hum0216</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Registration date</TAG>
        <VALUE>2020-01-20</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Submitting organization</TAG>
        <VALUE>National Cancer Center Hospital East, Division of Cancer Immunology</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Principal Investigator</TAG>
        <VALUE>Hiroyoshi Nishikawa</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Molecular Data Type</TAG>
        <VALUE>Whole exome sequncing</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Platform</TAG>
        <VALUE>Hiseq 2500</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Vendor</TAG>
        <VALUE>Illumina</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>List</TAG>
        <VALUE/>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Primary Phenotype</TAG>
        <VALUE>Non-small cell lung cancer</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>IDC-10 Disease Classification</TAG>
        <VALUE>Malignant neoplasm of bronchus and lung (C34.9)</VALUE>
      </STUDY_ATTRIBUTE>
    </STUDY_ATTRIBUTES>
  </STUDY>
  <STUDY alias="JSUB000312_Study_0001" center_name="Individual" accession="JGAS000217">
    <IDENTIFIERS>
      <SECONDARY_ID>JGAS00000000217</SECONDARY_ID>
    </IDENTIFIERS>
    <DESCRIPTOR>
      <STUDY_TITLE>Sequence analysis of colorectal serrated lesions</STUDY_TITLE>
      <STUDY_TYPES>
        <STUDY_TYPE existing_study_type="Case Set"/>
      </STUDY_TYPES>
      <STUDY_ABSTRACT>Recent studies have shown that colorectal serrated lesions, which include sessile serrated adenomas (SSAs) and traditional serrated adenomas (TSAs), are precursors of colorectal cancer. However, the molecular mechanisms underlying the carcinogenesis, particularly in TSAs, remain largely uncharacterized. To clarify their molecular and clinicopathological characteristics, we performed mutation and methylation analyses of cancer-associated genes in 78 serrated lesions, including TSAs, SSAs and microvesicular hyperplastic polyps. Target exon sequence analysis was performed with 39 genes, including genes known to be frequently mutated in colorectal cancers and/or serrated lesions. We also used bisulfite pyrosequencing to assess the methylation status of various cancer-associated genes and marker genes of the CpG island methylator phenotype (CIMP). The prevalence of mutations in genes associated with Wnt signaling was significantly higher in TSAs than SSAs (65% vs. 28%, p &lt; 0.01). Among those, RNF43 mutations were observed in 38% of TSAs and 17% of SSAs. In immunohistochemical studies of 39 serrated lesions, the prevalence of abnormal nuclear ?-catenin accumulation was significantly higher in TSAs (57%) than SSAs (8%) (P = 0.01). SMOC1 methylation was detected in 54% of TSAs but in no SSAs (p &lt; 0.01). Additionally, SMOC1 methylation was more prevalent among TSAs with KRAS mutation (82%) than with BRAF mutation (38%, p = 0.03). Lesions with CIMP-high or RNF43 mutations were detected only in TSAs with BRAF mutation, suggesting two distinct carcinogenic pathways in TSAs. Mutations in genes associated with Wnt signaling play a greater role in the carcinogenesis of TSAs than SSAs.</STUDY_ABSTRACT>
    </DESCRIPTOR>
    <GRANTS>
      <GRANT grant_id="16K09304">
        <TITLE>Molecular analysis of traditional serrated adenoma as a candidate precursor of alternative serrated pathway</TITLE>
        <AGENCY abbr="JSPS KAKENHI">Japan Society for the Promotion of Science</AGENCY>
      </GRANT>
      <GRANT grant_id="16H06279(PAGS)">
        <TITLE>Platform for Advanced Genome Science</TITLE>
        <AGENCY abbr="JSPS KAKENHI">Japan Society for the Promotion of Science</AGENCY>
      </GRANT>
      <GRANT grant_id="">
        <TITLE>Identification of carcinogenic pathway from serrated precursor lesions to poor-prognosis colon cancer</TITLE>
        <AGENCY>Grant-in-Aid from the Takeda Science Foundation</AGENCY>
      </GRANT>
      <GRANT grant_id="">
        <TITLE>Identification of carcinogenic mechanism of colorectal traditional serrated adenoma and application for endoscopic treatment</TITLE>
        <AGENCY>Grant-in-Aid from the Japanese Foundation for Research and Promotion of Endoscopy</AGENCY>
      </GRANT>
      <GRANT grant_id="">
        <TITLE>Molecular analysis of alternative serrated pathway originating from colorectal traditional serrated adenoma</TITLE>
        <AGENCY>Collaborative Research Grant of Cancer Research Institute, Kanazawa University</AGENCY>
      </GRANT>
    </GRANTS>
    <PUBLICATIONS>
      <PUBLICATION id="32092099" status="published">
        <DB_TYPE>PUBMED</DB_TYPE>
      </PUBLICATION>
    </PUBLICATIONS>
    <STUDY_ATTRIBUTES>
      <STUDY_ATTRIBUTE>
        <TAG>NBDC Number</TAG>
        <VALUE>hum0217</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Registration date</TAG>
        <VALUE>2020-01-16</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Submitting organization</TAG>
        <VALUE>Division of Translational and Clinical Oncology, Cancer Research Institute, Kanazawa University</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Principal Investigator</TAG>
        <VALUE>Takeshi Sawada</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Molecular Data Type</TAG>
        <VALUE>Target sequecning (Amplicon sequencing)</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Platform</TAG>
        <VALUE>Ion AmpliSeq Custom Panel</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Vendor</TAG>
        <VALUE>Target sequecning (Amplicon sequencing)</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>List</TAG>
        <VALUE>39 genes (112.8 kb )</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Primary Phenotype</TAG>
        <VALUE>Colon cancer</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Phenotype</TAG>
        <VALUE>Neoplasm of the colon</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>IDC-10 Disease Classification</TAG>
        <VALUE>Malignant neoplasm of colon (C18)</VALUE>
      </STUDY_ATTRIBUTE>
    </STUDY_ATTRIBUTES>
  </STUDY>
  <STUDY alias="JSUB000317_Study_0001" center_name="Individual" accession="JGAS000224">
    <IDENTIFIERS>
      <SECONDARY_ID>JGAS00000000224</SECONDARY_ID>
    </IDENTIFIERS>
    <DESCRIPTOR>
      <STUDY_TITLE>Identification of responsible genes and development of standardized medicine for familial breast cancer by genetic analysis with NGS technology </STUDY_TITLE>
      <STUDY_TYPES>
        <STUDY_TYPE existing_study_type="Tumor vs. Matched-Normal"/>
      </STUDY_TYPES>
      <STUDY_ABSTRACT>Aims: To clarify risk of germline variants of known causal genes for Hereditary Breast Ovarian Cancer Syndrome in Japan by combinatorial analysis of somatic and germline variants in the breast cancer tissue.
  Methods: Target caputure analysis by using Illumina HiSeq 2000; the panel genes are 119 genes including 30 HBOC known causal genes.
  Participants/Materials: 108 whole blood and 124 primary tumor samples from familial breast cancer patients.</STUDY_ABSTRACT>
    </DESCRIPTOR>
    <PUBLICATIONS>
      <PUBLICATION id="32566746" status="published">
        <DB_TYPE>PUBMED</DB_TYPE>
      </PUBLICATION>
    </PUBLICATIONS>
    <STUDY_ATTRIBUTES>
      <STUDY_ATTRIBUTE>
        <TAG>NBDC Number</TAG>
        <VALUE>hum0222</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Registration date</TAG>
        <VALUE>2020-03-12</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Submitting organization</TAG>
        <VALUE>The Cancer Institute Hospital of JFCR</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Principal Investigator</TAG>
        <VALUE>Shinji Ohno</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Molecular Data Type</TAG>
        <VALUE>Target caputure analysis</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Platform</TAG>
        <VALUE>Hiseq 2000</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Vendor</TAG>
        <VALUE>Illumina</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>List</TAG>
        <VALUE/>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Primary Phenotype</TAG>
        <VALUE>Hereditary Breast Ovarian Cancer Syndrome</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>ICD-10 Disease Classification</TAG>
        <VALUE>Breast Cancer (C50)</VALUE>
      </STUDY_ATTRIBUTE>
    </STUDY_ATTRIBUTES>
  </STUDY>
  <STUDY alias="JSUB000321_Study_0001" center_name="Individual" accession="JGAS000223">
    <IDENTIFIERS>
      <SECONDARY_ID>JGAS00000000223</SECONDARY_ID>
    </IDENTIFIERS>
    <DESCRIPTOR>
      <STUDY_TITLE>Influence of pre-analytical processing on blood protein profiles (AMED-Metabolites)</STUDY_TITLE>
      <STUDY_TYPES>
        <STUDY_TYPE existing_study_type="Other" new_study_type="Quantitative proteomics"/>
      </STUDY_TYPES>
      <STUDY_ABSTRACT>The purpose of the present study was to assess the differences between the human serum and plasma proteomes, and the stability of human plasma proteins under different storage conditions following blood collection, by means of SWATH-MS analysis. We compared plasma samples prepared by centrifugation after storage of blood at room temperature for 0, 15 or 30 minutes, or under refrigeration at 0-5?C for 1, 4 or 8 hours.</STUDY_ABSTRACT>
    </DESCRIPTOR>
    <GRANTS>
      <GRANT grant_id="19">
        <TITLE>AMED-Metabolites</TITLE>
        <AGENCY abbr="AMED">Japan Agency for Medical Research and Development</AGENCY>
      </GRANT>
    </GRANTS>
    <STUDY_LINKS>
      <STUDY_LINK>
        <URL_LINK>
          <LABEL>https://repository.jpostdb.org/entry/JPST000553.0</LABEL>
          <URL>https://repository.jpostdb.org/entry/JPST000553.0</URL>
        </URL_LINK>
      </STUDY_LINK>
      <STUDY_LINK>
        <URL_LINK>
          <LABEL>http://sohtsuki-lab.jp/ja/</LABEL>
          <URL>http://sohtsuki-lab.jp/ja/</URL>
        </URL_LINK>
      </STUDY_LINK>
    </STUDY_LINKS>
    <STUDY_ATTRIBUTES>
      <STUDY_ATTRIBUTE>
        <TAG>NBDC Number</TAG>
        <VALUE>hum0220</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Registration date</TAG>
        <VALUE>2020-03-24</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Submitting organization</TAG>
        <VALUE>Kumamoto University</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Principal Investigator</TAG>
        <VALUE>Sumio sohtsuki</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Molecular Data Type</TAG>
        <VALUE>Quantitative proteomics</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Platform</TAG>
        <VALUE>TripleTOF5600</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Vendor</TAG>
        <VALUE>Siex</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>List</TAG>
        <VALUE/>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Primary Phenotype</TAG>
        <VALUE>Blood protein</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Phenotype</TAG>
        <VALUE>Pre-analytical conditions</VALUE>
      </STUDY_ATTRIBUTE>
    </STUDY_ATTRIBUTES>
  </STUDY>
  <STUDY alias="JSUB000327_Study_0001" center_name="Individual" accession="JGAS000226">
    <IDENTIFIERS>
      <SECONDARY_ID>JGAS00000000226</SECONDARY_ID>
    </IDENTIFIERS>
    <DESCRIPTOR>
      <STUDY_TITLE>Mortality and risk of progression to adult T-cell leukemia/lymphoma in patients with HTLV-1-associated myelopathy/tropical spastic paraparesis </STUDY_TITLE>
      <STUDY_TYPES>
        <STUDY_TYPE existing_study_type="Tumor vs. Matched-Normal"/>
      </STUDY_TYPES>
      <STUDY_ABSTRACT>Human T-cell leukemia virus (HTLV)-1 causes the functionally debilitating disease HTLV-1-associated myelopathy/ tropical spastic paraparesis (HAM/TSP) as well as adult T-cell leukemia lymphoma (ATLL). Although there were concerns that the mortality of HAM/TSP could be affected by the development of ATLL, prospective evidence was lacking in this area. In this 5-year prospective cohort study, we determined the mortality, prevalence, and incidence of ATLL in 527 HAM/TSP patients. The standard mortality ratio of HAM/TSP patients was 2.25, and ATLL was one of the major causes of death (5/33 deaths). ATLL prevalence and incidence in these patients were 3.0% and 3.81 per 1,000 person-years, respectively. To identify patients at a high risk of developing ATLL, flow cytometry, Southern blotting, and targeted sequencing data were analyzed in a separate cohort of 218 HAM/TSP patients. In 17% of the HAM/TSP patients, we identified an increase in T-cells positive for cell adhesion molecule 1 (CADM1), a marker for ATLL and HTLV-1 infected cells. Genomic analysis of these patients revealed that somatic mutations of HTLV-1 infected cells were seen in 90% of the cases and 11% of them had dominant clone and developed ATLL in the longitudinal observation. In this study, we were able to demonstrate for the first time that the increased mortality in patients with HAM/TSP and a significant effect of ATLL on their prognosis. Having dominant clonal expansion of HTLV-1- infected cells with ATLL-associated somatic mutations may be important characteristics of patients with HAM/TSP who are at an increased risk of developing ATLL.</STUDY_ABSTRACT>
    </DESCRIPTOR>
    <STUDY_ATTRIBUTES>
      <STUDY_ATTRIBUTE>
        <TAG>NBDC Number</TAG>
        <VALUE>hum0225</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Registration date</TAG>
        <VALUE>2020-04-02</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Submitting organization</TAG>
        <VALUE>University of Tokyo</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Principal Investigator</TAG>
        <VALUE>Makoto Yamagishi</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Molecular Data Type</TAG>
        <VALUE>Target capture</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Platform</TAG>
        <VALUE>HiSeq 3000</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Vendor</TAG>
        <VALUE>Illumina</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>List</TAG>
        <VALUE/>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Molecular Data Type</TAG>
        <VALUE>Target capture</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Platform</TAG>
        <VALUE>HiSeq 2500</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Vendor</TAG>
        <VALUE>Illumina</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>List</TAG>
        <VALUE/>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Primary Phenotype</TAG>
        <VALUE>Myelopathy</VALUE>
      </STUDY_ATTRIBUTE>
    </STUDY_ATTRIBUTES>
  </STUDY>
  <STUDY alias="JSUB000332_Study_0001" center_name="Individual" accession="JGAS000230">
    <IDENTIFIERS>
      <SECONDARY_ID>JGAS00000000230</SECONDARY_ID>
    </IDENTIFIERS>
    <DESCRIPTOR>
      <STUDY_TITLE>Identification and characterization of molecular markers in aging and neuronal disorders</STUDY_TITLE>
      <STUDY_TYPES>
        <STUDY_TYPE existing_study_type="Transcriptome Sequencing"/>
      </STUDY_TYPES>
      <STUDY_ABSTRACT>Supercentenarians, people who have reached 110 years of age, are a great model of healthy aging. Their characteristics of delayed onset of age-related diseases and compression of morbidity imply that their immune system remains functional. We performed single-cell transcriptome analysis of peripheral blood mononuclear cells (PBMCs), derived from supercentenarians and younger controls. We identified a marked increase of cytotoxic CD4 T-cells (CD4 CTLs) as a novel signature of supercentenarians. Furthermore, single-cell T-cell receptor sequencing of two supercentenarians revealed that CD4 CTLs had accumulated through massive clonal expansion. The CD4 CTLs exhibited substantial heterogeneity in their degree of cytotoxicity as well as a nearly identical transcriptome to that of CD8 CTLs. This indicates that CD4 CTLs utilize the transcriptional program of the CD8 lineage while retaining CD4 expression. Our study reveals that supercentenarians have unique characteristics in their circulating lymphocytes, which may represent an essential adaptation to achieve exceptional longevity by sustaining immune responses to infections and diseases.</STUDY_ABSTRACT>
    </DESCRIPTOR>
    <PUBLICATIONS>
      <PUBLICATION id="31719197" status="published">
        <DB_TYPE>PUBMED</DB_TYPE>
      </PUBLICATION>
    </PUBLICATIONS>
    <STUDY_LINKS>
      <STUDY_LINK>
        <URL_LINK>
          <LABEL>https://aging-project.riken.jp/en/</LABEL>
          <URL>https://aging-project.riken.jp/en/</URL>
        </URL_LINK>
      </STUDY_LINK>
    </STUDY_LINKS>
    <STUDY_ATTRIBUTES>
      <STUDY_ATTRIBUTE>
        <TAG>NBDC Number</TAG>
        <VALUE>hum0229</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Registration date</TAG>
        <VALUE>2020-04-22</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Submitting organization</TAG>
        <VALUE>RIKEN Center for Integrative Medical Sciences</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Principal Investigator</TAG>
        <VALUE>Piero Carninci</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Molecular Data Type</TAG>
        <VALUE>Single-cell transcriptome sequencing</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Platform</TAG>
        <VALUE>HiSeq 2500</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Vendor</TAG>
        <VALUE>Illumina</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>List</TAG>
        <VALUE/>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Primary Phenotype</TAG>
        <VALUE>Aging</VALUE>
      </STUDY_ATTRIBUTE>
    </STUDY_ATTRIBUTES>
  </STUDY>
  <STUDY alias="JSUB000338_Study_0001" center_name="Individual" accession="JGAS000231">
    <IDENTIFIERS>
      <SECONDARY_ID>JGAS00000000231</SECONDARY_ID>
    </IDENTIFIERS>
    <DESCRIPTOR>
      <STUDY_TITLE>Analysis of mutational and proteomic heterogeneity of gastric cancer to monitor post-treatment tumor burden using circulating tumor DNA</STUDY_TITLE>
      <STUDY_TYPES>
        <STUDY_TYPE existing_study_type="Tumor vs. Matched-Normal"/>
      </STUDY_TYPES>
      <STUDY_ABSTRACT>It remains unclear whether complete spectrum of tumor heterogeneity is reflected in circulating tumor DNA (ctDNA). Here, we performed multi-regional target sequencing of primary tumors from 10 patients who underwent surgical resection for gastric cancer. A total of 126 non-synonymous mutations were identified from 30 samples from 10 tumors. Of these, 16 (12.7%) were likely mutations that occurred early in tumor development (i.e., present in all three regions) and were designated founder mutations. Among those validated with highly sensitive digital PCR (dPCR), 93% of non-founder mutations were found in all three regions. Variant allele frequencies (VAFs) of founder mutations were significantly higher than those of non-founder mutations. Phylogenetic analysis demonstrated that five of eight tumors (62.5%, excluding two hypermutator) had at least one identifiable truncal/founder mutation. These findings led us to prioritize founder mutations for ctDNA detection with individually-designed primer/probe sets for dPCR. Marked proteomic diversity was present across the tumor regions both within and between patients independent of mutational status. In preoperative plasma, the average ctDNA VAF of founder mutations was significantly higher than that of non-founder mutations (p = 0.039). Our present data demonstrated that high VAF mutations in the tumor likely represent founder or truncal mutations. However, mutation patterns alone appear insufficient to predict protein heterogeneity. These results suggest that, in practice, mutations having high VAF identified without multi-regional sequencing may be useful for ctDNA monitoring but are inadequate to fully predict proteomic heterogeneity of the tumor.</STUDY_ABSTRACT>
    </DESCRIPTOR>
    <GRANTS>
      <GRANT grant_id="16H01578">
        <TITLE>Establishment of selection process of molecular targeting drugs in response to biological heterogeneity in drug-resistant cancer cells</TITLE>
        <AGENCY abbr="jsps">Japan society for the promotion of science</AGENCY>
      </GRANT>
      <GRANT grant_id="15KK0317">
        <TITLE>Identification of compounds that potentially lead to the cancer relapse suppression on the basis of drug-resistant cancer subpopulation model (original)</TITLE>
        <AGENCY abbr="jsps">Japan society for the promotion of science</AGENCY>
      </GRANT>
      <GRANT grant_id="19K09224">
        <TITLE>Circumvent practical issues for introducing ctDNA into daily practice</TITLE>
        <AGENCY abbr="jsps">Japan society for the promotion of science</AGENCY>
      </GRANT>
      <GRANT grant_id="19K09130">
        <TITLE>Effect of immune response to Helicobacter pylori on adjuvant chemotherapy for gastric cancer</TITLE>
        <AGENCY abbr="jsps">Japan society for the promotion of science</AGENCY>
      </GRANT>
      <GRANT grant_id="17K10605">
        <TITLE>Development of monitoring system for esophageal cancer by quantifying circulating tumor DNA</TITLE>
        <AGENCY abbr="jsps">Japan society for the promotion of science</AGENCY>
      </GRANT>
    </GRANTS>
    <STUDY_ATTRIBUTES>
      <STUDY_ATTRIBUTE>
        <TAG>NBDC Number</TAG>
        <VALUE>hum0232</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Registration date</TAG>
        <VALUE>2020-05-22</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Submitting organization</TAG>
        <VALUE>Iwate Medical University</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Principal Investigator</TAG>
        <VALUE>Satoshi Nishizuka</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Molecular Data Type</TAG>
        <VALUE>Targeted-Capture (NGS)</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Platform</TAG>
        <VALUE>HiSeq 2000</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Vendor</TAG>
        <VALUE>Illumina</VALUE>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>List</TAG>
        <VALUE/>
      </STUDY_ATTRIBUTE>
      <STUDY_ATTRIBUTE>
        <TAG>Primary Phenotype</TAG>
        <VALUE>Gastric cancer</VALUE>
      </STUDY_ATTRIBUTE>
    </STUDY_ATTRIBUTES>
  </STUDY>
</STUDY_SET>